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ABSTRACT 
Liver sinusoidal endothelial cells (LSEC) constitute a unique population of 
endothelial cells with specialised liver-specific morphologic features and functions. 
LSEC are the only endothelial cells with fenestrations and which lack an organised 
basement membrane. They are involved in hepatic stellate cell (HSC) quiescence, 
endocytosis of small particles, selective transfer of substances from the blood, in 
the hepatic sinusoid, to the parenchymal cells and in liver regeneration. As the 
group of cells that form the inner lining of the capillaries of the liver sinusoids, and 
being the first to be in contact with blood-borne particles, pathogens, and 
xenobiotics, they are prone to the deleterious effects of these. The aims of this 
thesis were to investigate the unique features of human liver sinusoidal endothelial 
cells (HLSEC) in comparison with endothelial cells from other vascular beds, 
evaluate the sensitivities of HLSEC to a range of hepatotoxic drugs, including small-
molecule receptor tyrosine kinase inhibitors (RTKIs), such as regorafenib, and to 
explore the role of HLSEC in a triculture human liver microtissue. 
Results obtained from this study showed that HLSEC expressed phenotypic features 
of vascular and lymphatic endothelial cells, particularly vascular endothelial growth 
factor receptor 2 (VEGFR-2) which could be activated by VEGF-A to stimulate cell 
proliferation, migration and tubular morphogenesis. HLSEC also expressed 
functional VEGFR-3. Transcriptomic analysis indicated that HLSEC expressed 
specialised genes, such as plasmalemma vesicle associated protein (PLVAP), that 
support its liver-specific structure and functions. HLSEC were more sensitive to a 
range of small-molecule receptor tyrosine kinase inhibitors than other hepatic cells 
xvi 
 
(primary human hepatocytes [PHH] and human hepatic fibroblasts [HHF]) and 
endothelial cells from other vascular beds (human dermal microvascular 
endothelial cells and human dermal lymphatic endothelial cells). Regorafenib 
inhibited the activation of VEGFR-2 thereby abrogating cell proliferation, migration, 
tubular morphogenesis as well as upregulation of angiocrine factors involved in 
liver regeneration following activation by vascular endothelial growth factor A 
(VEGF-A). Regorafenib also caused a disruption of cytoskeletal structure of HLSEC 
and induced apoptosis via activation of caspase 3.  Triculture liver microtissues 
formed with PHH, HLSEC and HHF were vascularised with higher expression of liver-
specific drug-metabolising enzymes in comparison with the same combination of 
cells cultured as a monolayer. However, metabolic competence of triculture liver 
microtissues was significantly lower than in their monoculture counterparts 
(consisting of PHH only).  
This study has further confirmed the uniqueness of HLSEC as a specialised 
endothelial cell adapted to its anatomical role, which could respond to a range 
growth factors to initiate endothelial cell-specific functions. It has also been 
demonstrated that HLSEC are a direct target of hepatotoxic drugs. Triculture liver 
microtissues generated with PHH, HLSEC and HHF showed less metabolic 
competence than their PHH-only counterparts. Future studies need to investigate 
the role of RTKIs in vascular toxicity using in vivo models of sinusoidal obstruction 
syndrome (SOS) and liver regeneration. Finally, it would be informative to 
investigate the possibility of identifying HLSEC-specific biomarkers of liver toxicity.   
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CHAPTER ONE 
 
GENERAL INTRODUCTION 
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1.1 DRUG-INDUCED LIVER INJURY 
 
Drug-induced liver injury (DILI) ranks high among the causes of drug attrition during 
development and withdrawal from clinical use (Gahr et al., 2016) with about 20 
new cases per 100,000 persons in the overall population being reported annually 
(Leise et al., 2014). Research geared towards the understanding of DILI have placed 
the focus of attention mostly on hepatocytes, being the most abundant cell type of 
the liver and responsible for most liver functions. However, DILI events involve a 
complex, finely-orchestrated interplay between resident cell types.  Moreover, non-
parenchymal cells (NPCs), including liver sinusoidal endothelial cells (LSECs), hepatic 
stellate cells (HSCs), Kupffer cells (KCs) and biliary epithelial cells (BECs), play key 
roles in maintaining normal liver function. Only recently have we begun to 
appreciate the numerous and diverse functions of NPCs in shaping the liver’s 
response to injury and involvement in precipitating adverse outcomes and response 
to compound exposure. NPCs also have been recognized to be both direct and 
indirect targets of liver toxins and their metabolites. This thesis focuses attention 
on the role of liver sinusoidal endothelial cells (LSEC) in DILI. The sections that 
follow in this chapter will address the role of LSEC in liver physiology and pathology, 
as well as its use in organotypic liver microtissues. A brief review of endothelial cell 
physiology and drugs which affect this will be made. Finally, hepatotoxic drugs with 
potential to cause LSEC injury will be reviewed with a view to setting the 
background for what will be addressed in the experimental chapters that follow.   
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1.2 THE LIVER 
 
The liver is the largest mammalian organ which performs both exocrine and 
endocrine functions. Located in the right hypochondriac and epigastric region of the 
abdominal cavity, and attached to the diaphragm and protected by the ribs, the 
liver accounts for 2%–5% of the total body weight in the adult human (Si-Tayeb et 
al., 2010, Haschek et al., 2010, McCuskey, 2012). 
 
1.2.1 Structure and cell types 
 
The liver is divided into right and left lobes which are separated by the falciform 
ligament. The right lobe is posteriorly and inferiorly subdivided into the caudate 
and quadrate lobes (Figure 1.1). The liver receives a dual blood supply by means of 
the hepatic artery and the portal vein via its hilus, also the exit point for efferent 
bile ducts and the lymphatics.  About 80% of blood supply to the liver is via the 
portal vein which supplies poorly-oxygenated venous blood from the intestines, 
pancreas, spleen and gallbladder. The remaining 20% comes from the hepatic 
artery. The basic subunit of the liver is a hexagonal structure called the lobule which 
hosts the central vein by means of which blood supply into the hepatic sinusoids is 
emptied  (Haschek et al., 2010). In the angles of the lobules are the portal tract 
which contains bile ducts, hepatic artery, branches of the portal veins, nerves and 
lymphatics. The sinusoid, which separates hepatic plates, serves as a channel for 
blood flow from the portal tracts to the central vein.   
 
4 
 
 
Figure 1.1: Anterior (left) and posteroinferior (right) views of the human liver showing Lobes, 
surfaces, and ligaments. Adapted from McCuskey (2012) 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram of the basic hepatic lobule and acinus substructure showing the relative direction of 
blood flow from periportal microvasculature towards the central veins (red arrows). Adapted from 
LeCluyse et al. (2012a) 
 
Figure 1.2: Representation of the liver microstructure. 
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1.2.2 Embryonic development of the mammalian 
liver 
 
Liver organogenesis in humans commences in week 3 of gestation. This begins as an 
endodermal bud from the ventral foregut. The bud develops into the hepatic 
diverticulum and forms a cavity contiguous with the foregut. Within this time 
period, the hepatic diverticulum forms the septum transversum which has three 
portions namely: the hepatic portion which forms the hepatic parenchymal cells 
and intrahepatic bile ducts, the cystic portion which forms the gall bladder, while 
the ventral portion forms the head of the pancreas (McCuskey, 2012). Week 4 
marks the formation of blood vessels (Figure 1.3). From the hepatic diverticulum 
arise buds of epithelial cells which extend into the mesenchyme of the septum 
transversum and make thick multicellular anastomosing cords. This develops into 
the close association between the sinusoids and the parenchymal cells. On week 7, 
vitelline veins form the portal vein while the hepatic artery derives from the celiac 
axis and after the formation of bile ducts, ingrowths of the hepatic artery into the 
hepatic primordium take place. Between this period and birth, the foetal liver 
performs haematopoietic functions until the development of mature bone marrow 
that takes over as the main site of haematopioesis. In addition, the main serum 
protein in utero is alpha fetoprotein up until the end of the first trimester, while at 
16 weeks of gestation albumin is synthesised (McCuskey, 2012, Si-Tayeb et al., 
2010)     
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1.2.3 Hepatic cell types and their physiological 
functions  
 
The main cell type of the liver is the hepatic parenchymal cells or the hepatocytes 
which constitute about 80% of total liver volume and 60% of total cell population. 
Polyhedral in shape, the hepatocytes have two surfaces: the sinusoidal surface and 
  
 Figure 1.3: Embryonic development of the liver. 
(A) Section through the region of the hepatic bud of a 26 day-old human embryo. (B) Vascular channels 
associated with the developing liver in a human embryo of 30 somites. (C) Vascular channels at a later 
stage showing development of the sinusoidal network. (D) Portal hepatic circulation in a human 
embryo of 17 mm (7 weeks). Adapted from McCuskey (2012) 
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the basolateral canalicular surface. Blood from the portal vein and hepatic artery 
flows over the sinusoidal surface (Beath, 2003). Organised into plates or laminae, 
hepatocytes form tight junctions which create a canaliculus surrounding each 
hepatocyte and which collects bile and bile acids that are transported into the 
apical surface of the hepatocyte (Rogers & Dintzis, 2012). Microvilli on the 
hepatocytes protrude into the space of Disse and through the fenestrations on the 
sinusoidal endothelial cells (Haschek et al., 2010, Stolz, 2011b).  The space of Disse 
which lies between sinusoidal endothelial cells and the hepatocyte also contains 
the stellate cells. The Küpffer cells are attached to the sinusoidal endothelium. 
(Figure 1.4). Additionally, hepatocytes are oriented in cords which are made up of a 
single row of cells demarcated by the sinusoidal endothelial cells (Haschek et al., 
2010). There is a variation in the distribution of hepatocytes along sinusoids along 
the gradient of blood flow from the periportal to the centrilobular regions. This is a 
reflection of the physiological variation due to adaptation of hepatocytes to 
difference in the concentration gradient of nutrients, oxygen tension and other 
relevant substances along the sinusoids. Variation in hepatocyte distribution has 
resulted in the division of the hepatic lobule into three zones (1-3); zone 1 being in 
the periportal area with the highest oxygen supply, and zones 2 and 3 are in the 
order of decreasing oxygen tension towards the centrilobular area (Figure 1.4). 
Consequently, the hepatocytes in the centrilobular area are larger and richer in 
smooth endoplasmic reticulum than the periportal end of the sinusoid. Hepatocytes 
are responsible for energy storage in the form of glycogen, biotransformation of 
xenobiotics and endogenous chemicals required for regulation of physiological 
processes. In addition, they regulate the synthesis and transportation of 
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cholesterol, urea metabolism and the production of a vast array of plasma proteins, 
including albumin and Apo lipoproteins (Cattley & Cullen, 2013). Kupffer cells, 
which make up about 20% of non-parenchymal cells, are the macrophages of the 
liver (Wisse & Knook, 1977). They form the first line of defense in the liver which 
serves in the elimination of infectious bacterial materials via the blood supply from 
the gastrointestinal tract. Although they are ubiquitous within the lobule, Kupffer 
cells are more concentrated in the portal area to enable them to interact with 
incoming foreign bodies (Stolz, 2011b). They have also been reported to migrate 
along the surface of the sinusoidal endothelial cells (SEC), effecting a temporary  
blockage of blood flow, thereby facilitating an interaction between non-
parenchymal cells and leukocytes in circulation (MacPhee et al., 1995). Stellate cells 
(also called Ito cells, lipocytes, fat storing cells, or perisinusoidal cells) are fat-
storing cells that make up about 15% of non-parenchymal cells. They are resident in 
the space of Disse (between the LSEC and the hepatocytes). Because they envelop 
the endothelial cells and are capable of contraction, they are often referred to as 
sinusoidal pericytes (Sato et al., 2003). When quiescent, they store retinoids, 
triglycerides, cholesterol and other free fatty acids, but upon activation they lose 
these lipid stores, and secrete cytokines and proteins of the extracellular matrix 
(ECM). Changes in composition of the ECM and deposition of ECM into the space of 
Disse result in capillarisation or pseudocapillarisation (loss of LSEC fenestration). 
Stellate cells are reportedly responsible for liver fibrosis and cirrhosis (Yin et al., 
2013). Pit cells form part of the resident hepatic leukocyte population and make up 
about 2% of the total non-parenchymal cell population. They are resident in the 
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sinusoidal lumen and kill tumours as well as virally-infected cells (Nakatani et al., 
2004). 
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Figure 1.4: Structural zonation of the liver.  
Discrete microenvironments or zones of the liver between the portal triad (periportal region) and central vein (pericentral region) illustrating the differences in 
hepatocyte (HC) size and ploidy (diploidtetra/octaploid). Due to the flow of mixed blood from the portal vein and hepatic artery towards the central vein, inherent 
gradients are formed that vary in oxygen tension, nutrient concentrations and the levels of other soluble and bound factors.  These gradients are thought to play a role 
in the creation of localized differences in HC gene expression profiles and phenotypes, including the uptake and metabolism of both endogenous and exogenous 
substrates. Note that the greatest capacity for lipid uptake and metabolism is exhibited in HCs in zone 1 and the greatest capacity for xenobiotic uptake and metabolism 
is exhibited in HCs in zone 3. Adapted from (Turner et al., 2011). BEC: biliary epithelial cells, LSEC: liver sinusoidal endothelial cell, KC: Kupffer cell, HSC: hepatic stellate 
cell, HC: hepatocyte. 
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1.3 LIVER SINUSOIDAL ENDOTHELIAL CELLS 
Liver sinusoidal endothelial cells (LSECs) are highly specialised cells that form the 
basic tubular vessel for transvascular exchange between blood flowing in the 
sinusoid and the surrounding parenchymal cells (PC). In the early 1970s, by the use 
of electron microscopy, Wisse successfully characterized LSECs as the cell type on 
the surface of the liver sinusoid and distinguished them from Kupffer cells, thus 
ending the assumption that endothelial cells could develop into Kupffer cells 
(Wisse, 1970, Wisse, 1972). LSECs make up about 50% of the total number and 
volume of non-parenchymal cells (DeLeve, 2011). Lining the capillaries of the 
microvasculature, LSECs are unique to the liver as they are the only mammalian 
endothelial cells with open fenestrae and which lack an organized basement 
membrane (Hang et al., 2012). Hence it is the most permeable of all mammalian 
endothelial cells (DeLeve, 2011). These fenestrae (170 nm in diameter) lack 
diaphragms and are assembled in groups referred to as sieve plates. Due to their 
strategic location, LSECs are essentially the first cells to be in contact with blood 
flowing into the hepatic sinusoid (Figure 1.4). They are involved in the selective 
transfer of substances from the blood in the hepatic sinusoid to the parenchymal 
cells, hepatic stellate cell (HSC) quiescence, endocytosis of small particles, and liver 
regeneration. This section will focus on the embryological development of LSEC, 
role of LSEC in liver physiology and pathology as well as models that have been 
developed to study the involvement of LSEC in drug-induced liver injury (DILI).  
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1.3.1 LSECS in liver organogenesis 
 
The liver sinusoids are the first blood vessels to be formed during hepatogenesis 
and arise from septum transversum mesenchyme (STM) (Collardeau-Frachon & 
Scoazec, 2008, Couvelard et al., 1996). Precursory to the functional liver sinusoidal 
endothelial cells (LSEC) are angioblasts (Matsumoto et al., 2001) and these 
intercede between the thickening endoderm and the STM. Sinusoids are believed 
to be formed via angiogenesis as well as by introduction of endothelial cells of 
mesothelial origin (Perez-Pomares et al., 2004). Klein et al. (2008) have shown that 
Wnt2 signalling plays a key role in the proliferation and differentiation of the liver 
sinusoid. In a murine study, they demonstrated that Wnt2, which is expressed in rat 
LSEC has the potential to promote LSEC proliferation via β-catenin signalling. They 
concluded that an autocrine activity of Wnt2 cooperates with VEGF signalling to 
regulate LSEC growth. This was further confirmed when depletion of Wnt2 resulted 
in a reduction of the expression of VEGF receptor-2 (VEGFR-2) on rat LSECs. It has 
been shown that LSEC and their main signalling receptor, VEGFR-2, are required 
during organogenesis of the liver (Matsumoto et al., 2001). These nascent 
endothelial cells create the pattern for the lobular organization of the liver by 
directing the migration of the liver into cords (McLin & Yazigi, 2011). Interactions 
between newly-specified hepatic endoderm cells and LSECs are crucial for the 
endoderm's subsequent growth and morphogenesis into a liver bud (Figure 1.3). 
Therefore, these nascent cells are key in the provision of required growth stimulus 
needed by the hepatic bud even before formation of local vessels that supply blood 
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and oxygen. A similar interplay between LSECs and hepatocytes via VEGF signalling 
occurs during liver regeneration (Ding et al., 2010b, Rafii et al., 2016). 
 
1.3.2 Role of LSECs in liver physiology  
 
LSECs form the basic tubular vessel for transvascular exchange between blood 
flowing in the sinusoid and the surrounding parenchymal cells (Figure 1.9), recently 
reviewed by Sorensen et al. (2015). This unhindered access to circulating blood 
enables hepatocyte oxygenation, movement of substrates and lipoprotein to and 
from hepatocytes, and a more efficient clearance of xenobiotics (DeLeve et al., 
2004, Fraser et al., 1995). In healthy individuals, LSECs generally lack a basal lamina 
which enables solutes and small particles to have direct access to the perisinusoidal 
space where hepatic stellate cells (HSCs) and hepatic microvilli are found. This 
ensures an unhindered exchange of these substances (solutes and small particles) 
between the blood and the hepatic parenchymal cells. 
 
1.3.2.1 Delivery of oxygen 
Because only ~30% of the blood supply to the hepatic sinusoid is oxygen-rich, 
oxygenation of the hepatocytes is facilitated by the architectural and cytoplasmic 
features of the LSECs, such as the presence of fenestrations, a very narrow and 
spread cytoplasm, and the lack of an organized basement membrane, which reduce 
the distance required for oxygen diffusion. (DeLeve, 2011). In capillarised and 
pseudocapillarised livers, where there is a loss of fenestrations and alterations in 
the basement membrane, hepatocyte hypoxia ensues (Le Couteur et al., 2001). 
Figure 5: Microanatomy of the Liver 
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There is also evidence that there is a correlation between oxygen diffusion through 
the sinusoid and oxidative drug metabolism as Hickey et al. (1995) and Le Couteur 
et al. (1999) have demonstrated the re-establishment of drug metabolism in 
cirrhotic rat liver following oxygen supplementation.   
 
1.3.2.2 Nitric oxide production and signalling  
LSECs produce nitric oxide (NO) via endothelial nitric oxide synthase (eNOS) and 
inducible nitric oxide synthase (iNOS), the former being restricted to LSECs in the 
liver (Perri & Shah, 2005a). NO in the hepatic endothelium serves in the regulation 
of vascular tone in response to shear stress and other factors that cause a 
constriction of the hepatic sinusoids resulting in local dilation of the vascular bed 
and an enhancement of blood flow (Figure 1.6) (Shah et al., 1997). Endothelial NOS 
can also drive the production of NO by the action of agonists such as vascular 
endothelial growth factor (VEGF) and oestrogen. LSECs can also generate NO via the 
induction of iNOS in response to cytokines (e.g., interferon-γ [IFN-γ] and to 
lipopolysaccharides [LPS]) (Rockey & Chung, 1996). In capillarised liver, there is a 
perturbation of the NO-dependent pathway which disrupts the LSEC phenotype, a 
predisposing factor to liver fibrosis (reviewed in DeLeve (2015) and  Greuter and 
Shah (2016)).   
 
1.3.2.3 Stellate cell quiescence 
In vivo, LSECs help maintain hepatic stellate cell (HSC) phenotype and quiescence 
through NO signalling (DeLeve et al., 2004, 2008). In a quiescent state, HSCs are 
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responsible for the storage of triglycerides, retinol (vitamin A), cholesterol 
retinoids, and free fatty acids. However, upon activation, these lipid stores become 
depleted and HSCs proliferate and secrete a variety of cytokines and extracellular 
matrix (ECM) proteins and enzymes that modulate the external ECM composition, 
such as matrix metalloproteinase protein-9 (MMP-9). This change in ECM 
composition results in capillarisation or pseudocapillarisation which leads to fibrosis 
(Bosch, 2007, Iwakiri & Groszmann, 2007). Deleve et al. (2008) have demonstrated 
that LSECs in a differentiated state maintain HSC quiescence and can even revert 
activated HSCs towards a quiescent state via VEGF-stimulated nitric oxide (NO) 
production (Figure 1.6).  
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Figure 1.6: Liver sinusoidal endothelial cells in regulating stellate cell quiescence.  
 (A) In uninjured liver, shear stress or vascular endothelial growth factor-A (VEGF-A) act directly on 
liver sinusoidal endothelial cells (LSECs) to generate nitric oxide (NO) via endothelial nitric oxide 
synthase (eNOS) activity. NO produced via this process can help maintain hepatic stellate cells 
(HSCs) in a quiescent state. Furthermore, VEGF production by quiescent HSCs is an important factor 
in maintaining the differentiated or fenestrated phenotype of LSECs. (B) In the absence of this 
crosstalk (e.g., in the event of livery injury), HSCs become activated and transdifferentiate to 
myofibroblasts, resulting in the deposition and accumulation of extracellular matrix (ECM) within 
the space of Disse. Furthermore, LSEC fenestrae are compromised leading to capillarisation of the 
liver and an impedement of oxygen and nutrient delivery to the parenchymal cells. The activation of 
resident macrophages, or Kupffer cells (KCs), causes a myriad of proinflammatory and chemotactic 
cytokines to be released that modulate the phenotypic features of other cell types and influence the 
liver’s response to injury, including recruitment of extrahepatic inflammatory cells to the site of 
injury. This wound-healing response is dependent on a finely orchestrated balance and interplay 
between resident and recruited cell types. When this balance is disrupted (i.e., during chronic liver 
injury) excessive ECM deposition occurs and ultimately disrupts normal liver architecture and 
function, which over time become the hallmarks of liver fibrosis and cirrhosis. IL-1β, interleukin-1β; 
IL-8, interleukin-8; MCP-1, monocyte chemoattractant protein-1; PDGF, platelet-derived growth 
factor; TGF-β1, transforming growth factor-β1; ROS, reactive oxygen species.  
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1.3.2.4 Scavenger function 
As the first checkpoint for macromolecules and antigens entering the portal 
circulation from the intestine, LSECs play a complementary role to Kupffer cells 
(KCs) as a scavenger system in the clearance of these foreign waste products. While 
KCs phagocytose larger particulate matters and insoluble wastes, LSECs remove 
colloids, macromolecules and soluble components which are less than 0.23 μm in 
size from the blood (Smedsrod et al., 1990, Shiratori et al., 1993, Elvevold et al., 
2008). This function is enhanced  by the slow and intermittent blood flow through 
the sinusoids, the large surface area of the LSEC, positively-charged coated pits that 
facilitate endocytosis of negatively charged  particles, presence of the endocytic 
surface receptors and the highly-specific lysosomal enzymes which aid in the 
disposal of waste products (Knook & Sleyster, 1980, Sorensen et al., 2012). The 
main scavenger receptors on LSECs are the hyluronan/scavenger receptors, SR-H 
(Stabilin-1 and -2). These are responsible for the clearance of hyluronan, 
chondroitin sulphate, formaldehyde-treated serum albumin (employed as a test 
ligand for scavenger receptor-mediated endocytosis) (Blomhoff et al., 1984) and 
internalization of phosphorothioate-modified antisense oligonucleotides (ASO) 
(Miller et al., 2016). A second endocytosis receptor system on the LSEC is the CD206 
(collagen-α-chain/mannose) receptor which clears denatured collagen alpha chains 
in circulation (Malovic et al., 2007). The LSEC Fc receptor FcγIIb2 (CD32b or SE-1), 
clears immune complexes formed with IgG (March et al., 2009). Very recently, the 
scavenger receptor B1, an HDL receptor involved in cholesterol metabolism, has 
been shown to be highly expressed on LSECs (Ganesan et al., 2016). During 
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capillarisation, there is deterioration in LSEC-mediated endocytic functions (Ito et 
al., 2007). 
Table 2.1: Some markers present on the LSEC  
Marker  Description 
CD31 or PECAM-1  Cell surface marker on all endothelial cells but 
expressed in the cytoplasm in LSEC. It is involved in 
transendothelial leucocyte migration. 
Stabilin-2 LSEC-specific scavenger receptor 
CD33 A myeloblast antigen also present on LSEC surface 
CD4 Present on T cell monocytes, dendritic cells and LSEC 
Fcγ receptor IIb2 Involved in the endocytosis of immune complex 
CD36 Thrombospondin-1 receptor 
CD45 A leucocyte common antigen present on about 90% 
LSECs isolated by elutriation 
Integrin α1β1 Binds collagen preferentially 
Integrin α5β1 Binds fibronectin preferentially 
LYVE-1, CD46, CD 80, 
CD86 
Clearance of hyaluronan and other waste products 
from connective tissues 
        Source: DeLeve (2011) 
 
1.3.2.5 Clearance of drugs and small particles 
Protein-bound drugs pass through the fenestrations on the LSECs into the space of 
Disse; thus free drug can be cleared by adjacent hepatocytes. This allows bound 
drug to re-equilibrate with free drug thereby enabling newly-formed free drug to be 
cleared by the hepatocytes (DeLeve, 2011). This process accelerates the removal of 
free drug from circulation via the liver. Consequently, due to an appreciable drop in 
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oxidative drug metabolism and loss of fenestrae in capillarised and pseudo-
capillarised livers, drug disposition is expectedly compromised in fibrotic and aging 
liver. In a similar manner, chylomicron remnants are transported into the space of 
Disse when they are of smaller size than the fenestral diameter to be cleared by the 
hepatocytes. Chylomicrons are lipoprotein particles made up primarily of 
triglycerides, phospholipids, cholesterol and proteins (Hussain, 2000). Because they 
contain about 90% triglyceride, chylomicrons serve as a vehicle for the transport of 
triglycerides. In ageing- or fibrosis-related capillarisation, where there is a 
considerable loss of LSEC fenestrations, chylomicron and hence triglyceride 
clearance is impaired. This phenomenon is related to the initiation of 
atherosclerosis and hyperlipidaemia (Botham & Wheeler-Jones, 2007). Species with 
smaller fenestral diameter and lower sinusoidal porosity (e.g., chicken and rabbit) 
tend to develop atherosclerosis (Braet & Wisse, 2002).  
 
1.3.2.6 Liver regeneration 
LSECs have been reported to be involved in liver regeneration (reviewed in DeLeve 
(2013) and Forbes and Rosenthal (2014)). In a mouse model of partial hepatectomy, 
activation of vascular endothelial growth factor receptor 2 (VEGFR-2) on LSECs was 
observed to induce the upregulation of transcription factor Id1 which causes a 
release of angiocrine factors Wnt2 and hepatocyte growth factor (HGF) which are 
required for hepatocyte proliferation (Figure 1.7) (Ding et al., 2010a). This 
observation is not only limited to partial hepatectomy, Ding et al. (2014) have also 
shown induction of liver regeneration in acetaminophen (APAP)- and carbon-
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tetrachloride (CCl4)-induced liver injury. This observation highlights the importance 
of LSECs in effecting a cascade of events that begins with the initial release of 
vascular endothelial growth factor A (VEGF-A). This was first observed with a 30-
fold elevation of hepatic VEGF-A after administration of toxic doses of APAP in a rat 
study, whereas an exogenous administration of VEGF-A to another group of rats 
resulted in the abrogation of the hepatocellular necrosis observed in APAP 
overdose (Donahower et al., 2010b, Donahower et al., 2006). Because hepatocytes 
release VEGF-A that acts in an autocrine fashion to enchance LSEC survival, 
migration and proliferation (DeLeve et al., 2004), it is therefore conceivable that 
during  liver injury and/or hepatectomy, hepatocytes release VEGF-A which 
activates the VEGFR-2 on LSECs and initiates the cascade of events that results in 
liver repair and regeneration. Also, liver regeneration is dependent on angiogenesis, 
which when inhibited, prevents liver regeneration (Drixler et al., 2002, Greene et 
al., 2003, Taniguchi et al., 2001), a  process mediated by the anigiogenic factor 
VEGF-A (Taniguchi et al., 2001). 
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Figure 1.7: Role of liver sinusoidal endothelial cells (LSECs) in liver regeneration: 
 
VEGF-A VEGFR-2
Id 1
LSEC proliferation
HGF
HGF receptor
LSEC
HEPATOCYTES
ERK 
1/2
Hepatocyte injury/ 
partial hepatectomy
wnt2
Hepatocyte proliferation
LIVER REGENERATION
A simplified diagram showing the role of LSECs during liver injury and regeneration. After partial hepatectomy or toxic injury, hepatocytes release vascular endothelial 
growth factor A (VEGF-A), which causes activation of the VEGF receptors (VEGFR-2) in LSECs, resulting in the upregulation of transcription factor Id1 and release of Wnt2. 
The release of Wnt2 triggers the release of hepatocyte growth factor (HGF) from LSECs, which then activates its receptor, HGFR, on the hepatocyte surface and promotes 
hepatocellular proliferation and reconstitution of liver mass. Simultaneous, activation of VEGFR-2 on LSECs initiates a cascade of intracellular signalling that involves cell 
survival and proliferation. This also helps form tracts to guide the arrangement of the newly-formed hepatocytes into a lobular pattern and facilitate their vascularization 
(Ding et al., 2010b). It is important to note that this is not the sole pathway involved in liver regeneration. There are other cells and signalling molecules involved in liver 
regeneration including macrophages, hepatic stellate cells (HSCs), TGF-β1, angiopoietin-2, and progenitor cells (reviewed in (Forbes & Parola, 2011)).  
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1.3.2.7 LSEC fenestrations 
One of the principal hallmarks of the LSEC is its fenestrae. These transcellular pores 
span 50-150 nm in diameter and are collected into groups of 10-100 called sieve 
plates (Figure 1.8 and Figure 1.9). (Svistounov et al., 2012). Making up about 7% of 
the total endothelial surface area, the fenestrae form a selective barrier between 
the blood and hepatocytes. As discussed earlier, they also help in the clearance of 
colloids and soluble macromolecules from the circulation (Elvevold et al., 2008, 
DeLeve, 2011). Forced sieving and ‘LSEC massage’ have been described as being 
involved in the transendothelial movement of particulates somewhat larger than 
the size of the fenestrae (Wisse et al., 1996). Just as there is a variation in size and 
metabolic capabilities of hepatocyte from the periportal (zone 1) to centrilobular 
(zone 3) regions, there is also an increase in fenestral diameter and porosity along 
this gradient (Wack et al., 2001). Controlled by the actin cytoskeletal network, the 
diameters of the fenestrae can be adjusted by the pressure of blood flowing 
through the lumen, and in presence of vasoactive substances, alcohol, drugs, and 
toxins in the bloodstream (Braet et al., 1996). Fenestral diameter is also suggested 
to be regulated by serotonin (5-hydroxytryptamine, 5-HT) via the 5-HT2 receptor on 
LSECs. As a result of an influx of calcium, following 5-HT2 receptor activation, there 
is a phosphorylation of the myosin light chains resulting in an increase in actin-
activated myosin ATPase activity in areas surrounding the fenestral opening. This 
results in contraction which can be reversed by calcium channel blockers 
(Gatmaitan et al., 1996). Fenestrae can be induced by such microfilament inhibitors 
such as latrunculin A, cytochalasin B, and misakinolide (Braet & Wisse, 2002). LSEC 
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porosity is also known to be regulated by VEGF. Constitutively produced by 
contiguous hepatocytes and hepatic stellate cells (HSCs), VEGF stimulates an 
autocrine production of NO which serves to maintain fenestral integrity (DeLeve et 
al., 2004).   
 
(a) A low magnification image accentuating the anatomy of the hepatic plate bounded by 
sinusoids. (b) A high magnification micrograph of a sinusoid highlighting sieve plates (c) Transition 
of the portal venule into the sinusoid (SEC). There is an abrupt change of non-fenestrated to 
fenestrated endothelium from the portal venule to the sinusoid. SEC, sinusoidal endothelial cell; 
Hep, hepatocyte; BC, biliary cells; SD, space of Disse. Source:  Stolz, 2011 
 
Figure 1.8: Scanning electron micrographs of a section of mouse liver sinusoidal 
endothelial cells.  
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      Figure 1.9: Exchange of oxygen and soluble substances between blood and the perisinusoidal space  
 LSECs play an important role in the transport of oxygen from the sinusoidal blood to the hepatocytes (HCs). This is facilitated by their fenestrations, thin cytoplasm, and a lack 
of organised basement membrane. These features enable the passage and clearance of protein-bound drugs and phospholipids to and from the circulating blood. Loss of 
fenestrae (capillarisation) results in the inability of LSECs to clear lipoproteins, which is an important factor in the initiation of atherosclerosis.   
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1.3.3 Role of LSECS in liver pathology 
 
Given the physiological roles of LSECs which includes barrier function, scavenger 
function, clearance of small particles and hepatic stellate cell (HSC) quiescence, any 
interference with these could adversely affect hepatocytes and liver function, 
resulting in a liver disease. This section discusses some conditions that affect the 
LSECs with a consequent adverse effect on the liver in general.  
 
1.3.3.1 Capillarisation of the LSEC  
Capillarisation is a dedifferentiation process in which the LSEC phenotype is 
converted to a vascular phenotype, marked by defenestration and formation of an 
organized basement membrane (DeLeve et al., 2004). In vivo, capillarisation occurs as 
an onset of alcoholic liver disease, fibrosis, cirrhosis and ageing. However, the 
changes seen as a result of aging, are more significantly a loss of fenestration with 
partial changes in the basement membrane. Hence, this phenomenon in an ageing 
liver is more appropriately termed pseudocapillarisation (McLean et al., 2003). In 
capillarisation and pseudocapillarisation, clearance of lipoproteins is impaired leading 
to hyperlipidaemia and atherosclerosis. Other factors that contribute to 
defenestration as seen in these phenomena include generation of reactive oxygen 
species (ROS) and some toxins (Stolz, 2011b). In an in vivo study, Straub et al. (2007) 
have shown that a daily five-day administration of sub-lethal doses (250 parts per 
billion) of trivalent arsenic could cause capillarisation in rat LSECs. This observation 
was due to superoxides generated from NADPH oxidase (NOX), whereas NOX-
knockout mice did not experience this defenestration phenomenon (Straub et al., 
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2008). Oxidative stress and depletion of endogenous antioxidants (e.g., glutathione) 
also have been associated with capillarisation (Cogger et al., 2004).  
 
1.3.3.2 Alcoholaemia 
As mentioned above, alcohol induces an increase in fenestral diameter (Wisse et al., 
1996). On the other hand, chronic alcohol intake has been implicated in LSEC 
capillarisation, commonly associated with reduction in diameter and number of 
fenestrae and formation of basement membrane as seen in liver cirrhosis (discussed 
below). However, this is reversible upon abstinence from alcohol (Fraser et al., 1995). 
Acute alcohol consumption impairs the scavenger function of LSECs, while chronic 
alcoholic intake reduces receptor-mediated endocytosis. This means that bacterial 
antigens are not efficiently removed and this may lead to immune stimulation, and 
thus increased liver inflammation (Thiele et al., 1999).  
 
1.3.3.3 Liver cirrhosis 
In a cirrhotic liver, there is a general scarring of the liver accompanied by damage to 
the hepatic architecture. There is impedance to the hepatic circulation mainly due to 
a decline in the nitric oxide (NO) production that is brought about by an enhanced 
expression of nitric oxide synthase (NOS) inhibitory proteins and decreases in 
endothelial nitric oxide synthase (eNOS) phosphorylation (Perri & Shah, 2005a, 
Fulton et al., 2001). As discussed above, there is a shrinkage of and dramatic 
reduction in the number of fenestrae in LSECs which marks sinusoidal capillarisation. 
With the loss of NO, there is activation of hepatic stellate cells (HSCs) leading to the 
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production of ECM and fibrosis of the liver, which is correlated with a rise in serum 
hyaluronate. Although LSECs are involved in HSC quiescence, when stimulated by 
transforming growth factor-β1 (TGF-β1), they can produce ECM components like 
laminin, fibronectin, and collagen type IV (Rieder et al., 1993). A consequence of ECM 
production in cirrhotic liver is the poor oxygenation of the parenchyma which leads 
to hepatocellular hypoxia and necrosis.      
 
1.3.3.4 Sinusoidal obstruction syndrome 
Sinusoidal obstruction syndrome (SOS) is the pathological condition which leads to 
LSEC injury and obstruction of sinusoidal flow (Tallman et al., 2013). SOS takes place 
mainly in two settings: ingestion of pyrrolizidine alkaloid as well as chemotherapy 
alone or in combination with irradiation of the liver (Deleve, 2008a). This has been 
reported to be associated with an incidence of 70% morbidity and 67% mortality 
(Nakamura et al., 2012). Understanding the mechanism of LSEC injury in SOS has 
been enhanced by the use of a rodent model of the disease which exhibits similar 
symptoms of the disease in humans. Monocrotaline is activated by CYP3A4 to its 
pyrrole derivative which is electrophilic (DeLeve et al., 2003, Wang et al., 2005). It 
readily targets and depolymerizes the F-actin cytoskeleton, and activates matrix 
metalloproteinase-9 (MMP-9) which digests the extracellular matrix (ECM) of the 
LSECs. This results in a compromise of the tight junctions between LSECs which form 
the endothelial barrier of the hepatic microcirculation, paving the way for red blood 
cells to pass through the gap formed into the space of Disse. There occurs an 
embolism of the LSECs lining the sinusoids leading to obstruction of the hepatic 
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microcirculation, ischemic damage, centrilobular haemorrhagic necrosis (DeLeve, 
2011), coagulative necrosis of hepatocytes, and loss of LSECs (Nakamura et al., 2012). 
Loss of LSECs is accompanied by a corresponding drop in number of KCs in the liver. 
Additionally, the loss of LSECs leads to a drop in the level of NO which tonically 
inhibits the synthesis of MMP-9. Because monocrotaline pyrrole is electrophilic, it 
causes a depletion of glutathione (GSH), and enhances the activities of MMP-9. 
Hence supplementation with GSH or N-acetyl cysteine inhibits MMP-9 activity 
(DeLeve et al., 2003). Drugs that have been reportedly implicated in SOS in the clinic 
include oxaliplatin, busulfan, cyclophosphamide, 6-thioguanine, and actinomycin D 
(Robinson et al., 2013, Vreuls et al., 2016). This has recently been reviewed by Valla 
and Cazals-Hatem (2016). 
 
1.3.3.5 Non-alcoholic fatty liver disease 
As mentioned previously, LSECs are involved in the modulation of hepatic stellate cell 
(HSC) phenotype. Compromises of the LSEC-HSC nitric oxide (NO) signalling results in 
HSC activation, a prominent event in which the overproduction and deposition of 
ECM eventually leads to fibrosis (DeLeve, 2015). Activation of HSCs is common in 
non-alcoholic fatty liver disease (NAFLD) which is also preceded by excessive fat 
accumulation in hepatocytes (steatosis and phospholipidosis). This process begins 
with simple steatosis leading to non-alcoholic steatohepatitis (NASH), and may 
further progress into cirrhosis and hepatocellular carcinoma in the absence of 
chronic alcohol intake (Ashtari et al., 2015, Angulo & Lindor, 2002, Bellentani et al., 
2010). The link between LSEC injury and NAFLD was established in a recent study 
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published by Miyao et al. (2015) using a choline-deficient, L-amino-acid defined and 
high diet fat mouse model of NAFLD. The authors showed that LSEC capillarisation 
occurs during the early stages of this disease followed by inflammatory cell infiltrate, 
fibrosis, cirrhosis, and hepatocellular carcinoma.  
 
1.3.3.6 LSECs in drug-induced liver injury 
There have been several reports identifying LSECs as targets of hepatotoxic drugs. 
Dimethyl nitrosamine (DMN) has been reported to cause LSEC necrosis (very often 
with localized haemorrhage) in the centrilobular zone (Wang et al., 2012a) which is 
posited to be caused by toxic metabolites that diffuse from the hepatocyte towards 
the sinusoidal space (Cattley & Cullen, 2013). DMN is also known to cause hepatic 
fibrosis (Wang et al., 2012b). Microcystin-LR, an algal toxin produced by Mycrocystis 
aeruginosa found in drinking water in some parts of the world (Wei et al., 2008, 
Mereish et al., 1991), causes rapid destruction of the LSECs. Reports have shown that 
LSEC injury is followed by damage to the hepatocyte cytoskeleton, which in turn 
leads to blebbing and rounding of the hepatocytes, and liver necrosis (Hooser et al., 
1991). In APAP toxicity, LSEC injury precedes hepatocellular injury as early as 30 
minutes after exposure (Holt et al., 2010), which might be due to both direct and 
indirect metabolism-dependent effects (DeLeve et al., 1997) and, in either case, leads 
to hepatic congestion in vivo. Swelling of the LSECs, gap formation, fenestral 
coalescence leading to red blood cell infiltration and accumulation into the space of 
Disse have been reported (McCuskey et al., 2005, Ito et al., 2003, Ito et al., 2004, 
Walker et al., 1983). The molecular mechanism of LSEC-specific cell death in APAP 
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toxicity has been described to be through TNF-related apoptotic-inducing ligand 
(TRAIL) activation (Badmann et al., 2012). Other drugs known to cause LSEC injury 
include antimycin A (Braet et al., 2003), diclofenac (Triebskorn et al., 2004), and small 
molecule tyrosine kinase inhibitors (Koudelkova et al., 2015). 
 
1.3.4 LSECs in organotypic co-culture systems 
 
In an attempt to recapitulate a liver-like organotypic system, in vitro 
pharmacological, toxicological and drug metabolism studies have increasingly 
incorporated non-parenchymal cells (NPCs) including LSECs. These efforts have been 
geared towards creating more in vivo-relevant experimental models to better mimic 
and predict biological processes and response to xenobiotics (reviewed in Handa et 
al. (2014), Godoy et al. (2013) and Bale et al. (2014). Furthermore, because cell-cell 
interactions and paracrine signalling between constituent cells is necessary for 
maintenance of liver physiology (Patel et al., 2012, Bhatia et al., 1999) and primary 
human hepatocytes de-differentiate when cultured in vitro (Heslop et al., 2016), 
attention has been paid to a multicellular co-culture system with the goal of 
enhancing hepatocellular function. Several options have been explored, including a 
sandwich configuration where hepatocytes are cultured with endothelial cells and/or 
other NPCs in different layers (Kim et al., 2012), a scaffold system (Kostadinova et al., 
2013), and a monolayer co-culture of  endothelial cells and hepatocytes (Nelson et 
al., 2015). In order to recreate the native environment of the liver, and enhance 
hepatic functionality, 3D co-cultures of hepatocytes and endothelial cells has been 
attempted using different methods and materials (Inamori et al., 2009, Takezawa et 
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al., 1992, Takebe et al., 2014, Miyamoto et al., 2015, Otsuka et al., 2013, Messner et 
al., 2013, Chan et al., 2016, Kang et al., 2015). These have been found to be more 
functional and more predictive of in vivo liver physiology compared to their 2D 
counterparts (reviewed in Achilli et al. (2012)). For example, Takebe et al. (2013) 
created vascularized 3D liver buds using induced pluripotent stem cells (iPSCs), 
human mesenchymal stem cells and human umbilical vein endothelial cells. These 
authors observed a self-organization into a 3D system with a highly vascularized 
organoid. Not only did they demonstrate an expression of albumin and CYP enzymes, 
these liver organoids metabolized CYP-specific substrates.  
A major shortcoming of these models developed so far is the fact that they are not 
made up exclusively of primary liver cells. Also, the endothelial cells included in these 
studies were neither microvascular nor were they of liver origin. Whereas LSECs are 
unique in their expression of phenotypes of both vascular endothelial and lymphatic 
endothelial cells (Sorensen et al., 2015, Rafii et al., 2016), they are better suited in 
multicellular organotypic hepatic models. Owing to the fact that primary human 
hepatocytes de-differentiate in culture and are not readily available/accessible 
coupled with the effect of inter-individual variability, alternative sources of 
hepatocyte or hepatocyte-like cells are desirable (Nelson et al., 2015). Using stem-
cell-derived hepatocytes and immortalized cell lines like HepaRG makes for easy 
accessibility, availability, and reproducibility (Marion et al., 2010, Du et al., 2014). 
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1.3.5 LSECs in the future of toxicity testing 
 
Being the first point of contact with xenobiotics, antigens, and other foreign particles 
in blood flowing into the liver, LSECs are equipped with a robust system that protects 
the liver against such harmful agents. A compromise to this system as described 
above results in injury to both the LSECs and ultimately the liver parenchyma, 
resulting in liver injury. A very important factor in the regulation and function of 
LSECs in the liver is growth factor signalling. VEGF, which specifically acts on 
endothelial cells, is also involved in their pathophysiology and in the survival of the 
liver from toxic insults by known hepatotoxins (Donahower et al., 2010b, Ding et al., 
2014, Ding et al., 2010a). These effects are known to be mediated via the activation 
of the VEGFR-2 which leads to a series of intracellular signalling cascades that results 
in cell survival, proliferation, and migration (Holmes et al., 2007). It is therefore 
plausible that inhibition of these pathways might partly explain why certain small 
molecule tyrosine kinase inhibitors have caused liver toxicity in cancer patients (Shah 
et al., 2013, Weng et al., 2015, Karczmarek-Borowska & Sałek-Zań, 2015). This 
hypothesis is yet to be to confirmed and reported in the literature. Equally, LSECs 
have been reported to selectively express VEGFR-3 which gives them a unique 
phenotype in comparison to vascular endothelial cells (Ding et al., 2010a). It would 
be informative to explore the physiological role of this receptor and its activation on 
LSECs. Finally, in view of the role of LSECs in liver physiology, building an organotypic 
in vitro model of drug-induced liver injury (DILI) should ideally include primary LSECs 
alongside freshly isolated primary hepatocytes and other liver cell types derived from 
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the same species.  The following section focusses on the regulation of endothelial cell 
physiology by means of the tyrosine kinases. 
 
 
1.4   TYROSINE KINASES IN ENDOTHELIAL 
CELL PHYSIOLOGY 
 
1.4.1 Tyrosine kinases 
 
Tyrosine kinases are a family of enzymes that catalyse the phosphorylation of 
tyrosine residues present on proteins (Nelson et al., 2008). Phosphorylation involves 
the transfer of the γ-phosphate group from a high-energy nucleoside phosphate 
donor such as adenosine triphosphate (ATP) to the hydroxyl group of the tyrosine 
residue on the target protein substrate, thereby effecting a functional change of the 
protein (Hubbard & Till, 2000, Nelson et al., 2008, Ségaliny et al., 2015). Tyrosine 
kinases can be broadly grouped into receptor and non-receptor tyrosine kinases 
(Krause  & Van Etten 2005, Hubbard & Till, 2000). Non-receptor tyrosine kinases 
(NRTKs) are cytoplasmic kinases which, after receiving signals originating from 
extracellular cues, phosphorylate tyrosine residues on intracellular proteins in order 
to modulate their functions (Paul & Mukhopadhyay, 2004, Wan et al., 2014, Gocek et 
al., 2014).  NRTKs can be grouped into nine distinct families, categorised on the basis 
of the similarity of their domain structure in relation to the catalytic Src Homology 1 
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(SH1), p-Tyr binding Src Homology 2 (SH2), and protein-protein interaction Src 
Homology 3 (SH3) domains which share a high degree of homology. This has been 
comprehensively reviewed by Gocek et al. (2014). They lack characteristic features of 
receptors tyrosine kinase which include an extracellular ligand-binding domain, a 
transmembrane and an intracellular portions, described below. Some NRTKs are 
attached to the plasma membrane via amino-terminal modifications such as 
palmitoylation (Hubbard & Till, 2000). In general, NRTKs are involved in diverse 
signalling processes including regulation of the immune system, cytoskeletal 
remodelling and oncogenesis (Paul & Mukhopadhyay, 2004). On the other hand, a 
receptor tyrosine kinase is a transmembrane glycoprotein that are activated 
following binding with its specific ligands (cytokines, growth factors etc). This results 
in the generation of an extracellular signal which is transduced to its cytoplasmic 
domain, resulting in the phosphorylation of specific tyrosine residues on themselves 
or other intracellular proteins, thereby setting up a cascade of signalling events that 
result in such cellular processes as cell proliferation, migration, differentiation, and 
survival (Schlessinger & Ullrich, 1992). Receptors tyrosine kinase (RTKs) are broadly 
divided into 20 distinct subfamilies, among which are epidermal growth factor 
receptor (EGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial 
growth factor receptor (VEGFR) families (Robinson et al., 2000). RTKs are made up of 
three main parts; an N-terminal extracellular domain, a transcellular domain and a C-
terminal intracellular domain (Ségaliny et al., 2015) (Figure 1.10). For example, 
VEGFR-2 is a dimer containing an N-terminal extracellular domain made up of 7 
immunoglobulin-like domains; domains II and III are responsible for ligand binding, 
such that after ligand binding and dimerization with another receptor, domain VII in 
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the two receptor monomers are held together to bring about stability of the receptor 
dimer (Ruch et al., 2007). More importantly, this process helps hold the intracellular 
kinase domain in order to effect autophosphorylation (Holmes et al., 2007). The 
intracellular part of VEGFR-2 consists mainly of kinase domains 1 and 2, between 
which there is a kinase insert domain. Then there is a C-terminal tail at the end of the 
receptor. 
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Phosphorylation of specific tyrosine residues on the receptor kinase domain initiates 
a series of events that brings about the recruitment of certain intracellular proteins; 
Figure 1.10: Structure of a human VEGFR-2 showing phosphorylation sites  
 
 
Receptor consists an extracellular N-terminal consisting a 7 Ig-like domains and an intracellular C-
terminal consisting of different phosphorylation sites. The Ig-like domains II and III are suited for 
ligand recognition and binding while the domain VII helps hold the two monomers together. The 
different phosphorylation sites are denoted by yellow dots showing the position of tyrosine along 
the amino acid sequence. The different tyrosine residues on the sequence have their specific roles 
and proteins they bind to in order to initiate a cascade of intracellular signalling with their cellular 
responses as shown in Figure 1.11 below. Source: Holmes et al. (2007) 
 
 
37 
 
this triggers the pathway that the recruited protein is associated with (Figure 1.12). 
In a general sense, for endothelial cells, this results in the main endothelial 
physiological responses namely survival, permeability, proliferation and migration; all 
of these contribute to formation or maintenance of vasculature. Meanwhile, the next 
section focusses on vascular endothelial growth factor receptor family. 
 
1.4.2 Vascular endothelial growth factor ligands and 
their receptors  
 
1.4.2.1 Vascular endothelial growth factors  
 
Vascular endothelial growth factors are a group of glycoproteins which act on three 
related receptors tyrosine kinase denoted vascular endothelial growth factor 
receptors (VEGFR) -1, -2, and -3. The VEGF ligands are generally called VEGF-A, VEGF-
B, VEGF-C, VEGF-D, placenta growth factor (PIGF) (Zhuang & Ferrara, 2015). These 
ligands bind and activate the different receptors in distinctive manners. VEGF-A is 
the main ligand involved in the regulation of development and growth of blood 
vessels (Ferrara et al., 2003). VEGF-A is required for physiologic angiogenesis during 
embryogenesis. The lack of a single vegf-a allele in mice has been shown to be 
embryonically lethal due to inability to form a functional vasculature (Carmeliet et 
al., 1996). On the other hand, there is an overexpression of this growth factor in 
inflammation and tumour, leading to angiogenesis—abnormal vascularisation arising 
from a pre-existing blood vessels (Chung et al., 2010). Splice variations of VEGF-A and 
how they affect specificity and catalytic properties of VEGF-A has been reviewed by 
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Ferrara et al. (2003),  Holmes et al. (2007) and Zhuang and Ferrara (2015).  VEGF-B, is 
a growth factor critical for endothelial cell survival (Zhang et al., 2009a) rather than 
angiogenesis (Li et al., 2009). It bears 88 % amino acid sequence homology to VEGF-A 
and selectively binds to VEGFR-1 for its action (Sun et al., 2006, Olofsson et al., 1998).  
Unlike VEGF-A, it does not play a critical role in vascular development. During 
embryogenesis, VEGF-B knockout mice manifest cardiac malformation (Aase et al., 
2001). VEGF-C and VEGF-D are ligands required for lymphangiogenesis and 
angiogenesis during embryonic development. Their angiogenic and lymphangiogenic 
effects are mediated via activation of VEGFR-2 and VEGFR-3 respectively (Joukov et 
al., 1996). A complete absence of VEGF-C is embryonically lethal as shown in a 
murine study (Karkkainen et al., 2004) while VEGF-D is not as critical (Baldwin et al., 
2005).  
 
1.4.2.2 Vascular endothelial growth factor receptor family 
 
All vascular endothelial growth factor receptors belong to the receptor tyrosine kinase 
family. They are generally subdivided into three groups comprising VEGFR-1, VEGFR-2 
and VEGFR-3. Just as described above, they all possess an N-terminal extracellular ligand 
recognition and binding domain, as well an intracellular C-terminal catalytic domain 
(Ségaliny et al., 2015). VEGFR-1 is a 151 KDa protein expressed on vascular endothelial 
cells, monocytes (Sawano et al., 2001), dendritic cells and haemopoietic stem cells 
(Dikov et al., 2005). While not essential for vascular development, VEGFR-1 is required 
for vascular organisation during embryonic development, as shown in a study with 
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vegfr-/- mice. Lethality was observed due to the inability of the endothelial cells to 
organise into functional vascular channels but they were excessive and disorganised 
(Fong et al., 1995). It has been suggested that, in the vascular endothelium, VEGFR-1 
might actually play a negative regulatory role in vascular development. Hiratsuka et al. 
(1998) deleted the kinase domain in the vegfr-1 in a mouse embryonic model without 
affecting the recognition and ligand binding extracellular domain. VEGF-A-induced 
macrophage migration was supressed. However, the mice survived and developed 
normal vasculature. This suggests that VEGFR-1 might be involved in reducing the sheer 
amount of VEGF-A available for binding with VEGFR-2 during vascular development in 
order to regulate angiogenesis; this is reasonable as it is has also been shown that 
VEGFR-1 has a higher binding affinity for VEGF-A than VEGFR-2 (Kendall & Thomas, 
1993).   VEGFR-1 might also play a role in liver regeneration as shown by LeCouter et al. 
(2003). VEGFR-2 is a 225 KDa receptor tyrosine kinase with binding affinity for VEGF-A, 
VEGF-C and VEGF-D (Figure 1.11). Unlike VEGFR-1, VEGFR-2 is a key element in 
embryonic vasculogenesis. Shalaby et al. (1995) have demonstrated lethality in vegfr-2-/- 
mice as early as day 8.5. This was due to a defective haematopoietic and vascular 
formation. VEGFR-2 signalling is responsible for most of the downstream effects that 
characterise VEGF-A and which drive vascular endothelial cell physiology. These will be 
discussed in the next section. It also worth noting that liver repair and regeneration 
secondary to partial hepatectomy or hepatotoxin exposure involves VEGF-A/ VEGFR-2 
signalling as already discussed above (section 1.3.2.6). VEGFR-3 is a 153 KDa monomeric 
RTK which can dimerise with itself, VEGFR-2 or neuropilin-2 (Zhuang & Ferrara, 2015). 
VEGFR-3 shows ligand affinity with VEGF-C and VEGF-D to effect lymphangiogenesis. It is 
expressed in lymphatic endothelial cells and fenestrated vascular endothelial cells such 
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as LSEC. Paavonen et al. (2000) and Dumont et al. (1998) have shown that a knockout of  
VEGFR-3 is embryonically lethal. Since VEGFR-3 has been shown to be crucial for 
lymphangiogenesis (Zhang et al., 2010) the physiological relevance of its presence on 
liver sinusoidal endothelial cells remains to be understood.   
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Figure 1.11: Ligand-binding specificities of different vascular endothelial growth factor receptors.    
 
Broadly, the VEGF receptors are divided into receptors -1, -2 and -3. VEGFR-1 is mainly located on haematopoietic stem cells, monocytes, microphages 
and vascular endothelium; ligand-binding specificity includes VEGF-A, VEGF-B and PLG mainly leading to cell migration during haematopoiesis, while it 
is involved in mediating vascular endothelium-specific cellular and physiological effects. VEGFR-2 is located on the vascular and lymphatic endothelia; 
while it mediates proliferation, migration, permeability and survival on the vascular endothelium resulting in vasculogenesis and angiogenesis, it is 
more suited to cell proliferation and migration in the lymphatic endothelium, resulting in vasculogenesis and lymphangiogenesis. Ligand specificity is 
shown in the schematic diagram. VEGFR-3 is exclusively found on lymphatic endothelium and some specialised vascular endothelium like the LSEC. 
Upon binding with VEGF-C or VEGF-D, VEGFR-3 mediates cell proliferation and migration leading to vasculogenesis and lymphangiogenesis in the 
lymphatic endothelium, while it promotes vasculogenesis and angiogenesis in the LSEC.   Source: Holmes et al. (2007) 
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1.4.3 Cellular effect of VEGF-induced VEGFR activation  
 
As briefly mentioned earlier, the cellular effect of stimulation of VEGFR-2 leads to cell 
migration, permeability and survival. The section that follows shows the signalling 
cascades that bring about these effects.   
1.4.3.1 Cell proliferation 
Activation of VEGFR-2 after VEGF-A binding stimulates cell proliferation via the 
RAS/RAF/ERK/MAPK pathway (Meadows et al., 2001). This takes place following 
phosphorylation of the Y1175 tyrosine residue which in turn phosphorylates PLCγ 
and a subsequent activation of PKC (Takahashi et al., 2001). This takes place when 
the phosphorylated PLCγ induces the hydrolysis of the membrane phospholipid 
phosphatidylinositol (4, 5)-bisphosphate (PIP2) which results in the generation of 
diacylglycerol (DAG) and inositol 1, 4, 5-trisphosphate (IP3). The latter—IP3— effects 
an increase in intracellular Ca2+ while DAG activates PKC which has been implicated 
in the regulation of VEGF-A mediated proliferation (Wellner et al., 1999). Activation 
of PKC causes an activation of protein kinase D (PKD) which has been reported to 
induce the translocation of histone deacetylases (HDACs) 5 and 7 into the nucleus 
(Ha et al., 2008, Wang et al., 2008). Both the activation of PKD and ERK ultimately 
lead to cell proliferation (Koch & Claesson-Welsh, 2012) (Figure 1.12).  
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Figure 1.12: Signal transduction following VEGFR-2 activation   
 
As a result of a complex series of intracellular signalling mediated by VEGF-A, -C and –D, VEGFR-2 is activated via tyrosine phosphorylation at intracellular resulting in 
the activation of different pathways that mediate different endothelial cell responses. These include cell proliferation, migration, survival and permeability, and are 
required for the formation and/ or maintenance of endothelial vascular structures.  Source: Koch and Claesson-Welsh (2012) 
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1.4.3.2 Cell migration 
 
In order for endothelial cells to form new vascular structure, they need to migrate in 
response to and towards the relevant stimulant (e.g. growth factor like VEGF-A) 
(Gerhardt & Betsholtz, 2005). This they do by migrating through basement 
membrane that has been previously degraded by proteases (e.g. matrix 
metalloproteinases; MMPs). As illustrated in Figure 1.12, quite a few tyrosine 
residues (e.g. Y951, Y1175, and Y1214) are phosphorylated to effect endothelial cell 
migration. For example, phosphorylated Y1175 binds to SHB in an SRC-dependent 
manner; and SHB further binds to focal adhesion kinase (FAK) (Holmqvist et al., 
2004). This process has been described in the regulation of cell migration and 
attachment (Parsons, 2003). Other intracellular proteins and pathways are illustrated 
in Figure 1.12 and have also been reviewed (Holmes et al., 2007, Lamalice et al., 
2007, Koch & Claesson-Welsh, 2012).       
 
1.4.3.3 Cell Survival 
 
Cell survival occurs following receptor activation and phosphorylation which in turn 
activates PI3K activation. This is accompanied by the generation of membrane-bound 
PIP3 which initiates the recruitment of PKB/AKT towards the membrane and its 
phosphorylation by phosphoinositide-dependent kinases 1 and 2 (PDK1 and PDK2). 
AKT phosphorylates BCL-2-associated death promoter (BAD) and caspase 9 in order 
to inhibit their apoptotic activity (Cantley, 2002, Cardone et al., 1998), which results 
in cell survival. Also, VEGF-A activation of VEGFR-2 induces the expression of BCL-2 
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and A1, inhibitors of apoptosis (IAP) and survivin, which block the activation of pro-
apoptotic proteins caspases 3 and 7 (Gerber et al., 1998, Deveraux et al., 1998, Li et 
al., 1998). 
 
1.4.3.4 Cell permeability 
 
In order to ensure neovascularisation or angiogenesis, VEGF-A induces endothelial 
cell permeability. The process that results in vascular permeability involves the 
formation of transcellular endothelial pores and the transient opening of the 
endothelial cell-cell junction (Bates & Harper, 2002, Garrido-Urbani et al., 2008). 
Endothelial nitric oxide synthase (eNOS), can give rise to production of nitric oxide 
(NO) which induces cell permeability due to VEGF-A exposure. Prior to this, eNOS can 
be activated either by PLC-induced Ca2+ influx or AKT-mediated phosphorylation 
which results in production of NO and the subsequent induction of cell permeability. 
Other factors that impact on cell permeability are the presence of tight junction and 
adherens junction proteins on endothelial cells (Dejana et al., 2008, Tornavaca et al., 
2015). Adherens junction are made up of proteins belonging to the cadherin family. 
An important member of this family is VE-cadherin which is located at endothelial 
cell-cell junction which is important for the formation new vasculature during 
angiogenesis. Its main function is in the maintenance of regulation of endothelial 
junction, while still enabling movement of molecules though the junction 
(Vestweber, 2008). On the other hand, the tight junctional proteins responsible for 
the formation of a tight barrier between endothelial cells are required for endothelial 
cell integrity (Tornavaca et al., 2015). The main protein involved in this is the zonas 
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occludins-1 (ZO-1). The molecular mechanism underlining its regulation of cell 
permeability has been reviewed by (Wallez & Huber, 2008).  
1.4.4 Tyrosine kinase inhibitors 
 
Tyrosine kinase inhibitors (TKIs) are a group of antineoplastic drugs that inhibit the 
growth and progression of cancer cells by interfering with specific pathways required 
for the growth and development of tumours (Krause  & Van Etten 2005). Unlike the 
mainstream cytotoxic drugs which are non-selective and are toxic to all rapidly-
dividing cells, TKIs are designed to be targeted towards specific molecules that are 
highly expressed in or mutated in tumour cells (Gharwan & Groninger, 2016).  A 
hallmark of cancer is angiogenesis (Hanahan & Weinberg, 2000) which is the 
formation and development of new vessels from extant vasculature (Bergers & 
Benjamin, 2003). Angiogenesis helps to provide nutrients and oxygen to tumours 
beyond 1-2 mm3 to help sustain proliferation and metastasis (Verheul et al., 2004). 
The vascular endothelial growth factor (VEGF) pathway is one crucial pathway 
required for angiogenesis and is the main target of antiangiogenic TKIs (Gotink & 
Verheul, 2010a) 
 
1.4.4.1 Mechanisms of action of tyrosine kinase inhibitors 
 
Receptor tyrosine kinase inhibitors are small molecules which act by competitively 
targeting the ATP-binding site of a kinase in the intracellular domain of the receptor 
tyrosine kinase (Gotink & Verheul, 2010a). In fact, some of them bear structural 
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similarity to the adenine ring of ATP which makes them act like antimetabolites 
which were among the first class of chemotherapeutic agents that interfere with 
cellular functions due to their structural similarity to endogenous molecules required 
for nucleic acid synthesis (Parker, 2009). An example is illustrated in Figure 1.13 
below.  
    
 
 
 
 
 
 
Tyrosine kinase inhibitors can act via different mechanisms, which includes binding 
to the ATP-binding site by means of hydrogen bond in a manner similar to ATP, 
thereby competing with ATP. Other TKIs indirectly compete with ATP by binding to 
the allosteric site directly adjacent to the ATP-binding site, thereby modulating a 
kinase activity in an allosteric manner, blocking phosphorylation of the receptor and 
no signal transduction (Wan et al., 2004). Some other TKIs can covalently bind with 
cysteine at specific sites on the kinase. This covalent binding takes place when 
electrons are shared between the electron-rich sulphur group of the cysteine residue 
 
Figure 1.13: Structural similarity between ATP and tyrosine kinase inhibitors.  
Structural similarity is one of the conditions that enhance the inhibitory activities of tyrosine kinase 
inhibitors. This, in part, enable them to form hydrogen bond with the kinase domain in a manner similar to 
ATP in order for them compete with it.   
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of the kinase and the electrophilic group in the TKI. This prevents the formation of 
hydrogen bonds required for ATP to bind to its site on the kinase, thereby leading to 
inhibition of kinase activation (Kwak et al., 2005). The mechanism of action of TKIs 
via competitive inhibition of the ATP-binding on the kinase domain has been 
comprehensively reviewed by Zhang et al. (2009b).  In terms of spectrum of activity 
and anti-kinase actions, small molecule TKIs target a number of kinases which are 
involved in different angiogenic and oncogenic pathways. For example, the TKIs 
discussed below target not only the angiogenic pathway. They also target pathways 
that enhance tumour growth, thereby effecting a ‘silver-bullet’ response in cancer 
chemotherapy. Also, in terms of the anti-angiogenic effect of TKIs, a drug that targets 
the activation of VEGFR, FGFR and PDGR also seem to be a good fit as it can affect 
key pathways that are involved in formation and stability of blood vessels.  
1.4.4.2 Tyrosine kinase inhibitors and liver toxicity 
 
As earlier noted, many TKIs target multiple pathways and in some cases these may 
be the unintended ones. While the primary target of anti-angiogenic TKIs are tumour 
vasculature, the pathways they inhibit are also required for the physiology of blood 
vessels both in the vascular bed where the tumours are situated and in other organ-
systems.  The inability of TKI to differentiate non-tumour-associated vasculature to 
vasculatures in tumours is a potential for drug toxicity (Widakowich et al., 2007, 
Gotink & Verheul, 2010a).  There have been reported cases of vascular disorders 
even in patients receiving non-antiangiogenic TKIs (Valent et al., 2015, Pasvolsky et 
al., 2015). Other effects reported for TKIs include cardiovascular, haematological, 
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gastrointestinal, dermatologic and hepatic toxicities, which could range from mild to 
fatal (Gharwan & Groninger, 2016). Hepatotoxicity has also been reported for this 
class of drugs. Imatinib, which targets BCL-Abl in chronic myelogenous leukaemia 
(CML) was discontinued as a result of hepatotoxicity owing to reports of severe 
cytolytic hepatitis with necrosis resulting in acute liver failure (Cross et al., 2006, 
Ohyashiki et al., 2002).  
 
1.5 DRUG-INDUCED LIVER INJURY AND 
HEPATOTOXIC DRUGS 
 
As indicated in the introduction of this chapter, most studies intended to understand 
the mechanisms of DILI have focussed primarily on the hepatocytes, being the main 
cell types of the liver, and being at the centre of most liver functions (LeCluyse et al., 
2012b). However, the fact that other cells – for example, LSEC – play critical roles in 
liver functions also suggest toxic events that affect their physiology might also 
contribute to DILI. This has been highlighted in section 1.3.3.6. As revealed in section 
1.4.4.2 above, DILI events might be due to on-target effect, wherein the toxicity is 
due to cellular interaction that affects the physiology of the cell. On the other hand, 
it might affect a target different from the intended one, resulting in toxicity. In some 
cases, toxicity might arise from the physicochemical property of the xenobiotic 
thereby impacting on cellular components or processes (Rudmann, 2013).  As earlier 
noted, hepatotoxicity has been reportedly responsible for the withdrawal of drugs 
during development. In addition, some drugs were withdrawn during post-marketing 
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surveillance. There are some other drugs currently in clinical use which cause toxicity 
in selected population, or those that are toxic due to repeated use, over-dosage or as 
a result of metabolic bio-activation.  
1.5.2 Adverse reactions – types and classification 
The description of drug toxicities described above fits well with the well-documented 
classification of adverse drug reactions (ADRs) which can be grouped as types A, B, C , 
D, E and F as reported by Edwards and Aronson (2000). Class A ADRs are dose-
related and somewhat on-target. Toxic effects can be abrogated with withdrawal of 
the drug. Examples include cardiac glycosides like digoxin. Class B ADRs are non-
dose-related and are characteristic of idiosyncratic and immunological reactions as 
reported for β-lactam antibiotics (Amali et al., 2016) and which could lead to organ 
damage (Meng et al., 2016). Class C ADRs are dose-related and time-related. Toxicity 
results from chronic exposure to the drug of interest. Examples include 
hypothalamic-pituitary-adrenal axis suppression by corticosteroids. Class D ADRs are 
the uncommon types which are often delayed and uncommon, characteristic of 
carcinogenic drugs. Class E ADRs are also uncommon and often occur as a result of 
withdrawal of treatment as in myocardial ischaemia due to withdrawal of β-
adrenergic blockers. Finally, Class F ADRs occur as a result of failure of drug therapy. 
This is common with drug-drug interaction and often dose-related. It can be reversed 
with dosage increase.  The next subsection focuses on drugs of different therapeutic 
classes and varied mechanisms of DILI. Attention is paid to anti-angiogenic small 
molecule tyrosine kinase inhibitors which have been reported to induce liver toxicity, 
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which may also have potential for LSEC toxicity. Also, other drugs – clinically used or 
withdrawn due to adverse drug reactions – will be briefly reviewed. 
 
1.5.1 Small molecule tyrosine kinase inhibitors 
 
1.5.1.1 Regorafenib 
 
Regorafenib (Stivarga®) is a multikinase inhibitor which targets oncogenic, 
angiogenic, and stromal receptors tyrosine kinase (Wilhelm et al., 2011). It has been 
registered in the United States of America for the treatment of metastatic colorectal 
cancer and non-surgically removable advanced gastrointestinal stromal tumour 
(Strumberg et al., 2012, FDA, 2013) 
 
 
 
 
 
Regorafenib inhibits the activation of VEGFR -1, -2 and -3, PDGFR-β, FGFR and tie-2 
(Wilhelm et al., 2011, Waddell & Cunningham). Accordingly, it has been 
experimentally proven to be a potent inhibitor of VEGFR-2 and -3 mediated auto-
phosphorylation, migration and intracellular signalling in human umbilical vascular 
Figure 1.14: Regorafenib 
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and lymphatic endothelial cells, and has been effective in blocking the proliferation 
of a metastatic colorectal cancer liver metastasis model (Schmieder et al., 2014b).  
Regorafenib is metabolised by CYP3A4 to N-oxide and demethylated N-oxide 
derivatives that have been claimed to have similar molecular targets and potency as 
the parental compound (Zopf et al., 2014). However, regorafenib has been 
associated with elevated liver transaminases, bilirubin and fatalities secondary to 
liver damage (Grothey et al., 2013, Demetri et al., 2013, Sacre et al., 2016). In fact, 
there was a clinical case of sinusoidal obstruction syndrome in a patient managed 
with regorafenib (Takahashi et al., 2016a) 
 
1.5.1.2 Pazopanib 
Pazopanib (Votrient®) is a multi-targeted TKI which targets VEGFR -1, -2 and -3, 
PDGFR and c-kit (Kumar et al., 2009). It has demonstrated efficacy against renal cell 
carcinoma, lung and breast cancer, soft tissue sarcoma and pancreatic 
neuroendocrine tumours (Sloan & Scheinfeld, 2008, Motzer  et al., 2013, 
Figure 1.15: Pazopanib 
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Kwekkeboom, 2015). In a preclinical study, Kumar et al. (2005) demonstrated that 
pazopanib could inhibit VEGF-A-induced cell proliferation in HUVEC as well as inhibit 
tumour growth in a murine model. In addition to inhibiting cell proliferation and tube 
formation in HUVEC, Podar et al. (2006) have demonstrated the efficacy of pazopanib 
in growth inhibition and induction of apoptosis in a multiple myeloma model. 
Pazopanib also prolonged survival of a xenograft model of this cancer. Pazopanib is 
orally absorbed, metabolised mainly by CYP3A4 with minimal contributions from 
CYPs 1A2 and -2C8 (Deng et al., 2013). Like regorafenib, pazopanib has been 
associated with increased levels of transaminases during clinical trials (Zivi et al., 
2012, Kapadia et al., 2013, Phan et al., 2015). 
 
1.5.1.3 Axitinib 
 
Axitinib (Inlyta®) is another anti-angiogenic multi-targeted small molecule TKI with 
potency against VEGFR-1, -2 and -3 as well as PDGFR and c-kit (Inai et al., 2004). It 
has been approved for the treatment of renal cancer carcinoma and has 
demonstrated clinical efficacy in advanced pancreatic cancer in combination with 
gemcitabine (Spano et al., 2008). It has also been used in the treatment of advanced 
thyroid cancer (Cohen et al., 2008). Like regorafenib and pazopanib above, axitinib 
possesses the ability to inhibit both cancer cells and the growth of their vasculature. 
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For example, in a study reported by Zhu et al. (2006), axitinib was shown to inhibit 
PDGR-β and VEGFR-2 phosphorylation with a corresponding reduction in inhibition of 
vasculature formation. Also, they demonstrated its ability to induce a regression of a 
human bladder cancer xenograft. In a sensitivity testing of patient-derived cancer 
cells, axitinib induced an inhibition of BCR-ABL 1 fusion gene, an oncogene implicated 
in chronic myeloid leukaemia and acute lymphoblastic leukaemia (Pemovska et al., 
2015). Axitinib is metabolised by CYP3A4/5 and UGT1A1 to form a sulphoxide 
derivative and a glucuronide conjugate respectively; neither of these is 
pharmacologically active (Chen et al., 2013, Smith et al., 2014). During clinical trials, 
there have been reported cases of elevated serum transaminases in a quarter of 
patients (Rini et al., 2013) with only less than 5 % having alanine transaminase (ALT) 
and aspartate transaminase (AST) values greater than 5 times the upper limit of 
normal. However, there have been no instances of liver failure or fatality induced by 
liver injury reported (Shah et al., 2013).  
 
Figure 1.16: Axitinib 
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1.5.1.4 Sunitinib 
Sunitinib is a TKI approved for the treatment of renal cell carcinoma and imatinib-
resistant gastrointestinal carcinoma (Demetri et al., 2006). It has also shown efficacy 
against breast, lung and colon cancers (Mena et al., 2010) Sunitinib blocks the 
phosphorylation of VEGFR-1, -2, and -3 (Christensen, 2007).  Osusky et al. (2004) 
have shown the efficacy of sunitinib in the inhibition of cell migration and tube 
formation in an in vitro assay, while Abrams et al. (2003) demonstrated its inhibitory 
activity against the activation of c-kit and PDGFR.  Sunitinib was shown to display 
anticancer activity against a range of tumours in xenograft studies (Mendel et al., 
2003). Sunitinib is metabolised mainly via cytochrome P450-mediated routes; 
inducing N-de-ethylation and N-oxidation of the indolylidene and dimethylpyrrole 
groups on the molecule (Speed et al., 2012).  Sunitinib had been associated with 
fulminant hepatic failure—elevated AST, ALT and bilirubin—which was managed and 
reversed in the case of a patient being treated for renal cell carcinoma with sunitinib 
(Mueller et al., 2008)   
Figure 1.17: Sunitinib 
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1.5.2 Other hepatotoxic compounds 
 
1.5.2.1 Paracetamol 
 
Paracetamol (acetaminophen) is a widely used analgesic, anti-pyretic drug, 
discovered over a century ago but extensively for used some 50 years. Despite its 
widespread clinical use, its mechanism of action remains an enigma. Compared to 
non-steroidal anti-inflammatory drugs, the safety profile of paracetamol, explains 
why it is an extensively used over-the-counter medication. However, in the 
biomedical research community, paracetamol is rather infamous for its liver toxicity 
as clinical and experimental research data have shown. In fact, paracetamol is at the 
fore-front of acute liver failure in such western nations as Great Britain (40 %) 
(Hawton et al., 2013) and the United States (45%) (Larson et al., 2005) as a result of 
its overdosage or chronic use.  
 
 
 
 
 
Briefly, paracetamol has been commonly known to cause toxicity in high doses as a 
result of a rapid depletion of hepatic glutathione. Also, the detoxification pathways 
 Figure 1.18: Paracetamol 
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involving glucuronidation and sulphation are overwhelmed. This shifts metabolism to 
cytochrome P450 pathways— principally CYP 2E1—which results in the generation of 
a toxic and highly reactive nucleophilic metabolite N-acetyl-p-benzoquinone imine 
(NAPQI) (Figure 1.19) (Dahlin et al., 1984).   NAPQI covalently binds with cellular 
proteins, notably on the cysteine residue; this NAPQI-protein adduct can be highly 
immunogenic (Roberts et al., 1991). Following hepatocyte lysis, these adducts are 
released into circulation and can be measured (Roberts et al., 2016). Also, depletion 
of glutathione, an antioxidant tripeptide, readily predisposes the liver to oxidative 
stress and further production of other free radicals that might progressively cause 
lipid peroxidation, and hepatocellular damage (Muriel, 2009). This explains why 
sylimarin—a naturally-occurring antioxidant flavonoid—has been used as an 
adjunctive measure in paracetamol toxicity (Feher & Lengyel, 2012). The hepatic 
effect of paracetamol is not restricted to the hepatocyte as has already been 
reviewed (Section 1.3.3.6). In fact, LSEC have been found to be early targets of 
paracetamol toxicity (McCuskey, 2006). Also, in a murine model of paracetamol 
toxicity, increased serum levels of VEGF-A were detected, whereas an intraperitoneal 
administration of recombinant VEGF-A effected a significant reduction in 
paracetamol-induced hepatic necrosis (Donahower et al., 2006, Donahower et al., 
2010a). Since VEGF-A is involved in the pathophysiology of endothelial cells, LSEC is 
evidently a target of paracetamol and other hepatic toxicant.       
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Figure 1.19: metabolism of paracetamol 
Paracetamol is metabolised via the bioactivation route denoted in red colour and deactivated via 
the glucuronidation route denotes in blue. Paracetamol is metabolised principally by CYP2E1 and 
proceeds via N-hydroxylation to form NAPQI which is highly nucleophilic and highly reactive; it 
forms a conjugate with glutathione. On the other hand, paracetamol can be concomitantly 
glucuronidated or sulphated to render the parent compound more hydrophilic and extractable.    
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1.5.2.2 Benzbromarone 
 
Benzbromarone is a uricosuric drug developed four decades ago and widely used in 
gout patients (Lee et al., 2008). In gout or hyperuricaemia, there is an impairment in 
the excretion of uric acid whereby uric acid is reabsorbed into systemic circulation, 
mainly via urate transporter 1 (URAT1) (Ichida et al., 2004). 
 
 
 
 
 
 
This results in a high plasma concentration of uric acid which gets deposited as 
crystals in the joints, kidneys and soft tissues (Daskalopoulou et al., 2005, Eggebeen, 
2007). Uricosuric — or antihyperuricaemic— drugs including benzbromarone largely 
act on the proximal tubules in the kidney to inhibit the reabsorption of uric acid, 
thereby enhancing its renal excretion (Becker et al., 2005). The angiotensin II 
inhibitor losartan blocks URAT1 (Hamada et al., 2008).  Benzbromarone can be 
classed as a prodrug as the parental compound has a half-life of 3 hours, while its 6-
hydroxy metabolite is the main uricosuric agent (Lee et al., 2008). Despite its potent 
 
Figure 1.20: Benzbromarone 
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anti-gout activity and high clinical tolerability, benzbromarone was withdrawn from 
Europe in 2003 following four cases of hepatotoxicity which culminated in the death 
of two patients (Jansen et al., 2004). The likely mechanism of benzbromarone toxicity 
has been elucidated by McDonald and Rettie (2007) after incubation of a pool of 
human liver microsomes from 13 different liver samples with benzbromarone.  They 
found out that benzbromarone is sequentially metabolised by CYP2C9 to 6-
hydroxybenzbromarone which is further metabolised to a 5, 6-
dihydroxybenzbromarone—a catechol. Incubation of this product with human liver 
microsomes in the presence of glutathione formed a glutathione adduct. The two 
hydroxyl groups on the catechol were likely oxidised to form a quinone intermediate 
which is highly reactive, and which could have adducted with other cellular proteins 
(Figure 1.21).  Prior to this study, Kaufmann et al. (2005) have shown the production 
of reactive oxygen species in HepG2 cells incubated with benzbromarone. Further, 
this study demonstrated mitochondrial toxicity, apoptosis and necrosis in rat liver 
treated with benzbromarone. It has also been shown in a study also involving HepG2 
that benzbromarone is an uncoupler of the electron transport chain; it is also 
mitotoxic (Felser et al., 2014).   
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Figure 1.21: metabolism and bioactivation of benzbromarone 
Benzbromarone (BBR) is metabolised by CYP2C9 to 6-hydrxybenzbromarone (6-OH BBR) which is further hydroxylated to a dihydroxy product (5,6-OH BBR or 6,7-OH 
BBR). The OH groups of either of these products can be oxidised to form a quinone which is highly reactive and can covalently bind with cellular protein or nucleic acid 
and might deplete cellular glutathione.    Adapted from McDonald and Rettie (2007) 
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1.5.2.3 Desipramine 
 
Desipramine (Norpramin®) is a tricyclic antidepressant which is formed by N-
demethylation of imipramine—another tricyclic antidepressant (Linnet, 2004, 
Lemoine et al., 1993). It mainly acts by inhibiting the reuptake of 
noradrenaline and serotonin (5-hydroxytryptamine) from the post synaptic 
neuron in the brain, thereby prolonging the central excitatory effect of 
noradrenaline and/ or serotonin. In addition, desipramine has been shown to 
have affinity for and can activate the δ- and κ-opioid receptors in the basal 
ganglia and neocortical regions of the brain (Peppin & Raffa, 2015), implicating 
its reported  antinociceptive properties (Onali et al., 2009). It is interesting to 
note that opiates like tramadol have been considered as antidepressants due 
to the fact that activation of  the δ- and κ-opioid receptors enhance mood 
(Berrocoso et al., 2009). 
 
 
 
 
 
 
Figure 1.22: Desipramine 
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Desipramine is a potent inhibitor of CYP2D6 which coincidentally metabolises 
it (Hara et al., 2005, Shin et al., 2002, Reese et al., 2008). This is a potential for 
interaction with drugs that are metabolised by this enzyme. The first case of 
liver toxicity in desipramine was reported by Powell et al. (1968) who 
observed midzonal and central hepatic necrosis in a patient post-mortem. 
Later, another case hepatitis was reported (PRICE et al., 1983). There is paucity 
of data on the exact mechanism of desipramine-induced liver toxicity. Its 
inclusion in this study was to investigate its toxicity in LSEC in comparison with 
primary human hepatocyte and other endothelial cell types. 
 
1.5.2.4 Perhexiline 
 
Perhexiline (Pexsig®) is an antianginal drug developed about half a century ago 
(Ashrafian et al., 2007).  Angina pectoris occurs when myocardial oxygen 
supply does not meet requirement at a given point in time due to physical 
exertion among other factors. In most cases, this arises from myodardial 
ischaemia due to a reduction in blood flow to the heart, reduced oxygen-
carrying capacity of the blood or reduction in vascular tone of cardiac arteries 
(Hung et al., 2014).  This results in chest pain in patients. Perhexiline is a highly 
hydrophobic molecule with pharmaceutical preparations existing as a racemic 
mixture of the (+) and (-) enantiomers (Davies et al., 2007). Biochemically, 
perhexiline is a fatty acid oxidation inhibitor owing to its ability to inhibit the 
metabolism of fatty acid in the myocardium. Specifically, perhexiline is a 
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potent competitive inhibitor of carnitine palmitoyltransferase-1 (CPT-1) in the 
myocardium. (Kennedy et al., 1996).  
 
 
 
 
 
 
 
 
This is to improve efficiency as fatty acids consume more oxygen per unit of 
ATP generated in the mitochondrion. Inhibition of fatty acid oxidation switches 
myocardial energy generation to carbohydrate metabolism which consumes 
less oxygen. The 30 % increase in oxygen production improves the symptoms 
of angina (Essop & Opie, 2004, Ashrafian et al., 2007). However, perhexiline is 
hepatotoxic in a selected population; its toxicity is linked to its metabolism. 
Perhexiline is metabolised by CYP2D6 which is highly polymorphic (Sørensen et 
al., 2003, Gardiner & Begg, 2006). The link between metabolism and toxicity of 
perhexiline will be discussed in chapter 5.     
 
 
Figure 1.23: Perhexiline 
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1.5.2.5 Aflatoxin 
 
Aflatoxin belongs to a class of toxic and carcinogenic chemicals derived from 
mold of the Aspergillus family, which grows on eggs, milk, meat, grains, 
decaying vegetation and in the soil (Baydar et al., 2005). Aflatoxin B1 is of 
interest in this study due its reported liver toxicity (Neal et al., 1998, Hamid et 
al., 2013). Aflatoxin B1 is metabolised by CYP3A4 to form several products, 
one of which is an 8, 9-epoxide. This product is highly reactive and has 
hepatocarcinogenic potential (Guengerich et al., 1996, Ramsdell et al., 1991).  
 
 
 
Figure 1.24: Aflatoxin B1 
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The table below is a summary of the drugs reviewed in the sections above 
Table 1.3: Summary of drugs 
Test Compound Pharmacological 
class 
Therapeutic 
dose 
Plasma 
Cmax 
Molecular target Mechanism of liver toxicity 
Paracetamol Analgesic, 
antipyretic  
1 g oral dose, 
maximum of 4 
times daily 
20 µg/ml unknown Mitochondrial toxicity, metabolic 
bioactivation, cytolysis, lipid peroxidation 
etc 
Benzbromarone Uricosuric 50-200 mg oral 
daily dose 
3.51 
µg/ml 
Inhibition of 
urate transporter 
(URAT1), and 
xanthine oxidase. 
Mitochondrial toxicity, metabolic 
bioactivation and covalent binding with 
cellular proteins etc. 
Desipramine Tricyclic 
antidepressant 
25-300 
mg/day oral 
11.8 ng/ 
ml (after 
50 mg oral 
dose) 
Inhibition of 
reuptake of 
noradrenaline 
and serotonin  
Not characterised but may be due to 
inhibition of CYP 2D6 which also 
metabolises it. 
Perhexiline Antianginal 100- 500 mg 
oral daily 
0.6 mg/l Inhibition of fatty 
acid oxidation 
(inhibition of 
palmitoyltransfer
ase-1 inhibition). 
Mitochondrial toxicity—uncoupling of 
complexes I and II of oxidative 
phosphorylation. 
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Aflatoxin Food 
contaminant 
Not applicable Not 
applicable  
DNA adduction Metabolic bioactivation to epoxides 
which are carcinogenic by adduction to 
DNA. 
Regorafenib Tyrosine kinase 
inhibitor 
antiangiogenic, 
antocancer. 
160 mg 2.5 µg/ml Inhibits VEGFR-1, 
-2 and -3. PDGFR-
β, FGFR and Tie-2 
Uncharacterised. May be on-target, 
following inhibition of signalling 
pathways implicated in cell physiology. 
Pazopanib Tyrosine kinase 
inhibitor 
antiangiogenic. 
200-800 mg 
daily 
58.1 
µg/ml  
Inhibits VEGFR-1, 
-2 and -3. PDGFR-
β, and c-kit. 
Uncharacterised. May be on-target, 
following inhibition of signalling 
pathways implicated in cell physiology 
Axitinib Tyrosine kinase 
inhibitor 
antiangiogenic, 
anticancer. 
10 mg  27.8 ng/ml Inhibits VEGFR-1, 
-2 and -3. PDGFR-
β, and c-kit. 
Uncharacterised. May be on-target, 
following inhibition of signalling 
pathways implicated in cell physiology 
Sunitinib Tyrosine kinase 
inhibitor 
antiangiogenic, 
anticancer. 
37.5 mg daily 69 ng/ml Inhibits VEGFR-1, 
-2 and -3. PDGFR-
β and c-kit,  
Uncharacterised. May be on-target, 
following inhibition of signalling 
pathways implicated in cell physiology 
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1.6 AIMS OF THESIS  
 
This project was conceptualised following reports that paracetamol overdose 
in rats induced elevation of VEGF-A and that an exogenous administration of 
VEGF-A to paracetamol-intoxicated mice resulted in improved liver physiology 
(Donahower et al., 2010a, Donahower et al., 2006). Further, liver sinusoidal 
endothelial cells were damaged in paracetamol toxicity, even prior to 
hepatocyte damage (Walker et al., 1983, Ito et al., 2003, Ito et al., 2004, 
McCuskey et al., 2005). Other studies have demonstrated that liver sinusoidal 
endothelial cells were integrally involved in liver regeneration following partial 
hepatectomy and toxic injury (Ding et al., 2010b, Ding et al., 2014). Finally, 
some antiangiogenic receptor tyrosine kinase inhibitors are hepatotoxic (Shah 
et al., 2013) 
Consequently, this thesis is aimed at; 
1. Characterising human liver sinusoidal endothelial cells (HLSECs) and 
evaluating their phenotypic and functional difference to vascular and 
lymphatic endothelial cells from a different vascular bed.  
2. Examining the sensitivity of LSEC to a broad range of hepatotoxic drugs 
with focus on small molecule receptor tyrosine kinase inhibitors. 
3. Developing a triculture liver micro-tissue model in order to test the 
effect of liver sinusoidal endothelial cells on the physiology of the 
hepatocyte. 
69 
 
 
The main hypotheses of the thesis are: 
1. Liver sinusoidal endothelial cells are a unique endothelial cell 
population with phenotypes that better suit them to their liver micro 
environment; 
2. Liver sinusoidal endothelial cells are direct targets of hepatotoxins. 
3. There is a direct link between the toxicity of small-molecule receptor 
tyrosine kinase inhibitors and their inhibition of physiology of liver 
sinusoidal endothelial cells. 
4. Inclusion of liver sinusoidal endothelial cells in a tri-culture liver micro-
tissue, helps retain the physiology of hepatocytes which de-
differentiate in culture. 
5. Presence of liver sinusoidal endothelial cells in liver micro-tissues 
protect the hepatocyte from hepatotoxicity, especially in the presence 
of VEGF-A and/ or VEGF-C.     
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CHAPTER TWO 
 
 
 
 
MATERIALS AND METHODS 
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2.1 MATERIALS AND REAGENTS 
 
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich, 
(MO, USA). 
2.1.1 Reagents and buffers 
 
Fibronectin from human plasma (F0895), Collagenase type IV (C5138), 
Dexamethasone (D1756-100MG),  Paracetamol (A7085), Collagen-I coated 
plates (Corning, 356400), Sterile water (Kays Medical,  WAT230S), Williams E 
medium(W1878-6X500ML),  L-glutamine (G7513-100ML),  Pen/strep (P0781-
100ML), Insulin-Transferrin-Selenium (Life Technology, 41400045),  Calcium 
Chloride (Fisher Scientific,  10171800), Dimethyl sulfoxide (DMSO) (Fisher 
Scientific,  10080110), D-Glucose (Fisher Scientific, 10141520), HEPES (H3375-
100G), Potassium Chloride  (Fisher Scientific, 10375810), Sodium Chloride 
(1Kg) (Fisher Scientific, 10428420), Human collagen solution (Vitrocol® 
Advanced BioMatrix, 5007-A), Sodium chloride, Tris base, Glycine, 
polyoxyethylenesorbitan monolaurate (Tween-20), Sodium dodecyl sulfate 
(SDS), were purchased from Fisher Scientific. Ammonium persulfate (APS), 
ammonium chloride, Triton X-100, ethidium bromide, Tris-EDTA (TE) buffer 
solution (pH8.0), Dimethyl sulfoxide (DMSO). Dulbecco’s Phosphate-Buffered 
Saline (PBS) without Ca2+ and Mg2+ (BE17-212F, Lonza, Switzerland), 
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Dulbecco’s Phosphate-Buffered Saline (PBS) with Ca2+ and Mg2+ (17-513F, 
Lonza, Switzerland). 0.5% (w/v) Gelatin solution containing 0.1% (w/v) gelatin 
from porcine skin, (type A, cell culture tested) (Sigma-Aldrich (Poole, UK) in 
ddH2O and autoclaved. Acetonitrile (MeCN)(Thermofisher, 10616653, LC-MS 
grade), Formic Acid (FA) (Sigma-Aldrich, 56302, LC-MS grade), Water (H2O) 
(Thermofisher, 10777404, LC-MS grade), Dimethylsulphoxide (DMSO), (Sigma-
Aldrich, D8418, MOL BIO grade), Acetic Acid (AcOH), (Sigma-Aldrich, 49199, 
LC-MS grade), Acetone (ACE), (Thermofisher, 10131560, HPLC grade), 
Methanol (MeOH), (Thermofisher, 10653963, LC-MS grade).  
 
2.1.2 Growth factors 
 
 SDF-1, VEGF-A165, VEGF-C, VEGF-D, FGF-2, PDGF-BB, EGF, and HGF were 
purchased from Peprotech EC (Rocky Hill, NJ, U.S.A).  
2.1.3 Test Compounds and compounds for LC-
MS/MS   
 
Sunitinib maleate (S1042), lapatinib GW-572016 (S2111), and staurosporine 
(S1421) were purchased from Selleckchem (U.S.A). Cytochalasin D (1233) was 
purchased from R&D systems. Aflatoxin-B1 (A6636-1MG), Benzbromarone 
(B5774-1G), Desipramine-HCL (D3900-1G). Fluconazole (F8929, SIGMA-
ALDRICH), D4-Fluconazole (F421002, Toronto Research Chemicals), Perhexiline 
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Maleate (FP27567, CARBOSYNTH), Perhexiline-d11 Maleate, (Mixture of 
Diastereomers), (P287322, Toronto Research Chemicals), cis-Hydroxy 
Perhexiline (H948905, (Mixture of Diastereomers), Toronto Research 
Chemicals 
trans-Hydroxy Perhexiline(Mixture of Diastereomers) (H948910, Toronto 
Research Chemicals), cis-Hydroxy Perhexiline-d11(Mixture of Diastereomers) 
(H948907, Toronto Research Chemicals) 
 
 
2.1.4 Protein extraction and Western blot kits 
 
Bicinchoninic acid solution, copper (II) sulfate solution, Aprotinin, leupeptin, 
pepstatin, phenylmethylsulfonyl fluoride (PMSF), sodium orthovanadate 
(Na3VO4), paraformaldehyde, 2-mercaptoethanol, Nu-PAGE® 4-12% Bis-Tris 
gels, 1.5mm cassettes, 4X lithium dodecyl sulfate (LDS) sample buffer, Full-
range rainbow molecular weight marker (12-225kDa), Hybond® ECL® 
nitrocellulose membrane, enhanced chemiluminescence (ECL) were purchased 
from GE healthcare (Amersham, U.K). Agarose (electrophoresis grade), 
NuPAGE® MES SDS Running Buffer (20X) (ThermoFisher Scientific). 
2.1.5 RNA extraction, cDNA synthesis and real-
time PCR kit 
 
RNeasy RNA extraction kit (74106), sterile RNase and DNase free water, 
fibrous tissue RNA extraction kit (7404), DNase I, were purchased from Qiagen 
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Sciences (MD, USA).Oligo dT (Life technologies), dNTP mix (10 mM), 5X first 
strand buffer, DTT (0.1 M), of RNaseOUT (40 unit/ µl), M-MLV reverse 
transcriptase (200 units/µl) were purchased form Invitrogen, (Canada). 96 well 
semi-skirted PCR plates, 384 well PCR plates, clear polypropylene sealing film 
for PCR were purchased from Starlab, UK.  96-well Ultra-Low Attachment Plate 
(7007, Corning Life Sciences, UK). DreamTaq Green PCR Master Mix (2X) 
[Thermo Scientific. #K1081] 
 
2.1.6 Animal sera  
 
Goat serum (005-000-121) and donkey serum (017-000-121) were purchased 
from Jackson ImmunoResearch Laboratories (USA),  
 
2.1.7 Human liver sinusoidal endothelial cell 
isolation and culture kit 
 
PERCOLL (170891-01, GE Health Care, Buckinghamshire, UK), Mouse 
Monoclonal EP-CAM antibody (HEA 125) (61004, Progen Biotechnik GmbH, 
Heidelberg, Germany), Goat anti-Mouse IgG Dynabeads. (11033, Life 
Technologies LTD, UK), Mouse antihuman Dynabeads® CD31 Endothelial Cell. 
(11155D, Life Technologies LTD, UK), Pooled Human AB Serum (IPLA-SERAB, 
Innovative Research, Inc, Michigan, USA), TrypLE™ Express Enzyme (12605-
010, Life Technologies LTD, UK.) 
 
75 
 
 
2.1.8 Cell culture media   
 
Endothelial full growth medium: Endothelial Cell Basal Medium MV2 C-22221 
(PromoCell, Heidelberg, Germany)  supplemented with Foetal calf serum (5 %), 
Epidermal growth factor (recombinant human) 5 ng/ml, Basic fibroblast 
growth factor-A (recombinant human) 10 ng/ml, Insulin-like growth factor 
(long R3 IGF) 20 ng/ml, Vascular endothelial growth factor 165 (recombinant 
human) 0.5 ng/ml, Ascorbic acid 1 g/ml, Hydrocortisone 0.2 g/ml. 
Fibroblast Full growth media: Fibroblast Basal Medium 3 C-23230 (PromoCell 
Heidelberg, Germany) supplemented with Foetal calf serum 0.1 ml/ml, 
fibroblast growth factor (recombinant human) 1 ng/ml, Insulin (recombinant 
human 5 g/ml). DMEM Full growth media: Dulbecco’s Modified Eagle’s 
Medium – High Glucose (DMEM) D6429 Sigma-Aldrich (Poole, U.K), 
supplemented with Glucose, L-glutamine, Sodium pyruvate, Sodium 
bicarbonate 4500 mg/L, Fetal calf serum 0.1 ml/ml. Low serum endothelial 
cell medium: Endothelial Cell Basal Medium MV2 C-22221 (PromoCell, 
Heidelberg, Germany) supplemented with foetal bovine serum (1 %). HLSEC 
medium: Human endothelial SFM (Invitrogen, UK) supplemented with 10% 
(v/v) heat-inactivated human serum [Human Serum, Innovative Research Inc.], 
60 μg/ml benzyl penicillin, 100 μg/ml streptomycin and [all from Sigma, UK] 
and 10 ng/ml of vascular endothelial growth factor (VEGF) and hepatocyte 
growth factor (HGF) [both from Peprotech, UK]). ScienCell HLSEC Medium: 
Endothelial cell medium (1001, ScienCell Research Laboratory (Carlsbad, 
USA)), FBS (10%), penicillin-Streptomicin (1%), Endothelial cell growth 
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supplement (1%). Upcyte HLSEC Medium: Endothelial basal medium (ML 
5003, Upcyte Technology GmbH, Hamburg, Germany), FBS (10 %), HGF, VEGF-
A. Primary Human hepatocyte complete medium: Williams E medium 
supplemented with 1 % insulin–transferrin–selenium [Life Technologies, 
Carlsbad, CA], 2 mM L-glutamine [Sigma-Aldrich, St. Louis, MO], 10−7 M 
dexamethasone and penicillin [100 units/ml] /streptomycin [100 µg/ml] 
[Sigma-Aldrich, St. Louis, MO]). 
2.1.9 Other reagents 
 
Hoechst 33342 purchased from Molecular Probes Europe BV (Leiden, The 
Netherlands). Prolong gold anti-fade reagent purchased from Life 
Technologies (Paisley, U.K). 
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Table 2.1: Primary antibodies 
Antibody Vendor Catalogue # Dilution 
Factor 
Application 
R α Albumin  Abcam Ab135575 1:50, 1:500 WB, IF 
Sh α CD-31 R & D  AF806 1:1000, 1:200 IF, IHC 
G α CD-31 SCBT sc-1506 1:500 WB 
R α Actin SCBT sc-1615 1:1000 WB 
R α Anti-ZO-1  CST 40-2200 1:400 IF 
R α GAPDH CST 5174 1:2000 WB 
M α Collagen 1 SCBT sc-59772 1:100, 1:1000 IF 
R α Caspase-3 CST 9662 1:1000 WB 
R α AKT CST 9272 1:1000 WB 
R α P-AKT 
(Ser473)  
CST 4060 1:2000 WB 
R α VEGFR-2  CST 2479 1:1000 WB 
R α P-VEGFR-2 CST 3770 1:1000 WB 
R α VEGFR-3 SCBT sc-321 1:1000 WB, IF 
R α CYP 2D6 Abcam Ab62204 1:200 WB 
R α CYP 3A4 Millipore Ab1254 1:1000 WB 
R α CYP 2E1 Abcam Ab19140 1:3000 WB 
G α UGT 1A1 R&D 
Systems 
AF6490 1:1000 WB 
R α Albumin  Abcam Ab135575 1:50, 1:500 WB, IF 
Species in which antibodies were raised are indicated as: R, rabbit; M, mouse; sh, 
sheep; G, goat. Vendors are abbreviated as: CST, cell signalling technologies (UK); 
SCBT, SantaCruz biotechnology (USA). 
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Table 2.2: Secondary antibodies used for western blotting 
All antibodies were supplied by Jackson ImmunoResearch Laboratories (USA) 
 
Table 2.3: Secondary antibodies used for Immunofluorescence 
staining 
Antibody Catalogue 
Number 
Dilution  
Factor 
Alexa Fluor 568 Phalloidin A12380 1:300 
Alexa Fluor 488 Donkey anti-mouse IgG 
(H+L) 
A21202 1:1000 
Alexa Fluor 488 Donkey anti-sheep IgG 
(H+L) 
A11015 1:1000 
Alexa Fluor 568 Donkey anti-rabbit  A10042 1:1000 
Alexa Fluor 568 Donkey anti-mouse  A10037 1:1000 
 
Alexa Fluor 680 Donkey anti-mouse  A10038 1:1000 
Alexa Fluor 680 Donkey anti-rabbit  A10043 1:1000 
Alexa Fluor 488 Donkey anti-rabbit  
 
A21206 1:1000 
Hoechst 33342 
 
H-21492 1:5000 
  
All Antibodies were supplied by Invitrogen (Paisley, U.K).
Antibody Catalogue Number Dilution  
Factor 
HRP Goat anti-
Rabbit  
111-035-144 1:5000 
HRP Goat antimouse  
 
115-035-166 1:5000 
HRP Donkey 
antigoat  
 
705-035-147 1:5000 
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Table 2.4: Externally sourced cells 
 
All HDMEC, HDLEC and NHDF were supplied by PromoCell (Heidelberg, Germany), 
Human hepatic sinusoidal endothelial cells (HLSEC SC) were supplied by ScienCell 
Research Laboratory (Carlsbad, USA), Medicyte HLSEC were supplied by Upcyte 
Technology GmbH, Hamburg, Germany. 
 
 
 
 
 
Cell type Source Lot #,  Catalogue # 
 HDMEC (Adult)  #1 
 
Abdomen of a 32-year old 
female, Caucasian. 
0092101.2,  C-12212 
 HDMEC (Adult)  #2 
 
Breast of a 44-year old female 
Caucasian. 
406Z013.1,  C-12212 
HDMEC (Adult)  #3 
 
Temple of a 60-year old female 
Caucasian. 
394Z028.3,  C-12212 
 HDMEC (juvenile) 
 
Foreskin of a 3-year old male 
Caucasian. 
6060707.1,  C-12210 
 HDLEC (juvenile) 
 
Foreskin of a 4-year old male 
Caucasian. 
2011204,  C-12216 
 HDLEC Adult #1 
 
Breast of a 46-year old female 
Caucasian. 
394Z027.3,  C-12217 
HDLEC Adult #2 
 
Temple of a 60-year old female 
Caucasian. 
394Z016.2,  C-12217 
NHDF Juvenile 
 
Foreskin of a 5-year old male, 
Caucasian. 
0083002.2,  C-12300 
 
HLSEC SC 
 
 13884, 5000 
Medicyte HLSEC 
 
 462-ULO-
C00W0013. 
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2.1.10 Human liver tissues for cell isolation  
Liver tissues were obtained from liver resection following surgery at Aintree 
University Hospital, Liverpool, UK after full patient consent and ethical 
approval were obtained. Patients were adult males. For experiments reported 
in this study, cells were isolated from 10 different patient liver samples. 
Although the underlying liver pathology ranged from cholangiocarcinoma to 
rectal cancer, isolations were carried out on areas of the liver that were 
normal. All samples, cells isolated and products thereof were handled 
according to the Human Tissue Act of 2004.   
 
2.2 METHODS 
2.2.1 Isolation of human hepatic cells 
2.2.1.1 Primary human hepatocytes 
 
Primary human hepatocytes were isolated using a two-step collagenase 
method previously described by LeCluyse et al. (2005) and (Heslop et al., 
2016). Tissues were kept stored in Hepes-buffered saline and transported on 
ice to the laboratory. Tissues were perfused at 37 ˚C with Hepes-buffered 
saline (HBS; 10 mM Hepes, 5 mM KCl, 136 mM NaCl, 5 g/l glucose), and 
digested with 0.2 mg/ml Collagenase A or IV (Roche, Basel, Switzerland or 
Sigma-Aldrich, St. Louis, MO) in HBS containing 700 µM CaCl2. After digestion 
(noted by tenderness of the tissue), the capsule was cut open using a pair of 
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scissors and isolated cells were gently strained through a gauze into a sterile 
glass beaker. For complete and efficient cell recovery, the digested tissue 
matrix on the gauze was washed down the gauze using ice-cold Williams E 
medium (Sigma-Aldrich, St. Louis, MO, USA). The resulting cell suspension was 
centrifuged twice at 80g for 5 mins at 4 ˚C and resuspended in Williams E 
medium. Cell viability was determined using the trypan blue exclusion 
method.  Cell viability of 89 % and above was considered suitable for 
experiments. Hepatocytes were resuspended at a density of 106 cells/ml in 
primary human hepatocyte complete medium.  For monoculture monolayer 
experiments, cells were plated on collagen-coated cell culture plates (Corning, 
UK) at  250,000 cells/cm2 to achieve full confluency and incubated at 37 ⁰C  
and 5 % CO2 for 3 h after which medium was changed to remove dead, non-
attached cells.     
 
2.2.1.2 Human liver sinusoidal endothelial cells 
 
Human LSEC and HHF were isolated using a modified version of the method 
previously described (Lalor et al., 2002). Briefly, supernatants obtained from 
digested liver tissue from primary human hepatocyte isolation were spun 
down at 2000 rpm and 4˚C.  Pellets formed were resuspended in ice-cold PBS 
and centrifuged 3-4 times as above and the resulting final pellets were 
suspended and made up to 18 ml with ice-cold PBS. Approximately 3 mls of 
suspension containing a mixture of non-parenchymal cells was layered on 6 
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mls of 33 % - 77 % Percoll gradient in 15 ml centrifuge tubes and centrifuged at 
2000 rpm using minimum acceleration and deceleration for 25 min at 4 ˚C. The 
resulting top-layer was tipped off and the band of cells at the interphase was 
removed and transferred to a 50 ml centrifuge tube and made up to 50 ml 
with ice-cold PBS. This was centrifuged at 2000 rpm for 5 min at 4 ˚C to 
remove any residual Percoll. This step was repeated 2-3 times on the ensuing 
pellets. The final pellet was resuspended in 500 µl of PBS and incubated with 
50 µl of monoclonal mouse anti-human epithelial cell adhesion molecule 
antibody (EP-CAM) (Progen) at 37 ˚C for 30 min with intermittent agitation. 
Thereafter, 14 ml of ice-cold PBS was added to the cell mixture and 
centrifuged at 2000 rpm for 5 min at 4 ˚C. The resulting pellet was 
resuspended in 500 µl ice-cold PBS and 10 µl ice-cold goat anti-mouse 
Dynabeads (Invitrogen) was added and incubated for 30 min at 4 ˚C with 
constant agitation. Ice-cold PBS (5 mls) was added to the cell mixture and 
placed in a magnet (DynaMag™-15, Invitrogen) for 2 min to remove biliary 
epithelial cells which been had bound to the magnetic bead. The supernatant 
was carefully removed and transferred to a fresh tube. The supernatant was 
placed in the magnet for 2 mins to remove any residual beads. The resulting 
supernatant was centrifuged at 2000 rpm for 5 min and the pellets formed 
were resuspended in 500 µl of ice-cold PBS. Thereafter, 10 µl of CD31-
conjugated Dynabeads (Invitrogen) was added and allowed to incubate for 30 
min at 4 ˚C with continual mixing on a rocking platform.  Then, 5 mls of ice-
cold PBS was added and the mixture was placed in the magnet for 2 min after 
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which the supernatant was removed. The magnetic beads were washed in 5 
ml of ice-cold PBS and the above step was repeated twice more. Finally, the 
magnetic beads (containing CD-31-positive cells) were resuspended in 5 ml of 
HLSEC medium and transferred to a 25 cm2 tissue-culture flask and incubated 
at 37 ˚C in a humidified incubator at 5 % CO2. Cells were not used beyond 5 
passages for all experiments.  
 
2.2.1.3 Human Hepatic fibroblast 
 
To isolate human hepatic fibroblasts, the supernatant generated from the 
separation of LSEC was decanted into a 15 ml centrifuge tube and volume was 
made up to 14 ml and centrifuged at 2000 rpm for 5 min at 4 ˚C. The 
supernatant was decanted and the pellet resuspended in fibroblast medium in 
a 25 cm2 cell culture flask (Corning, UK)  and incubated at 37 ˚C and 5% CO2. 
 
2.2.2 Cryopreservation and recovery of liver 
sinusoidal endothelial cells and human 
hepatic fibroblasts 
 
Medium was aspirated off cells in a 75 cm2 flask and cells were washed with 
about 5 mls of Versene solution (PBS without Ca2+/Mg2+ containing 0.5 µM 
EDTA). Then 2 mls of Tryp-LE™ (Life Technology, UK) was added to the cells 
and the flask was placed in the incubator at 37 ˚C for about 5 min to allow cells 
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to dissociate from the surface of the flask. Cells were further suspended using 
about 5 ml of medium and transferred into a 15 ml centrifuge tube. Cells were 
counted using a haemocytometer. The cell suspension was spun down at 1500 
rpm for 5 min, medium taken off and the cells were resuspended (2 X 105 
cells/ ml for LSEC and 5 X 105 cells/ ml for HHF) in 10% DMSO/ 90% foetal 
bovine serum. Aliquots of 1 ml were carefully transferred into cryovials which 
were then placed into Mr Frosty™ Freezing containers which enabled the cells 
to freeze at a constant rate of -1 ˚C / min when placed in a -80 ˚C ultra-freezer.  
Thereafter, cells were cryo-stored in liquid nitrogen at -196 ˚C. To recover 
cryopreserved cells, vials of cells were taken out of liquid nitrogen, placed in a 
water bath at 37 ˚C to thaw the contents and these were transferred into 
about 8 ml of cell culture medium. The cells were then plated out in collagen-
coated 25 cm2 cell culture flasks (or uncoated flasks for HHF) and allowed to 
attach for 3 h after which the medium was taken off to remove traces of 
DMSO, and fresh medium added. Cells were then grown on as required.  
 
2.2.3 Cell culture 
 
In general, cell culture was performed in an Airstream® Class II biological 
safety cabinet (ESCO GB Ltd, UK) with lamina airflow (inflow: 0.54 m/s, 
Downflow 0.37 m/s). The working surface was disinfected with 70 % iso-
propanol before and after cell work. Similarly, materials used in the safety 
cabinet were carefully sprayed with 70 % iso-propanol and allowed to dry 
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before commencement of cell culture. Cells were passaged by aspirating off 
the culture medium, washing cells with Versene and incubating cells with the 
appropriate volume of Tryp-LE™ (Invitrogen, UK) for a maximum of 4 min to 
allow cells to fully detach from surface of the tissue culture flask or dish. Cells 
were then observed under microscope to confirm detachment, suspended 
with culture medium, counted (if needed) and reseeded on appropriate 
vessels. For the duration of all experiments, cells were grown in a humidified 
cell incubator maintained at 37 °C and 5% CO2 level. 
 
2.2.4 Coating of dishes 
 
A 1.7 % (v/v) [a 1:58 dilution] solution of Human collagen type I (Advanced 
BioMatrix) was made in PBS with Ca2+/Mg2+ and 4 ml transferred to a 75 cm2 
tissue culture flask (volume depends on size of dish or flask in use) and 
allowed to adhere for 30 min at 37 oC.  The collagen solution was aspirated 
immediately prior to adding cells and cell media. Alternatively, after aspirating 
off the collagen solution, coated flasks were left with lid open in the cell 
culture safety cabinet for up to 8 h to dry up the flask and stored, preferably at 
4ᵒC for future use. When the coating agent was gelatin, a 0.5 % (v/v) solution 
of sterile gelatin was used as described above. Coating with fibronectin: flasks 
were coated with human fibronectin (Sigma-Aldrich, MO, USA) at a surface 
density of 2 µg/cm2 overnight (37 ᵒC, 5 % CO2). 
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2.2.5 Preparation of liver microtissues 
 
This followed a modified version of the method described by Bell et al. (2016). 
Isolated primary human hepatocytes were plated at a density of 1500 cells per 
well in a round-bottom 96-well ultra-low attachment (ULA) plate (Corning Life 
Sciences, UK). Cells were allowed to settle in the plate for approximately 10 
min and then centrifuged at a speed of 130 g for 3 min at 25 oC. Plates were 
then placed in a humidified incubator (37 oC, 5 % CO2) to allow cells to self-
aggregate. After 96 h, cells were microscopically observed at a magnification 
of X 10 to check for formation of microtissues after which the medium was 
changed. After another 72 h, liver microtissues were harvested and further 
processed as required. In order to prepare tri-cellular micro-tissues, the 
procedure above was repeated with cells as follows: (PHH: LSEC: HHF at a ratio 
of 8:2:2). Other experiments were based on cell ratios 2:1:1, 4:1:1, 10:7:2—
based on literature (Takebe et al., 2013, Takebe et al., 2014) or based on the 
hepatocyte cell ratios 
 
2.2.6 Protein analysis 
2.2.6.1 Preparation of protein lysate from liver 
microtissues  
 
Liver microtissues were harvested into a clean reagent reservoir kept on ice, 
transferred into a 15 ml centrifuge tube, centrifuged at 130 g for 5 min at 4 oC 
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to allow them to collect at the bottom of tube. Medium was removed and the 
micro-tissues washed with ice-cold PBS and spun down as above. The process 
was repeated with micro-tissues transferred to a 1.5 ml centrifuge tube, spun 
down as above, PBS was carefully removed and 150 µl of RIPA lysis buffer 
(Sigma-Aldrich, St. Louis, MO) was added. Micro-tissues were sonicated on a 
Soniprep 150 Plus ultrasonic Disintegrator (Henderson Biomedical, UK) 3 times 
at an amplitude of 5 and nominal frequency of 23 KHz for 5 s. Lysates were 
centrifuged at 17,000 g (14,000 rpm) for 20 min at 4 oC and the supernatant 
containing the whole cell contents were collected in a new centrifuge tube and 
assayed for total protein as described below. 
 
2.2.6.2 Preparation of liver homogenates 
 
About 0.5 mg of tissue was weighed out, placed in a sterile 2 ml centrifuge 
tube, 600 µl RIPA lysis buffer added and a sterile sharp-edge metal ball bearing 
was placed in the tube. Tubes were placed in a Retsch Mixer Mill MM400 
(Cole-Parmer, UK) and tissues were homogenised at 30 oscillations / sec for 3 
mins. Homogenates were aliquoted into a fresh tube and centrifuged at 
17,000 g (14,000 rpm) for 20 mins at 4 ˚C and the supernatant containing the 
tissue protein contents were collected in a new centrifuge tube and assayed 
for total protein as described below.  
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2.2.6.3 Protein determination in whole cell lysate and 
whole liver homogenates 
 
Protein contents in whole cell or tissue lysates were quantified using the BCA 
assay (Smith et al., 1985) which is a colourimetric method based on the 
protein-induced biuret reaction that causes a reduction of Cu (II) to Cu (I) and 
a subsequent chelation of Cu (I) by two molecules of bicinchoninic acid (BCA) 
to form a water-soluble purple-coloured complex that absorbs strongly at 
562nm, the intensity of which increases with increasing protein concentration. 
A 7-point standard curve (0 - 1 mg protein/ml) was produced by serially 
diluting the 1mg/ml bovine serum albumin protein standard using deionised 
water. Aliquots (20 μl) of both the protein standards and 10  μl  of samples 
were pipetted into a clear-bottom 96-well plate and then 200 μl Working 
Reagent (WR; 50 parts of reagent A (sodium carbonate, sodium bicarbonate 
and sodium tartrate in 0.1 N sodium hydroxide) to 1 part reagent B (4% cupric 
sulphate)) was added. The plate was then incubated at 37°C for 30 min, cooled 
for 2-3 min and absorbance determined using an the Varioskan Flash plate 
reader (Thermo Scientific,  USA) at a wavelength of 562 nm. A standard curve 
was constructed and protein concentration of samples calculated.  
 
2.2.6.4 Western blotting  
 
Whole cell lysates (20 µL containing approximately 10 μg of proteins) were 
added to 5 μL of sample loading buffer (4X LDS and 2-mercapto ethanol) 
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(Sigma, MO, USA). The sample was then heated up for 5 min at 90 oC to allow 
protein denature.  4 μL of the molecular weight marker (protein kaleidoscope 
standards or rainbow marker) and the whole denatured samples were loaded 
on a 15-well Bolt™ 4-12% Bis-Tris Plus polyacrylamide gel using Mini Gel Tanks 
and NuPAGE® MES SDS Running Buffer. Samples were run at 70 mA and 200 V 
for 45 min. The separated proteins in the gels were transferred onto hybond 
nitrocellulose paper (GE Healthcare, UK) at 230 mA for 120 min using a Mini 
Blot Module (ThermoFisher Scientific).  Membranes were blocked for 1 h in 5 
% w/v BSA solution or 10 % w/v non-fat milk (Bio-Rad) made up in TBST on an 
orbital shaker.  Membranes were probed overnight with anti CYP 2D6 (Abcam, 
UK, 1:200 in 2% non-fat milk), CYP 3A4 (Millipore, UK. 1:8000 in 2 % w/v in 
non-fat milk), CYP 2E1 (Abcam, UK. 1:3000 in non-fat milk), UGT 1A1 (R&D 
Systems, UK. 1:1000 in 2% non-fat milk), anti-phospho-AKT473 (1:1,000 in 
TBS-Tween containing 2 % (w/v) BSA),  caspase 3 (1:1,000 in TBS-Tween 
containing 2 % (w/v) BSA), phospo-Erk 1/2 (1:1,000 in TBS-Tween containing 2 
% (w/v) BSA), anti-VEGFR-3 (1:1,000 in TBS-Tween containing 2 % (w/v)), anti 
CD-31 (1:500 in TBS-Tween containing 2% (w/v)and anti GAPDH (1:1,000 in 
TBS-Tween containing 2% (w/v) or anti β-actin (1:1,000 in TBS-Tween 
containing 2% (w/v) used as loading control. Membranes were washed for 6 x 
10 min in TBS-Tween and probed for 1 h with the appropriate HRP-linked 
secondary antibody. The following secondary antibodies were used: goat anti-
rabbit HRP (1:5,000 in TBS-Tween containing 2 % (w/v) BSA or 5 % w/v non-fat 
milk), rabbit anti-goat HRP (1:5,000 in TBS-Tween containing 2 % (w/v) BSA or 
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2 % (w/v) non-fat dry milk), goat anti-mouse HRP (1:5,000 in TBS-Tween 
containing 2 % (w/v) or 2 % w/v non-fat dry milk). Membranes were washed 
FOR 6 x 10 min in TBS-Tween and visualised in the dark by the addition of 
enhanced western lightening chemiluminescence reagents Hyperfill ECL 
(Perkin Elmer, UK) to the membrane, a film placed on the membrane to pick 
up bands and exposed to Kodak developer and fixer solutions in ratio 1:1. 
Band intensity was quantified and analysed using the Image-J software (NIH, 
USA).  
 
2.2.7 Nucleic acid analysis  
2.2.7.1 Primer design 
 
In order to design primers to genes of interest its accession number was 
determined online from 
http://www.qiagen.com/products/quantifastprobeassay.aspx which was used 
to determine the correct mRNA sequence on 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=Nucleotide. The sequence was 
pasted into the website 
http://tools.invitrogen.com/content.cfm?pageid=9716. A careful selection of 
the base pair was made using some stringent conditions of primer size (Min 18, 
Opt 20, Max 27), melting temperature (Min 57, Opt 60, Max 63), the percentage 
GC (Min 40, Opt 50, Max 60) in the sequence, product size and salt 
concentration. The selected pair was run through the website: 
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http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi?LINK_LOC=BlastHome to determine what set of genes they 
were specific for and the set of gene with the highest specificity and least self-
complementarity and self-3’ complementarity was selected and ordered 
online from ThermoFisher Scientific, UK. Upon receiving the primer pair, they 
were constituted to 100 µM using Tris-EDTA Buffer pH 8.0 (Sigma, UK). 
Thereafter, the primers were tested as below. 
 
 
2.2.7.2 Primer testing by agarose gel electrophoresis 
 
Reconstituted primers were tested using the DreamTaq Green PCR Master Mix 
kit (Thermo Scientific). Briefly, reaction mix was prepared in a PCR reaction 
tube with 10 μl of  DreamTaq Green PCR Master mix,  4.4μl of nuclease-free 
water, 2 μl of forward primer, 2 μl of reverse primer and 1.6 μl of cDNA. The 
mix was run on a thermal cycler (GeneAmp® PCR System 9700, Applied 
Biosystems, UK) as follows: 95˚C for 10 min,   95˚C for 15 sec and 60˚C for 1 
min over 30 cycles. A volume of 10 µl  of the reaction mix was run on a  3% 
agarose gel mixed with 7.5 µl of ethidium bromide to a final concentration of 
0.5 ug/ml. Quick-Load 100 bp DNA ladder (New England Biolab) was used as 
marker. Samples were run electrophorectically for 45 min at 100V and 
products formed were viewed using a transilluminator. Primers were deemed 
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good when a single band was formed; implying the absence of primer dimer 
and this was further confirmed by RT-PCR. 
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Table 2.5: List of PCR primers 
 
Primer 
Name 
Forward Sequence (5' to 3') Reverse Sequence (5' to 3') 
ALB CCTGTTGCCAAAGCTCGATG ATCTCCATGGCAGCATTCCG 
UGT 1A1 TTAATCAGCCCCAGAGTGCT AATGGCACATGTCATCCTGA 
CYP2D6 TTCCCAAGGGGTGTTCCTGG TCACGGCTTTGTCCAAGAGA 
CYP2E1 ACCCTGAGATCGAAGAGAAGC AAATGGTGTCTCGGGTTGCT 
CYP3A4 AGAAATCTGAGGCGGGAAGC GGAATGGAAAGACTGTTATTGAGAG 
Stabilin-1 CTCTTCACAGCGGGTCTCTC CCCCTCCTCAGAAATGTTCA 
Stabilin-2 TTGGCAACAAACAATGGCTA GGCCAGAAGAGAGTGACTGG 
LYVE-1 GCTTTCCATCCAGGTGTCAT GCCAAACTTAGTCCCAGCAG 
Prox-1 CAAAAATGGTGGCACGGAG CCTGATGTACTTCGGAGCCTGT 
CD31 CAGGAGCACCTCCAGCCAACTT ATCCTGGGCTGGGAGAGCATTTCG 
ZO-1 GGAGAGGTGTTCCGTGTTGT GGCTAGCTGCTCAGCTCTGT 
PDGFR-β  GAGGAATCCCTCACCCTCTC GGGTATATGGCCTTGCTTCA 
VEGFR-1 TGTGCCAAATGGGTTTCATG TGCAAGACAGTTTCAGGTCCTC 
VEGFR-2 CAAACGCTGACATGTACGGTCT CCAACTGCCAATACCAGTGGA 
VEGFR-3 GCTCCTACGTGTTCGTGAGAGA TCCTGTTGACCAAGAGCGTG 
VEGF-A CCTTGCTGCTCTACCTCCACC TCCTCCTTCTGCCATGGG  
VEGF-B GGG CAC ACA CTC CAG GCC ATC CCTTGACTGTGG AGCTCATGGGCC 
VEGF-C TCAGGCAGCGAACAAGACC TTCCTGAGCCAGGCATCTG  
VEGF-D TCCAGGAACCAGCTCTCTGT TTTTTGGGGTGCTGGATTAG 
Id-1 CGGATCTGAGGGAGAACAAG TCCCACCCCCTAAAGTCTCT  
POD CTGCTCTTCGTTTTGGGAAG GGTTCCTGGAGTCACCACAT 
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2.2.7.3 RNA extraction from whole liver  
 
 This was done using RNA mini kit (Qiagen, UK) according to manufacturer’s 
instruction. Approximately 30 mg of tissue was weighed out, rinsed 3 times in 
PBS and transferred into a sterile 2 ml centrifuge tube. A sterile sharp-edge 
metal ball bearing was placed in the tube and 300 µl of lysis buffer (300 µl of 
buffer RLT plus 3 µl of 2-mercaptoethanol) was added. Tubes were placed in a 
Retsch Mixer Mill MM400 (Cole-Parmer, UK) and tissues were homogenised at 
30 oscillations / sec for 3 mins. Beads were removed with sterile tweezers 
which were cleaned with ethanol between each tube. RNase-free water (590 
µl) and 10ul protinase K (Qiagen) were added to the lysate and vortex mixed. 
The mix was incubated at 55 ˚C for 10 min on a heater block (Grant-bio PCH1), 
centrifuged at 10,000 g for 3 min, and supernatant transferred into a new 2ml 
tube. A volume of 100 % ethanol which was half the volume of sample liquid 
was added (400 µl of ethanol was added to 800 µl of sample) and was pipette 
mixed. Then 700ul of sample was transferred to mini column and centrifuged 
at 8000 x g for 15 s, and flow through (liquid collected in bottom clear tube) 
was discarded. This was repeated until all sample had been passed through 
the column. Thereafter, 350 µl of RWI was buffer added and centrifuged at 
8000 xg for 15 seconds, flow through discarded and 80 µl of DNase 1 master 
mix (10 µl of DNase with 70ul of buffer RDD (Qiagen)) was pipetted unto the 
silica surface of the column. This was incubated at room temperature for 15 
min, 350ul RW1 buffer was added, centrifuged at 8000 g for 15 s, flow through 
discarded, 500ul buffer RPE added, centrifuged at 8000 g for 15 s, and flow 
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through discarded. Another 500 µl volume of buffer RPE was added and 
column centrifuged at 8000 g for 2 min, and flow through discarded. The 
collection tube was replaced by a 1.5 ml centrifuge tube, 50ul of RNase-free 
water was added unto the column and was centrifuged for 1 min at 8000 g. 
The eluted mRNA sample was quantified using the Nanodrop 
spectrophotometer (ND-1000, Thermo Scientific, UK). 
 
2.2.7.4 RNA extraction from cells  
 
Medium was aspirated off cells cultured in monolayer and were washed twice 
with ice-cold PBS. RNA lysis buffer (350 µl with 3.5 µl of 2-mercaptoethanol) 
was added to the cells on ice. After 15 min, cells were scrapped and using a 
cell scrapper and lysates transferred into a clean centrifuge tube. Thereafter, 
245 µl of 100 % ethanol was added to the lysate and was mixed by pipetting 
up and down. Then 700ul of sample was transferred to mini column, 
centrifuged at 8000 g for 15 s, and flow through (liquid collected in bottom 
clear tube) was discarded. This was repeated until all sample had been passed 
through the column. Thereafter, 350 µl of RWI was buffer added and 
centrifuged at 8000 g for 15 s, flow through discarded and 80 µl of DNase 
master mix 10 µl of DNase [Qiagen] with 70ul of buffer RDD) was pipetted 
unto the silica surface of the column. This was incubated at room temperature 
for 15 mins, 350ul RW1 buffer was added, centrifuged at 8000 g for 15 s, flow 
through discarded, 500ul buffer RPE added, centrifuged at 8000 g for 15 s, and 
flow through discarded. Another 500 µl volume of buffer RPE was added and 
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column centrifuged at 8000 xg for 2 minutes, and flow through discarded. The 
collection tube was replaced by a 1.5 ml centrifuge tube, 50ul of RNase-free 
water was added unto the column and was centrifuged for 1 minute at 8000 g. 
The eluted mRNA sample was quantified using the Nanodrop 
spectrophotometer (NanoDrop™ 1000 Spectrophotometer, Thermo Fisher 
Scientific). 
 
2.2.7.5 Reverse transcription of RNA 
 
Messenger RNA extracted above was diluted to a concentration of 100 ng/µl 
with sterile RNase-free, DNase-free dH2O to a total volume of 10 µl. This was 
followed by addition of 1 µl of Oligo dT and 1 µl of 10 mM dNTP mix, 
incubated at 70°C for 5 min and samples were rapidly cooled on ice to prevent 
formation of secondary structures.  Then 8 µl of the master mix (containing 4 
µl of 5X first strand buffer, 2 µl of DTT (0.1 M), 1 µl of 40 unit/ µl of RNaseOUT 
and 1 µl of 200 units/ µl of M-MLV reverse transcriptase) was added to the 
samples. This was followed by cycles of annealing (25 °C, 5 min), cDNA 
synthesis extension (37 °C for 60 min.), and reaction inactivation (70°C, 15 
min.). Finally, 130 µl of RNase-free, DNase-free dH20 was added to dilute cDNA 
to a final concentration of 6.66 ng/μl.   
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2.2.7.6 Real-time quantitative polymerase chain reaction 
 
RT-PCR was performed according to the manufacturer’s protocol using the 
SYBR Green master mix (Invitrogen).  Briefly, 1.4 μL of cDNA (10 ng), 3 μL of 
nuclease-free dH20, 12.5 μL of 2x SYBR Green, 4 μL each of both forward and 
reverse primers were mixed in a 500 μL centrifuge tube and centrifuged. From 
this, 10 μL was transferred in duplicates into a 384-well plate and sealed with 
an optically-clear QPCR adhesive seal sheet. This was centrifuged for 15 s at 
700 g (1800 rpm) at 4 °C. Polymerase chain reaction was run using the ViiA 7 
PCR machine (Life Technologies, UK) with 40 cycles of 95 ˚C for 15 s per cycle 
and 60 ˚C for 1 min per cycle. A dissociation curve was generated in order to 
determine the specificity of the primers and accuracy of the SYBR green 
fluorescence.  
2.2.7.7 Relative quantitation of gene expression  
 
From the Ct values obtained from the PCR run the relative gene expression 
was calculated using method described by Livak and Schmittgen (2001) as 
follows: 
 Ct = Ct target gene – Ct reference gene 
 Ct = Ct stimulated samples (sample of interest) - Ct Control 
sample (sample with lowest    Ct value) 
Fold change (gene expression) in relation to the control sample was calculated 
as: 
 Fold change relative to control = 2-Ct
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2.2.8 Analysis of endothelial cell physiology 
 
2.2.8.1 Co-culture angiogenesis assay 
 
This was performed according to a method previously described by Hetheridge et al. 
(2011). Briefly, normal human dermal fibroblasts (juvenile) were seeded at 7.8 X 103 
cells/ cm2 on a gelatin-coated 24-well plate or on gelatin-coated glass coverslips in 1 
ml fibroblast growth medium. Fibroblasts were grown for 72 h under standard 
conditions until confluent. Then, medium was aspirated, cell washed with PBS and 
endothelial cells at a density 2.1 x 104 cells/ cm2 in 0.5 ml endothelial cell full growth 
media for 24 h. Then medium was aspirated from the wells, washed once with PBS.  
Endothelial cell media containing 1% FBS containing the growth factors or inhibitors 
required was added to a total volume of 0.5 ml/well for 72 h. Thereafter, medium 
was aspirated and replaced with fresh medium containing 1 % FBS and the growth 
factors/inhibitors for 48 h. Then, medium was aspirated and cells gently washed with 
PBS twice and fixed in 200 µl of 2% PFA for 15 min at room temperature on the 
rocker set at 30 rpm. Cells were washed in 1 ml PBS twice, permeabilised using 200 µl 
0.25% (w/v) Triton X-100 for 10 min at room temperature. Cells were then washed 
twice in 1X TBS. Cells were blocked with 1 % BSA for 1 h at room temperature. After 
which primary antibody was added for 1 h, cells washed three times in TBST.  
1. For colorimetric assay, anti-sheep IgG whole molecule alkaline phosphatase 
conjugate secondary antibody (diluted 1:200 in 1% BSA in TBST) was added 
for 1 h at room temperature on the rocker set at 30rpm.  Then cells were 
washed in dH2O 1ml per well three times. Then 200μl of substrate (1 SIGMA 
Fast BCIP/NBT tablet per 10 ml distilled water) was added per well and left at 
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37°C for 15 min. Cells were washed with dH2O and about 300 µl of dH2O was 
added and plates were either stored at 4 °C or imaged immediately on Nikon 
Microscope using 4X objective. Images were quantified using the Angioquant 
programme.  
 
2. For immunofluorescent staining, secondary antibody diluted as instructed by 
manufacturer on 1% BSA in TBST for 1 h at room temperature on the rocker 
set at 30rpm.  Thereafter Hoechst nuclear stain (diluted at 1:5000 in 1% BSA 
in TBST)   was added and incubated at room temperature for 10 min on the 
rocker set at 30rpm.  Cells were washed  three times  in 1 ml of TBST and 
mounted on slides after about 20 µL of prolong gold and sealed around with 
nail varnish. 
 
 
2.2.8.2 Agonist stimulation of cells for intracellular signalling 
 
 Endothelial cells were seeded at a density of 2.1 X 104 cells/cm2 in a 12-well plate for 
48 h after which medium was removed and washed twice with sterile PBS and cells 
were incubated with medium containing 1 % FBS overnight. Cells were incubated 
with 50 ng/ ml of growth factor or basal medium for 10 min at 37 °C after which they 
were washed twice with ice-cold PBS on ice and lysed with 120 µl of modified RIPA 
lysis buffer for 15 min. Cells were scraped and assayed for protein contents as 
described.     
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2.2.8.3 Cell migration assay 
 
Endothelial cells were seeded in a 12-well collagen-coated tissue culture plate until 
confluent. Medium was removed and cells washed twice with PBS and medium 
containing 1 % FBS was added overnight. A straight scratch was vertically drawn with 
a sterile 200 µl pipette tip using a ruler disinfected with 70 % iso-propanol. Medium 
was aspirated off to remove dead cells which were further washed once with PBS. 
Cells were pre-treated with the respective dilution(s) of inhibitor(s) or medium 
containing 1 % FBS for 30 mins. Thereafter, 50 ng/ml of growth factors diluted in 
medium containing 1 % FBS or medium containing only 1 % FBS was added. Images of 
scratches were taken using light microscope to mark time t= 0h. Then cells were 
incubated for 16 h 37C and 5 % CO2. Then medium was aspirated off and cells 
washed twice with PBS at room temperature. Then they were fixed with 2 % 
paraformaldehyde for 15 min and washed twice with PBS before being stained with 
crystal violet. After the removal of PBS from the wells, 200 µl of crystal violet was 
added to each well, ensuring the surface of the well was covered and incubated for 
15 min at room temperature. Cells were then washed with water in sink to remove all 
excess stain. Plates were stored in PBS at 4°C whenever storage was required before 
imaging using light microscopy.   
 
2.2.8.4 Cell proliferation assay 
 
Endothelial cells were seeded at 4, 000 cells per well in a collagen-coated 96-well 
plate and cultured for 48 h after which medium was removed and cells washed with 
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PBS. Medium containing 1 % FBS was added to the cells for 16 h after which cells 
were incubated with 50 ng/ml of growth factors constituted in medium containing 
1% FBS for 72 h. Thereafter, cells were washed with ice-cold PBS which was aspirated 
off and 100 µl of PBS was added followed by 20 µl of Cell Titer Glo Reagent (Promega) 
per well. Plates were placed on a shaker for 20 min and allowed to stand for 10 min 
to allow luminescence signal to stabilise. Thereafter, 100 µl of cell lysates were 
transferred from each well into a white-bottomed 96-well plate (Greiner bio-one, UK) 
and plates were read for luminescence using Varioskan Flash plate reader (Thermo 
Scientific, USA) at a wavelength of 100 nm. Luminescence reading, proportional to 
ATP contents (a measure of cell viability) was recorded and represented as 
percentage of basal which was set at 100 %.    
 
2.2.9 Cell and microtissue imaging 
2.2.9.1   Immunofluorescent staining of cells 
 
Cells grown on collagen-coated glass cover slips were fixed with 2% PFA/PBS for 15 
min at room temperature. Cells were washed once in freshly made quench solution 
(50mM NH4Cl in PBS) followed by a further 10 min incubation in the quench solution. 
Cells were washed three times in PBS and permeabilised for 10 min with a 0.2% 
Triton X-100 solution at room temperature. Cells were then washed two times in TBS 
followed by a 1 h block with 5 % serum (from animal source of 2° antibody) for 1 h at 
room temperature. Primary antibody (200 µL), diluted as optimised or instructed by 
manufacturer in TBS containing 1% BSA and 0.1% Tween-20, was added to the cells 
on cover slips. Sufficient volume of diluted antibody was added to cover the glass 
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region of the dish, and incubated for 1 h at room temperature. Cells were washed 
three times  in TBST and incubated with fluorescently-labelled secondary antibody 
(diluted 1:1000) for 1 h at room temperature with dishes containing cells covered 
with foil in order to protect fluorescent dyes which are light sensitive. Then cells were 
washed twice in TBST and incubated with 2µg/ml Hoescht stain for  10 min and 
washed again three times in TBST. Coverslips were mounted by adding 10μl of 
Prolong Gold (Invitrogen) directly onto the glass slide and then any excess liquid 
gently blotted out and coverslips placed face down onto slide. Coverslips were gently 
pressed with forceps to remove any bubbles and were sealed with nail varnish. Cells 
on coverslips were then imaged using Zen Axio Observer Z.1 fluorescence microscope 
(Carl Zeiss, GmbH).   
 
2.2.9.2 Immunofluorescent staining of liver microtissues 
 
After 7 days in culture, liver microtissues were harvested in the ULA plates. Medium 
was carefully taken off to avoid losing the micro-tissues. Medium was replaced with 
PBS at room temperature until the well was clear, indicating a total removal of the 
culture medium. Microtissues were then fixed in 4% paraformaldehyde (PFA) for 1 h 
after which they were washed 3 times with PBS. Thereafter, micro-tissues were 
permeabilised overnight with 0.5% Triton X-100 in PBS, followed by a two-hour block 
step in 3 % bovine serum albumin (BSA) in TBST at room temperature. The primary 
antibody made up at the determined concentration in 1% BSA /TBST/0.1% Triton-X 
was added overnight at 4 ºC after which micro-tissues were washed 3 times (1 h per 
wash) with TBST/ 0.1% Triton-X at room temperature. Thereafter, fluorescently-
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conjugated secondary antibody (usually diluted at 1:1000 in 1% BSA/ TBST/ 0.1% 
Triton-X) was added overnight at 4 ˚C. Micro-tissues were then washed with TBST/ 
0.1 % Triton-X (once for 1 h.) followed by addition of Hoechst (diluted at 1:5000 in 
TBST/0.1% Triton-X) for 1 h. After the removal of Hoechst, micro-tissues were quickly 
washed with TBST/0.1% Triton-X and another one-hour wash. After much of the wash 
buffer was removed from the wells, micro-tissues were removed and transferred 
onto a microscope slide and excess buffer removed with a clinical tissue paper. Then 
a about 30 µl of Prolong Gold (Invitrogen) was added to cover the micro-tissues after 
which a cover slip was gently placed on top and sealed on the side with a transparent 
nail polish.  Microtissues were imaged using a Zen Observer Z.1 fluorescence 
microscope (Carl Zeiss, GmbH).   
 
2.2.9.3 Scanning electron microscopy 
 
Endothelial cells were seeded on collagen coated glass slides in a 24-well tissue 
culture plate at a density of 1.1 X 106 cells/cm2 for 24 h after which medium was 
replaced with LSEC full growth medium alone or supplemented with 50 ng/ml of 
VEGF-A or VEGF-C for 48 h. Thereafter, medium was removed and cell washed with 
PBS and fixed with 4% PFA and 2.5% glutaraldehyde in 0.1M phosphate buffer (pH 
7.4) at room temperature for 2 h. Cells were washed for 3 min twice in 0.1M 
Phosphate buffer (pH 7.4) at room temperature. Cells were then incubated with 
reduced osmium staining [2% OsO4 in H2O + 1.5% potassium ferrocyanide in ddH2O] 
(20s on-20s off-20s on-20s off. 20Hg). Cells were then washed for 3 min, three times 
in ddH2O at room temperature and incubated with the mordant containing: 1% 
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thiocarbohydrazide (TCH) in ddH2O (20s on-20s off-20s on-20s off. 20Hg). Thereafter, 
cells were washed in ddH2O three times and 3 min each at room temperature.  Cells 
were exposed to a second osmium staining with 2% OsO4 in ddH2O (20s on-20s off-
20s on-20s off. 20Hg) and washed ddH2O five times for 3 min. each at room 
temperature. They were then stained with 1 % uranyl acetate in ddH2O overnight at 
4°C and washed with ddH2O five times for 3 min each at room temperature. Cells 
were then dehydrated in graded ethanol (30, 50, 70, and 90 %) in ddH2O for 5min 
each and then 3 times in 100% ethanol, followed by critical-point drying. Cells were 
then sputter coated with 10 nm of Au/Pd. Then cover glasses were placed on 
scanning electron microscope (SEM) stubs with conductive silver epoxy and left to 
dry overnight. Images were taken with FEI Quanta 250 scanning electron microscope 
(FEI UK Limited, Cambridge, UK).  Fenestrations were quantified by manual counting 
and an average of four images were taken.  
 
 
2.2.10   Transcriptomic analysis of endothelial cells  
 
Human dermal microvascular endothelial cells, human dermal lymphatic endothelial 
cells or human liver sinusoidal endothelial cells were seeded at a density of 9.1 X 103 
on a collagen-coated 10 cm plastic tissue culture dish for 48 h. Medium was aspirated 
off and cells washed two times with ice-cold PBS on ice. Thereafter, cells were lysed 
with 600 μl of RLT RNA lysis buffer (containing 600 µl of buffer RLT with 6 µl of 2-
mercaptoethanol). RNA was extracted as described above (section 2.2.7.4) Then, RNA 
samples (free from genomic DNA) were quantified using the Qubit BR RNA kit, and 
the quality of the RNA assessed using the Agilent 2100 Bioanalyser and RNA Pico 
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chip. Samples were prepared for hybridisation onto Affymetrix Human Transcriptome 
(HTA 2.0) arrays, following the WT Plus labelling kit version 3 protocol. 100 ng of total 
RNA was used as input into the labelling reactions. Amplification of cRNA was 
checked by bioanalyser before proceeding to ss-cDNA. 5.5 µg of ss-cDNA was 
fragmented and labelled, prior to hybridisation onto HTA 2.0 arrays and hybridised 
for 16 h at 45˚C, 60 rpm in a GeneChip Hybridization Oven 645. Following 
hybridisation, the  arrays were  washed  on a GeneChip® Fluidics Station 450 using  
the  GeneChip Hybridisation, Wash and Stain kit and fluidics script  FS450_0001 and 
scanned using  the  GeneChip® Scanner 3000  7G. 
 
 
2.2.10.1 Bioinformatics analysis 
 
The resulting gene expression intensity data obtained from the GeneChip® Scanner 
above was analysed with the Expression Console® (EC) software (Affymetrix, UK) 
which was used to estimate and normalise gene expression using the SST-RMA 
mode. The data thus generated was an estimate of the expression of the genes of 
interest converted to log2. The EC software enabled the generation of a PCA plot. 
The output from this analysis was further analysed using the Transcriptome Analysis 
Console (TAC) software (Affymetrix, UK). TAC was used to identify the differentially-
expressed genes, the signal intensities of any particular gene in the sample of 
interest. Using signal intensity data generated, each group was compared with the 
other to generate the linear fold change (FC) in gene expression relative to the other. 
The estimated log2 fold change (logFC) in the genes of interest were compared 
between the groups of interest using t-test. The estimated p-values for each logFC 
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values were adjusted for multiple testing using the False Discovery Rate (FDR) 
method. Significantly differential expression were those whose FDR had adjusted p-
value < 0.05. The number of differentially-expressed genes in each paired 
comparison and the direction of the expression were plotted into an MA plot. The 
TAC software was also used to generate a heatmap that helps to visually identify the 
signal intensities of the genes of interest in the samples.   
 
2.2.11 Drug metabolism in liver microtissues 
2.2.11.1.1  Preparation and treatment of liver 
microtissues 
 
Liver micro-tissues were made as previously described above (section 2.2.6.1). After 7 
d, micro-tissue were dosed with 5 μM of perhexiline for 24 h following which drugs 
were taken off and transferred into another set of 96-well plates and rapidly frozen 
on dry ice. Samples were stored at -80˚ C until required for analysis as described 
below.  
 
2.2.11.2. Analysis of metabolite formation by LC-MS/MS  
 
2.2.11.2.1.  Stock solutions 
 
Stock solutions of hydroxy-perhexiline (PHX-OH) metabolites and internal standards 
were prepared in DMSO/Methanol (50/50 v/v). All other stock solutions were 
prepared in DMSO. The solutions were prepared and stored in glass vials. 
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2.2.11.2.2.  Working solutions 
 
All working solutions were prepared in glass vials using positive displacement 
pipettes. The fluconazole (Fluc) stock was diluted with MeCN to give a solution 
containing 1 µg/mL. This was followed by a dilution of the D4-fluconazole (D4-Fluc) 
stock with MeCN/water (25/75, v/v) to give a solution containing 1 µg/mL. Then the 
perhexiline parent compound, metabolites and internal standards were prepared in 
MeCN/water (50/50, v/v) as follows:  
 
 PHX : 0.05, 0.5 & 5 µM 
 cis-PHX-OH: 0.005, 0.05, 0.5 µM (total concentrations) 
 trans-PHX-OH: 0.005, 0.05, 0.5 µM (total concentrations) 
 D11-PHX & D11-cis-PHX-OH: 0.5 µM 
 
In order to test extraction recoveries of the test compounds from medium, medium 
validation samples were prepared by spiking incubation medium with concentrations 
of analytes corresponding to the low, medium and high calibration standards, after 
dilution, using positive displacement pipettes. 
2.2.11.2.3. Calibration standards 
 
Independent calibration lines were prepared for PHX, cis-PHX-OH and trans-PHX-OH, 
directly in a 2mL 96-deep well analysis block, using the following solutions and 
volumes. 0.1% FA reduces otherwise significant carry/over and buildup of the 
analytes in the LC-MS/MS system.  
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2.2.11.2.4. PHX calibration standards 
 
std Conc (µM) Vol (µL) 
no CAL WS WS IS diluent A diluent B total 
1 0.0010 0.05 10.0 10.0 230 250 500 
2 0.0020 0.05 20.0 10.0 220 250 500 
3 0.0040 0.05 40.0 10.0 200 250 500 
4 0.0100 0.5 10.0 10.0 230 250 500 
5 0.0200 0.5 20.0 10.0 220 250 500 
6 0.0400 0.5 40.0 10.0 200 250 500 
7 0.1000 5 10.0 10.0 230 250 500 
8 0.1500 5 15.0 10.0 225 250 500 
9 0.2000 5 20.0 10.0 220 250 500 
 
IS = corresponding internal standard 
Diluent A = MeCN/water (50/50, v/v) 
Diluent B = Diluent A containing FA (0.2%, v/v) 
Metabolite calibration standards were prepared using the same volumes as 
tabulated above except that the concentrations of the calibration standards and the 
working solutions were 10-fold lower and diluent B contains FA (0.2%, v/v) in water. 
 
 
2.2.11.2.5. Treatment of test samples 
All initial handling and treatment of test samples was carried out at 4°C. The 
following procedure was based on samples supplied in a 96-well flat bottomed 
microtitre plates: Samples were removed from storage at -20°C and allowed to thaw. 
Then, 40 µL of each sample was transferred to a clean well of a separate round-
bottomed microtitre plate, Fluc-MeCN (120 µL) added to each well to give a volume 
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ratio of MeCN:sample of 3:1. Plate was capped and contents briefly mixed (600 rpm, 
30 seconds). Then the plate was centrifuged (3000 rpm/1811 g, 4°C, 20 min).  
Thereafter, two separate aliquots of the treated sample were transferred to separate 
wells of a clean 2mL 96-deep well analysis block, one for analysis of parent drug and 
the other for analysis of metabolites, using the volumes tabulated below: 
 
Analytes Overall 
dilution 
Vol (µL) 
Sample 
extract 
IS* Fluc-
IS 
Water diluent A diluent B total 
Parent 500 10 25 10 0 595 625 1250 
Metaboli
tes 
50 40 10.0 10 190 220 0 500 
 
Diluent A = MeCN/water (50/50, v/v) 
Diluent B = Diluent A containing FA (0.2%, v/v) 
* IS = D11-PHX for analysis of parent & D11- Cis-Hydroxy-PHX for analysis of 
metabolites 
 
Plate(s) were capped and contents were briefly mixed (600 rpm, 30 seconds), 
followed by centrifugation (3000 rpm/1811 g, 4°C, 10 min) and analysis by LC-
MS/MS. Treated, un-diluted, samples were stored in sealed plates at 4°C for at least 1 
week. For longer term storage this had to be at -20°C with the plates being tightly 
sealed to prevent entry of atmospheric water. 
 
2.2.11.2.6. Preparation of Fluconazole reference samples 
Two sets of references corresponding to the two different dilutions were prepared as 
described above. Blank, cell-free, Incubation medium samples (n=3) to test samples 
(n=3) of solutions were treated to give these samples. Alternatively, if extraction 
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recovery of fluconazole was quantitative, water was used instead of incubation 
medium. 
 
2.2.11.2.7.  LC-MS/MS conditions 
Analyses were carried out with the following pieces of equipment: LC PUMP 
(QUATERNARY) (G1312B, Agilent Technologies UK Limited), (DEGASSER G1379B, Agilent 
Technologies UK Limited), COLUMN OVEN (G1316B, Agilent Technologies UK Limited), 
AUTOSAMPLER (HTS PAL, CTC Analytics), MASS SPECTROMETER (6500 Triple Quadrupole, AB 
Sciex), COMMUNICATIONS HUB, (Edgeport 8-port, Digi International), NITROGEN 
GENERATOR (Genius 3031, Peak Scientific). 
 
2.2.11.2.8. HPLC conditions common to all analyses 
 
HPLC Column:    50 x 2.1mm ID 2.6 µm Kinetex XBC18 
(Phenomenex) 
Guard:     Upchurch pre-column filter with 0.5 µm frit 
(Sigma-Aldrich) 
Temp. (°C):    40 
Mobile Phase A:   H2O +0.1% v/v FA 
Mobile Phase B:   MeCN +0.1% v/v FA 
Autosampler Wash Solvent 1:  H2O: AcOH (99/1, v/v) 
Autosampler Wash Solvent 2:  MeOH:ACE:IPA:AcOH (40/30/30/1, v/v) 
 
Autosampler Washes: 
 
Wash No. of washes 
Post Clean with Solvent 1 1 
Post Clean with Solvent 2 2 
Valve Clean with Solvent 1 1 
Valve Clean with Solvent 2 2 
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2.2.11.2.9. MS parameters common to all analyses 
 
IONISATION MODE:ELECTROSPRAY POSITIVE (ESI +ve) 
CUR:  35 
CAD:  9 
IS:  5500 
TEM:  500 
GS1/GS2: 50/40 
 
 
 
2.2.11.2.10. Analysis of Perhexiline 
 
Volume (µL) injected: 10 
Diverter valve timings (to MS): 0.6->1.9 minutes 
 
HPLC Gradient: 
 
Time (min) Flow Rate(µL/min) A (%) B(%) 
0 500 95 5 
0.1 500 95 5 
1.1 500 5 95 
1.6 500 5 95 
1.7 500 95 5 
2.3 500 95 5 
 
Analyte-Specific MS parameters: 
 
Q1 Mass Q3 mass dwell time (ms) Analyte ID DP EP CE CXP 
278.3 95.2 30 PHX  60 10 40 10 
289.3 95.2 30 D11-PHX IS 60 10 40 10 
307.3 220.2 30 FLUCON OFF 60 10 40 10 
311.3 223.2 30 D4-FLUCON OFF 60 10 40 10 
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2.2.11.2.11. Analysis of single hydroxy metabolite 
 
Volume (µL) injected: 25 
Diverter valve timings (to MS): 2->3.8 minutes 
 
HPLC Gradient: 
 
Time (min) Flow Rate(µL/min) A (%) B(%) 
0 500 95 5 
0.1 500 95 5 
4.1 500 50 50 
4.2 500 5 95 
4.7 500 5 95 
4.8 500 95 5 
5.4 500 95 5 
 
Analyte-SpecIfic MS parameters: 
 
Q1 Mass Q3 mass dwell time (ms) Analyte ID DP EP CE CXP 
305.2 96.1 20 D11-CIS-OH IS 60 10 40 10 
294.2 95.1 20 CIS PHX-OH 60 10 40 10 
294.2 95.101 20 TRANS PHX-OH 60 10 40 10 
307.3 220.2 20 FLUCON* 60 10 40 10 
311.3 223.2 20 D4-FLUCON* 60 10 40 10 
294.201 95.1 20 CIS PHX-OH 2  60 10 40 10 
* CE offset to avoid saturation of detector with high signal 
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2.2.11.2.12. Data processing and reporting of concentrations 
Calibration lines were contructed using the area ratio of analyte to internal standard, 
a linear fit and and an appropriate weighting factor, typically 1/y2. The D11-cis-
hydroxy metabolite internal standard was used for measurements of all single 
hydroxyl metabolites. Also, the calibration standards were used to determine the 
concentrations of PHX and its two major single hydroxyl metabolites in the diluted 
sample extracts (Cdil) and then dilution was corrected for as follows: 
Cfnd = Cdil x dilution factor 
Fluconazole reference samples were used to correct for losses of MeCN on storage of 
treated samples and for errors in the dilution stages by using the following formula: 
Ccorr = Cfnd x (Ref fluc/Samplefluc) 
Reffluc = Mean peak area ratio (n=3) of Fluc/D4-Fluc for the reference samples at that 
particular dilution  
Samplefluc = peak area ratio of Fluc/D4-Fluc for the test sample at that particular 
dilution  
The concentrations of the trans-hydroxy metabolites are subject to an extra 
correction to account for the presence of two diastereomers, e.g. for isomer A: 
CFINAL(TOHA) = Ccorr(TOHA) x Mean Ratio (Peak Area (T-OHA)/(Peak-Area (T-OHA)+ Peak Area (T-
OHB))) 
The mean ratio was calculated over all the calibration standards. 
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2.2.11.2.13.   Semi-quantitative measurements of total concentrations 
of metabolites 
The metabolites were assumed to have identical MS responses to PHX-OH reference 
standards. A single-point calibration standard was used – based on the mean of the 
response from trans and cis-OH standards. The total peak areas across all peaks in 
the expected MRM channel were employed for each class of metabolite (single –OH, 
di-OH, etc.) 
 
 
2.2 STATISTICAL ANALYSIS 
 
Unless otherwise stated, numerical data  are  expressed  as  mean  ±  S.D  from  3  
independent  experiments.  Also, one way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparison test to determine statistical 
significance between test groups. Statistical analysis was performed using 
GraphPad Prism® version 5.04 (GraphPad Prism Software Inc, CA, USA). The 
significance of differences between two groups was assessed with an unpaired 
student t-test. A p value of ≤ 0.05 was considered to be statistically significant.  
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CHAPTER THREE 
 
 
 
 
 
CHARACTERISATION OF 
ISOLATED HUMAN LIVER 
SINUSOIDAL ENDOTHELIAL CELLS 
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3.1 INTRODUCTION 
 
Liver sinusoidal endothelial cells (HLSEC) are a unique population of endothelial cells 
with features of vascular and lymphatic endothelial cells (Lalor et al., 2006, Sorensen 
et al., 2015). They are the only endothelial cell population which lack an organised 
basement membrane and have transcytoplasmic pores termed fenestrations which 
are organised into groups of sieve plates (DeLeve, 2007, Stolz, 2011a). Liver 
sinusoidal endothelial cells were isolated from human volunteer liver using the 
immunomagnetic separation method with CD-31 conjugated beads described in 
chapter 2 (Lalor et al., 2002). This chapter deals with the validation of the isolated 
cells as authentic liver sinusoidal endothelial cells and different from endothelial cells 
from other vascular beds, specifically the dermis. Further, it shows the purity of the 
preparation by absence of other hepatic contaminants. Using a transcriptomic and 
bioinformatics approach, HLSEC will be compared with human dermal microvascular 
endothelial cells (HDMEC) and human dermal lymphatic endothelial cells (HDLEC). In 
addition to phenotypically characterising the isolated HLSEC for the expression of 
endothelial-cell-specific markers, this chapter shows the response of HLSEC to 
angiogenic factors which modulate endothelial cell physiology. This includes 
activation of growth factor receptors to induce intracellular signalling, cell 
proliferation, cell migration, and tubular morphogenesis. The chapter concludes with 
a comparative analysis of in-house isolated HLSEC with commercially-sourced ones. 
This shall set the stage for the assays in the subsequent experimental chapters that 
show the potential roles of HLSEC in drug-induced liver injury using single cell and 
multicellular liver microtissue systems.           
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3.2 RESULTS 
 
3.2.1 Phenotypic characterisation of isolated   human 
liver sinusoidal endothelial cells 
 
3.2.1.1 Analysis of purity of the isolated liver sinusoidal 
endothelial cells 
 
The process of isolating the human sinusoidal endothelial cells (HLSEC) used in the 
study entailed the enzymatic digestion of human liver tissue, followed by separation 
of constituent cells. HLSEC were separated using CD-31 conjugated magnetic beads 
as described in the materials and methods section. After separation of HLSEC and 
culture, there is likelihood of contamination by other hepatic cells. In order to 
evaluate the purity of the isolated cells, mRNA from the samples were analysed by 
qPCR for the expression of albumin and collagen type-1 which are markers of 
hepatocyte and fibroblast respectively. As shown in figure 3.1, the expression of 
albumin in primary human hepatocyte (PHH) was significantly (p < 0.001) higher as 
compared with HLSEC, with an almost 200 million fold higher expression. Also, 
collagen type I was significantly (p < 0.001) highly expressed in human hepatic 
fibroblast (HHF) in comparison with HLSEC where there was almost no expression. 
This shows that that HLSEC thus isolated was pure and free from major hepatic 
contaminants. 
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Figure 3.1: HLSEC do not express other hepatic markers 
Relative expression of albumin and collagen-1 in HLSEC and other liver cell types. HLSEC, HDMEC, 
HDLEC or HHF were cultured for 48 h or until 90% confluent. After removal of culture medium, cells 
were washed with ice-cold PBS twice and mRNA was extracted, cDNA synthesised and analysed for the 
expression of albumin or collagen by quantitative real-time PCR as described. Freshly isolated PHH was 
spun down at 80 g and lysed with buffer RLT to extract mRNA and processed as above.  Results are 
expressed as mean ± SD, (n=3) from 3 separate experiments and analysed using one way analysis of 
variance ANOVA followed by Dunnett’s multiple comparison test. Values are significant at ****p < 
0.0001. HLSEC: human liver sinusoidal endothelial cells, HDMEC: Human dermal microvascular 
endothelial cells, HDLEC: Human dermal lymphatic endothelial cells, PHH: primary human hepatocyte, 
HHF: human hepatic fibroblast. 
 
 
3.2.1.2 Liver sinusoidal endothelial cells are fenestrated 
 
A hallmark of HLSEC is the presence of fenestrations that enable the transfer of 
substances between the blood circulating in the sinusoids and the underlying 
hepatocytes. In order to show that HLSEC maintained this primary characteristic 
following isolation and culture, they were processed for imaging by scanning electron 
microscopy. Figure 3.2 below shows an electron micrograph which compares the 
surface characteristics of liver sinusoidal endothelial cells with those of the human 
dermal microvascular endothelial cells (HDMEC). The electron micrograph shows that 
on HLSEC, there were fenestrations grouped into a cluster referred to as sieve plates 
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(circled in red) which were absent on HDMEC. 
 
Figure 3.2: Scanning electron micrograph of HLSEC and HDMEC 
Human dermal microvascular endothelial cells (HDMEC) or human liver sinusoidal endothelial cells 
(HLSEC) were plated out at a density of 2.6 X 104 cells/cm2 on a collagen coated glass coverslip for 72 
h. HDMEC and HLSEC were both cultured in the same medium. Cells on cover slips were then 
processed for scanning electron microscopy as described in materials and methods. Images above 
shows that fenestrations are absent on HDMEC but present on HLSEC. 
 
 
 
 
 
3.2.1.3 Expression of endothelial markers on HLSEC and 
other endothelial cell types 
 
In order to show that the isolated HLSEC expressed endothelial cell-specific genes, 
mRNA from HLSEC was analysed for platelet-endothelial adhesion molecule or CD-31, 
VEGFR-1 and VEGFR-2. Figure 3.3 shows the relative expression of endothelial 
markers on HLSEC, HDMEC and HDLEC. While all cells expressed the endothelial cell 
markers, HLSEC had a significantly higher expression of VEGFR-1 and CD-31 in 
comparison with HDLEC and a significantly (p < 0.0001) higher expression of VEGFR-2 
when compared with HDMEC. While this is an indication of the endothelial nature of 
the HLSEC that were isolated, it also shows that HLSEC better preserve these markers 
than the tested endothelial cell populations.   
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Figure 3.3: Expression of endothelial markers on HLSEC 
Relative expression of VEGFR-1, VEGFR-2 and CD-31 in HLSEC and other endothelial cell types. HLSEC, 
HDMEC, HDLEC were cultured for 48 h or until 90% confluent. After removal of culture medium, cells 
were washed with ice-cold PBS twice and mRNA was extracted, cDNA synthesised and analysed for the 
expression of VEGFR-1, VEGFR-2 and CD-31 by quantitative real-time PCR as described. Results are 
expressed as mean ± SD, (n=3, three separate donor liver) and analysed using one way analysis of 
variance ANOVA followed by Dunnett’s multiple comparison test. Values are significant at ****p < 
0.0001 HLSEC: liver sinusoidal endothelial cells, HDMEC: Human dermal microvascular endothelial 
cells, HDLEC: Human dermal lymphatic endothelial cells. VEGFR-1, vascular endothelial growth factor 
receptor 1; VEGFR-2, vascular endothelial growth factor receptor 2.  
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3.2.1.4 Expression of lymphatic markers on HLSEC 
 
To confirm reports in literature that HLSEC express markers of lymphatic 
endothelium (Mouta Carreira et al., 2001, Nonaka et al., 2007), mRNA from HLSEC 
was analysed for the expression of VEGFR-3, LYVE-1, PROX-1 and podoplanin – classic 
lymphatic endothelial markers (Salven et al., 2003, Lalor et al., 2006). Figure 3.4 
shows the relative expression of VEGFR-3, LYVE-1, PROX-1 and podoplanin in HLSEC, 
HDMEC and HDLEC. VEGFR-3 was significantly (p < 0.0001) and highly expressed in 
HLSEC and HDLEC in comparison with HDMEC. HLSEC had a significantly (p < 0.0001) 
higher expression of LYVE-1 in comparison with HDLEC. There was no difference in 
the expression of LYVE-1 between HDMEC and HDLEC. On the other hand, 
podoplanin and PROX-1 were significantly highly expressed in the lymphatic 
endothelium positive control, HDLEC, in comparison with HLSEC. This data agrees 
with literature (Dudas et al., 2004) that, while HLSEC expressed some lymphatic 
markers, it did not express others. Figure 3.5 further confirms the expression of the 
lymphatic marker, VEGFR-3, in HLSEC at the protein level using immunofluorescent 
staining.  
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Figure 3.4: Expression of lymphatic endothelial markers on HLSEC 
Relative expression of VEGFR-3, LYVE-1, PROX-1 and podoplanin on HLSEC and other endothelial cell 
types. HLSEC, HDMEC, HDLEC were cultured for 48 h or until 90% confluent. After removal of culture 
medium, cells were washed with ice-cold PBS twice and mRNA was extracted, cDNA synthesised and 
analysed for the expression of VEGFR-3, LYVE-1, PROX-1 and podoplanin by quantitative real-time PCR 
as described. Results are expressed as mean ± SD, (n=3, three separate donor liver) and analysed using 
one way analysis of variance ANOVA followed by Dunnett’s multiple comparison test. Values are 
significant at ***p < 0.001 and ****p < 0.0001. HLSEC: liver sinusoidal endothelial cells, HDMEC: 
Human dermal microvascular endothelial cells, HDLEC: Human dermal lymphatic endothelial cells. 
PROX-1, Prospero homeobox protein 1; LYVE-1, Lymphatic vessel endothelial hyaluronan receptor 1. 
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Figure 3.5: Immunofluorescent micrograph of HLSEC and HDMEC showing the expression of VEGFR-3 
Cells were seeded on collagen-coated glass coverslips until they were at least 60 % confluent. They 
were fixed in 2 % paraformaldehyde for 15 min after removal of medium and two-time PBS washes. 
This was followed by processing for immunofluorescent microscopy as earlier described in materials 
and methods. Cells on coverslips were stained for VEGFR-3 [red] (lymphatic endothelial marker) and 
CD-31 [green] (vascular endothelial marker) and Hoechst [blue] (nuclear stain). VEGFR-3, vascular 
endothelial growth factor receptor 3.     
 
 
3.2.1.5 Expression of HLSEC specific markers  
 
The genes analysed above are vascular and/or lymphatic endothelium-specific. 
However, other genes have been reported in literature to be more specific to HLSEC. 
An example is the blood coagulation factor VIII otherwise known as anti-haemophilic 
factor (Do et al., 1999). Others include Stabilin-2 and L-SIGN which are involved in the 
scavenging and immunological functions of HLSEC (Cormier et al., 2004, Nonaka et 
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al., 2007). Figure 3.6 below shows that while factor VIII, L-SIGN, stabilin-1 and 
stabilin-2 were significantly (p < 0.0001) highly expressed in HLSEC in comparison 
with HDMEC. HDLEC also had a significantly high expression of Stabilin-2 in 
comparison with L-SIGN.  
 
  
Figure 3.6: Expression of HLSEC-specific markers 
Expression of coagulation Factor VIII and L-SIGN and Stabilin-2 on HLSEC and other endothelial cell 
types. HLSEC, HDMEC, HDLEC were cultured for 48 h or until 90% confluent. After removal of culture 
medium, cells were washed with ice-cold PBS twice and mRNA was extracted, cDNA synthesised and 
analysed for the expression of coagulation Factor VIII and L-SIGN and Stabilin-2 by quantitative real-
time PCR as described. Results are expressed as mean ± SD, (n=3, three separate donor liver) and 
analysed using one way analysis of variance ANOVA followed by Dunnett’s multiple comparison test. 
Values are significant at ****p < 0.001. HLSEC: liver sinusoidal endothelial cells, HDMEC: Human 
dermal microvascular endothelial cells, HDLEC: Human dermal lymphatic endothelial cells 
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3.2.1.6 Transcriptomic Analysis 
 
In order to comprehensively compare liver sinusoidal endothelial cells with cells from 
other vascular beds, a whole transcriptome analysis was carried out on the mRNA 
extracted from liver sinusoidal endothelial cells, human dermal microvascular 
endothelial cells (HDMEC) and human dermal lymphatic endothelial cells (HDLEC) 
using GeneChip® Human Transcriptome Array 2.0 (HTA 2.0) (Affymetrix, UK). 
Experiments were carried out on endothelial cells from three different donors for 
each group. After the quality and integrity of the mRNA extracted from these samples 
were ascertained, they were analysed for differentially expressed genes to show the 
difference within and between the groups. 
 
3.2.1.6.1 Principal component analysis 
 
Signal intensity data generated from the GeneChip® Human Transcriptome Array, 
expression profiles were analysed using the Expression Console software (Affymetrix, 
UK). By means of a mathematical algorithm, principal component analysis (PCA) plots 
were generated to identify components with largest of variations and these were 
plotted against a second component which were independent of and uncorrelated 
with the first components, but show the largest variation (Ringner, 2008). This 
mathematical approach enables the separation of the individual samples analysed in 
directions that represent the overall variation in them based on their gene expression 
pattern, and to graphically show the level at which they compare with other samples 
in the overall analysis. Figure 3.7 below shows the principal component analysis (PCA) 
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of the samples from the three endothelial cell groups.  While the plot shows a clear 
distinction between the three different endothelial cells groups, it shows a similar 
clustering pattern within each group. This is an indication of the homogeneity in gene 
expression within each of the groups.  
 
 
  
Figure 3.7: Principal component analysis of HLSEC, HDMEC and HDLEC. 
Cells (HLSEC, HDMEC and HDLEC) were grown to 90% confluency, mRNA extracted and quantified as 
earlier described in materials and methods section. Then, mRNA samples were hybridised onto 
Affymetrix Human transcriptome (HTA 2.0) arrays and scanned using the Genechip Scanner 3000 7G. 
The resulting gene expression intensity data was analysed with the Expression Console® software 
(Affymetrix, UK) which was used to effect a quality control of the experiment as well as generate the 
principal component analysis (PCA) plot as shown in the figure above. The PCA plot helps to separate 
the samples into components with the largest amount of variation which is a function of the pattern of 
gene expression in the samples. The three-dimensional PCA plot reveals that 3 samples groups can be 
clearly separated, implying the existence of DE (Differentially Expressed) genes. 
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3.2.1.6.2 Analysis of differentially-expressed genes 
 
In order to have a clearer picture of the difference between the three endothelial cell 
populations, each group was compared with every other group to show the pattern 
of gene expression. Figure 3.9 below is an MA plot showing the amount of variation 
between each matched pairs of cells. In comparison with HDMEC there were 371 
upregulated genes in HLSEC, while there were 451 downregulated genes. Also there 
were 502 upregulated genes in HLSEC when compared with HDLEC. By contrast, 
there were 430 genes more highly expressed in HLSEC as against HDLEC. Comparing 
HDMEC with HDLEC, there were 265 upregulated genes while 328 genes were 
downregulated.  Table 3.1 below shows 19 of the genes upregulated in HLSEC in 
comparison with HDMEC. Notable among these are coagulation factor VIII and 
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) which have both been 
reported to be expressed in LSEC. Others genes upregulated in HLSEC versus HDMEC 
include mannose receptor C 1, C-type lectin domain receptor 1B both of which are 
scavenger receptors reviewed in chapter 1 of this thesis.  Also, in the differential 
expression of HLSEC relative to HDLEC, similar genes were upregulated in HLSEC 
(Table 3.3). On the other hand, among the genes downregulated in HLSEC relative to 
HDMEC were transforming growth factor beta 2 (TGFB2), fibroblast growth factor 16, 
claudin 1. Of particular interest are genes downregulated in HLSEC relative to HDLEC 
(Table 3.4). These include the lymphatic markers, podoplanin and PROX-1.  Claudin 1 
was also downregulated in the comparison with HDMEC (Table 3.2). 
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Figure 3.8: Heatmap showing expression of some of 5000 most highly expressed genes in the three 
groups of endothelial cells. 
Cells (HLSEC, HDMEC and HDLEC) were grown to 90% confluency, mRNA extracted and quantified as 
earlier described in materials and methods section. Then, mRNA samples were hybridised onto 
Affymetrix Human transcriptome (HTA 2.0) arrays and scanned using the Genechip Scanner 3000 7G. 
The resulting gene expression intensity data was analysed with the Expression Console® software 
(Affymetrix, UK) which was used to effect a quality control of the experiment as well as estimate the 
expression of the genes of interest into log2 expression. The output from this analysis was further 
analysed using the Transcriptome Analysis Console (TAC) software (Affymetrix, UK). TAC was used to 
determine identify the differentially-expressed genes, the signal intensities of any particular gene in 
the sample of interest. The signal intensity data was then sorted by the 5000 most highly expressed 
genes, which were then visualised using hierarchical clustering to generate a heatmap. The heatmap 
above shows a general profile of gene expression indicated by signal intensity graphically depicted in 
colours, with green being the samples with the lowest gene expression while red are samples with 
highest gene expression.  
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Figure 3.9: MA plot showing differentially-expressed genes between the groups of endothelial cells. 
Cells (HLSEC, HDMEC and HDLEC) were grown to 90% confluency, mRNA extracted and quantified as earlier described in materials and methods section. Then, 
mRNA samples were hybridised onto Affymetrix Human transcriptome (HTA 2.0) arrays and scanned using the Genechip Scanner 3000 7G. The resulting gene 
expression intensity data was analysed with the Expression Console® software (Affymetrix, UK) which was used to effect a quality control of the experiment as 
well as estimate the expression of the genes of interest into log2 expression. The output from this analysis was further analysed using the Transcriptome Analysis 
Console (TAC) software (Affymetrix, UK). TAC was used to determine identify the differentially-expressed genes, the signal intensities of any particular gene in the 
sample of interest. Using signal intensity data generated, each group was compared with the other to generate the linear fold change (FC) in gene expression 
relative to the other. The estimated log2 fold change (logFC) in the genes of interest were compared between the groups of interest using t-test. The estimated p-
values for each logFC values were adjusted for multiple testing using the False Discovery Rate (FDR) method. Significantly differential expression were those 
whose FDR had adjusted p-value < 0.05. The number of differentially-expressed genes in each paired comparison and the direction of the expression were 
plotted into an MA plot shown; M = log fold change, A= log expression.  
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Table 3.1: Most upregulated genes in HLSEC vs HDMEC 
Gene Description Fold Change  
Ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) 49.14 
plasmalemma vesicle associated protein (PLVAP) 46.27 
regulator of G-protein signaling 7 binding protein (RGS7BP) 38.67 
placenta specific 8 (PLAC8) 35.64 
tissue factor pathway inhibitor 2 (TFPI2) 30.55 
tissue factor pathway inhibitor 2 (TFPI2) 29.4 
protocadherin 17(PCDH17) 28.69 
nitric oxide synthase trafficking (NOSTRIN) 28.17 
guanylate binding protein 4 (GBP4) 22.74 
EH domain containing 3 (EHD3) 19.58 
acyl-CoA synthetase medium-chain family member 3 (ACSM3) 19.34 
selenoprotein P, plasma, 1 (SEPP1) 19.28 
SH3 and cysteine rich domain(STAC) 18.39 
Meis homeobox 2(MEIS2) 17.56 
acyl-CoA synthetase medium-chain family member 3 (ACSM3) 15.14 
coagulation factor VIII, procoagulant component (F8) 14.69 
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) 14.15 
neural cell adhesion molecule 2 (NCAM2) 11.47 
junctional adhesion molecule 2 (JAM2) 11.43 
 
Table 3.2: Most down-regulated genes in HLSEC vs HDMEC 
Description Fold change 
cholinergic receptor, nicotinic alpha 1 (CHRNA1) -17.79 
RAB3B, member RAS oncogene family (RAB3B) -19.66 
transforming growth factor beta 2 (TGFB2) -19.67 
ADAM metallopeptidase domain 23 (ADAM23) -21.13 
chemokine (C-X-C motif) ligand 6 (CXCL6) -21.9 
chemokine (C-X3-C motif) ligand 1 (CX3CL1) -23.34 
matrix metallopeptidase 10 (MMP10) -26.92 
cholinergic receptor, nicotinic alpha 1 (CHRNA1) -44.22 
Transgelin (TAGLN) -55.49 
sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 1 (SPOCK1) 
-56.53 
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Table 3.3: Most upregulated genes in HLSEC vs HDLEC 
Description Fold Change  
ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) 79.42 
interferon, alpha-inducible protein 27 (IFI27) 77.62 
interferon, alpha-inducible protein 27 (IFI27) 74.54 
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) 47.22 
nitric oxide synthase trafficking (NOSTRIN) 43.46 
regulator of G-protein signaling 7 binding protein (RGS7BP) 37.96 
guanylate binding protein 4 (GBP4) 30.55 
placenta specific 8 (PLAC8) 26.2 
plasmalemma vesicle associated protein (PLVAP) 25.51 
vesicle amine transport 1-like (VAT1L) 23 
acyl-CoA synthetase medium-chain family member 3 (ACSM3) 21.89 
acyl-CoA synthetase medium-chain family member 3 (ACSM3) 21.8 
chemokine (C-X-C motif) receptor 4 (CXCR4) 21.44 
CAP, adenylate cyclase-associated protein, 2 (yeast) (CAP2) 21.42 
protocadherin 17 (PCDH17) 19.68 
epithelial membrane protein 3 (EMP3) 18.91 
bone marrow stromal cell antigen 2 (BST2) 18.46 
SPARC like 1 (SPARCL1) 18.21 
5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled 
(HTR1D) 
17.86 
junctional adhesion molecule 2 (JAM2) 17.05 
 
Table 3.4: Most down-regulated genes in HLSEC vs HDLEC 
Description Fold Change 
prospero homeobox 1 (PROX1) -19.37 
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary 
glycoprotein) (CEACAM1) 
-21.89 
sulfotransferase family 1C member 4 (SULT1C4) -23.33 
transient receptor potential cation channel, subfamily C, member 6 
(TRPC6) 
-25.4 
protein tyrosine phosphatase, receptor type, S (PTPRS) -26.75 
reelin(RELN) -29.92 
deltex 4, E3 ubiquitin ligase (DTX4) -30.81 
podoplanin(PDPN) -34.5 
solute carrier family 2 (facilitated glucose transporter), member 12 
(SLC2A12) 
-39.62 
cholinergic receptor, nicotinic alpha 1(CHRNA1) -108.66 
 
 132 
 
3.2.2 Functional characterisation of HLSEC 
 
In addition to validating HLSEC for the expression of endothelial cell-specific genes, 
it is important to functionally characterise them; namely evaluating their response 
to growth factors that are important in their physiology.   This sub-section focusses 
on the response of HLSEC to VEGF-A and VEGF-C to elicit endothelial-specific 
responses – activation of cell surface receptors to induce intracellular signalling that 
result in cell proliferation, migration and ultimately formation of vasculature.   The 
effect of growth factors on HLSEC fenestrations was also investigated. 
 
3.2.2.1 Effect of growth factor stimulation on HSLEC 
fenestrations 
 
Following reports that fenestrations on HLSEC are regulated by VEGF-A, HLSEC was 
cultured in the presence of VEGF-A as well as VEGF-C to see their effect on the 
fenestration in HLSEC. Scanning electron micrographs in figure 3.10 shows that 
upon stimulation with VEGF-A, there was a significant (p<0.01) increase in the 
number of the fenestration on HLSEC, whereas stimulation with VEGF-C did not 
induce any significant difference when compared with basal. Also, fenestral porosity 
was increased in the VEGF-A group.  
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Figure 3.10: Scanning electron micrograph showing effect of growth factor on HLSEC 
Cells were plated out at a density of 2.6 X 104 cells/cm2 on a collagen coated glass coverslip for 24 h after which they medium was replaced with full growth 
medium supplemented with growth factor (B,C) or full growth medium alone (A) for 48 h. Cells on cover slips were then processed for scanning electron 
microscopy as described in materials and methods. Fenestrations are circled in dotted red lines. Fenestrations were counted from 4 randomly-selected images 
and represented mean ± SD (n=4). Groups were compared using ANOVA followed by Dunnett’s multiple comparison test. Values are significant at **p < 0.01
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3.2.2.2 Activation of intracellular signalling by growth 
factor stimulation 
 
As shown above, HLSEC express VEGFR-1, VEGFR-2 and VEGFR-3. In order to assess 
the activation of these and any other similar receptors they might express, HLSEC, 
HDMEC and HDLEC were screened with a range of growth factors. Figure 3.11 
shows that VEGFR-2 was activated by the two VEGF-A isoforms (VEGF-A121 and 
VEGF-A165), and by VEGF-E in all three cell types. This was accompanied by a 
corresponding activation of ERK 1/2 (regulator of cell proliferation) and AKT 
(regulator of endothelial cell survival). VEGF-B and VEGF-C did not activate VEGFR-2 
at the concentration used. AKT and ERK 1/2 were phosphorylated in response to 
FGF, EGF and HGF, but not by PDGF. In HDLEC there was a strong activation of AKT 
following VEGF-C stimulation.  
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Figure 3.11: Activation of intracellular signalling pathway in endothelial cells 
Cells were cultured until 90% confluent, kept on medium containing 1% FBS for 16 hours and then 
stimulated with 50 ng/ml of growth factors for 10 min. Cells were lysed for total protein contents 
using modified RIPA buffer, solubilised in LDS sample buffer, denatured at 90 ⁰C. Protein was 
separated using SDS PAGE for 45 min., transferred unto nitrocellulose membrane for 2 h. and 
blocked with 5% BSA. Membranes were then probed with respective antibodies for phosphorylated 
VEGFR-2, total VEGFR-2, phosphorylated AKT, phosphorylated ERK 1/2 and GAPDH.  FBS: foetal 
bovine serum, VEGF-A: vascular endothelial growth factor A, VEGF-B: vascular endothelial growth 
factor B, VEGF-C: vascular endothelial growth factor C, VEGF-E: vascular endothelial growth factor E, 
FGF: fibroblast growth factor, EGF: epidermal growth factor, PDGF: platelet-derived growth factor. 
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3.2.2.3 Cell proliferation 
 
A downstream effect of the activation of these intracellular signalling pathway 
following phosphorylation of VEGFR-2 is cell proliferation. In order to show this, 
HLSEC, HDMEC, and HDLEC were incubated with the same range of growth factors 
used to activate the growth factor receptors. Figure 3.12 shows the proliferation of 
HLSEC, HDMEC, and HDLEC in response to a range of growth factors. Hepatocyte 
growth factor and growth factors of the VEGF family, except VEGF-B induced a 
highly significant (p< 0.001) increase in cell proliferation in HLSEC compared to 
basal. The trend was similar in HDMEC and HDLEC with a highly significant (p<0.01) 
increase in cell proliferation in comparison with the basal.  Fibroblast growth factor 
and hepatocyte growth factor induced a highly significant (p<0.01) increase in cell 
proliferation in HLSEC while only HDMEC but not HDLEC had a highly significant (p< 
0.01) increase in cell proliferation in response to FGF.  
 
Figure 3.12: Cell proliferation assay 
Cell proliferation in HLSEC and endothelial cells from other vascular beds. Cells were plated at 1.5 X 
104 cells/ cm3 on a collagen-coated plate for 48 h after which they were washed and placed on a 
culture medium containing 1% FBS for 16 h. Cell were stimulated with 50 ng/ml of growth factor in  
culture medium containing 1% FBS for 72h. Cells were thereafter washed with ice-cold PBS twice and 
lysed with Cell Titer Glo reagent and assayed for ATP content as described in methods. Results are 
expressed as mean ± SD, (n=3) and analysed using one way analysis of variance ANOVA followed by 
Dunnett’s multiple comparison test, with growth factor stimulated groups compared against. Values 
are significant at *p<0.05, **p<0.01, ***P<0.001. 
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Also, while HDLEC experienced a significant (p<0.05) increase in cell proliferation in 
response to EGF, this was not observed in HDMEC. Platelet-derived growth factor 
did not induce any significant effect on cell proliferation in any cell type.    
 
3.2.2.4 Cell migration 
 
Cell migration represents a critical component of angiogenesis as endothelial cells 
migrate in response to growth factor stimulation.  In order to confirm the ability of 
HLSEC to migrate in response to angiogenic growth factors, HLSEC, HDMEC and 
HDLEC were stimulated with VEGF-A or VEGF-C after the introduction of scratch 
unto endothelial cells grown to confluence in tissue-culture plates. Figure 3.13 
below shows the effect of VEGF-A and VEGF-C on cell migration in endothelial cells. 
After 16 h of exposure to VEGF-A and VEGF-C, there was a highly significant (p< 
0.0001) increase in wound closure in HLSEC and HDMEC when compared with 
unstimulated control. As for HDLEC, VEGF-A induced a highly significant (p<0.001) 
increase in wound closure when compared with basal, while a significant (p<0.01) 
increase in wound closure was obtained in response to VEGF-C.  
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Figure 3.13: Cell Migration 
Cell migration in HLSEC. HLSEC, HDMEC or HDLEC were plated on a collagen-coated 12-well tissue 
culture plate at 2.1 X 104 cells/cm2 until fully confluent. Medium was removed; cells washed twice 
with PBS and then place on medium containing 1% FBS for 16 hours after which straight-line 
scratches were introduced with a sterile 200 µl pipette tip. Cells were washed with PBS after removal 
of culture medium to remove floating cells and 50 ng/ml of VEGF-A, VEGF-C or basal medium was 
added unto the cells. Pictures of the scratch-wounds were taken (mag X4) Cells were incubated at 
37° C for 16 h after which there washed twice with PBS at room temperature, and fixed with 2% PFA 
for 15 minutes, washed twice again with PBS twice and further processed as earlier described. 
Images of scratch wounds were taken (t=16 h) and compared with those taken at an earlier time 
point (t= 0 h). Cell migration was calculated as percentage wound closure (area covered by growth 
factor stimulated compared with unstimulated at t= 0 h). Wound areas were measured using the 
scratch wound plugin of the Image-J software Results are expressed as mean ± SD, (n=3, three 
independent experiments) and analysed using one way analysis of variance ANOVA followed by 
Dunnett’s multiple comparison test, with growth factor stimulated groups compared against. Values 
are significant at **p<0.01, ***P<0.001, ****p<0.00001. VEGF-A: Vascular endothelial growth factor 
A, VEGF-C: Vascular endothelial growth factor C. scale bars= 100 µm.      
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3.2.2.5 Tube formation 
 
Upon activation of VEGF receptors to induce phosphorylation of intracellular 
signalling which effect cell proliferation and migration, an additional effect is cell 
permeability. This is required to enable the cells to reorganise to form new 
vasculature or new vasculature from pre-existing ones. In order to assess this in 
HLSEC, an in vitro angiogenesis assay which incorporates endothelial cells seeded 
upon a ‘lawn’ of confluent fibroblasts was carried out. Figure 3.14 shows the effect 
of VEGF-A and VEGF-C on the formation of tubular network in an in vitro 
angiogenesis assay in HLSEC and HDMEC. VEGF-A induced a highly significant 
(p<0.01) increase in tube formation in HLSEC and HDMEC in comparison to control. 
Also, VEGF-C induced a significant effect on both HLSEC and HDMEC when 
compared with the basal control.    
 
Figure 3.14: Tube formation assay 
In vitro angiogenesis assay in HLSEC. Juvenile NHDF were cultured at 7.9 X 10 cells/ cm2  for 3 days in 
a collagen coated glass  24-well plates for 72 h when the cells are fully confluent,  after which HLSEC 
were plated on top at a density of 21 X 103 cells/ cm2 for 24 h. Then cells were treated with growth 
medium containing 1% FBS and/ or 50 ng/ml of VEGF-A, VEGF-C for 72 h and then re-exposed to 
same for another 48 h. Cells were then washed in PBS at room temperature and fixed with 2% PFA 
for 15 min., washed twice with PBS and then stained for CD-31 following the colorimetric 
immunocytochemical methods already described. Angiogenesis was quantified using Angioquant 
(NIH, USA) which quantifies number of branches and tube lengths. Bars represent mean ± SD (n=3, 
three independent experiments) and basal state compared with growth-factor stimulated state by 
Student t-test. Data are significant at **p<0.01.  
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3.2.3 Comparative study between in-house HLSEC and 
commercially sourced HLSEC 
 
Commercially-available cells are a viable source of liver sinusoidal endothelial 
cells. The potential advantage they confer is easy availability and the time saved 
from cell isolation. In order to assess the viability of commercially-sourced HLSEC, 
HLSEC procured from two commercial sources were compared with in-house 
isolated HLSEC. Cells were cultured till they were 90 % confluent and were 
analysed for key endothelial, lymphatic and LSEC marker genes by quantitative 
real-time PCR. 
  
3.2.3.1 Commercially-sourced HLSEC express key 
endothelial and lymphatic makers at a very low 
level 
 
In order to validate the endothelial identity of the commercial HLSEC, they were 
assessed by PCR for the expression of endothelial cell-specific genes. Also, they 
were assessed for the expression of lymphatic markers VEGFR-3, LYVE-1, PROX-1 
and podoplanin. Figure 3.15 below shows relatively low levels of all endothelial 
marker genes in commercial HLSEC in comparison with in-house isolated HLSEC. 
The relative expression of VEGFR-1 in the group marked HLSEC SC (LM) was 
significantly lower than in their in-house isolated contemporary (HLSEC D141). The 
expression of VEGFR-2 in the in-house isolated HLSEC was significantly higher than 
the HLSEC SC (PM) group. The trend is similar for CD-31, which is another 
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important endothelial cell marker. Although there was a relatively-low expression 
of the above genes in comparison with HLSEC 141, the HLSEC MED group has a 
significantly higher expression of the endothelial-specific genes in comparison 
with the HLSEC SC group. A similar trend can also be seen for the lymphatic 
markers, VEGFR-3, PROX-1 and LYVE-1. Nevertheless, the expression of 
podoplanin was relatively higher in HLSEC SC when compared with HLSEC 141 
(figure 3.16). 
 
3.2.3.2 Commercial HLSEC had relatively low expression of 
LSEC-specific genes 
 
In order to further investigate the possibility of the commercial HLSEC expressing 
genes that are LSEC-specific, mRNA extracted from these were evaluated for the 
expression of coagulation factor VIII, stabilin-1, stabilin-2 as well as L-SIGN. Similar 
to findings with regards to the expression of endothelial genes, figure 3.17 shows 
that the in-house isolated HLSEC had a significantly higher expression of coagulation 
factor VIII and L-SIGN in comparison with HLSEC SC (PM) and the other commercial 
samples. The expression of stabilin-1 and stabilin-2 were highly expressed in HLSEC 
D141 in comparison to the HLSEC SC groups.
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Figure 3.15: Expression of endothelial markers on HLSEC 
Relative expression of VEGFR-1, VEGFR-2 AND CD-31 in in-house HLSEC and commercially-sourced ones. Cells were cultured for 48 h or until 90% confluent. After removal 
of culture medium, cells were washed with ice-cold PBS twice and mRNA was extracted, cDNA synthesised and analysed for the expression of the respective genes by qPCR 
as described. Freshly isolated PHH was spun down at 80 g and lysed with buffer RLT to extract mRNA and processed as above.  Results are expressed as mean ± SD, (n=3, 
three independent experiments). HLSEC D141: in-house isolated human liver sinusoidal endothelial cell, LSEC SC (PM): Commercially-sourced liver sinusoidal endothelial cell 
from Sciencell cultured on their proprietary medium, HLSEC SC (LM): Commercially-sourced liver sinusoidal endothelial cells from Sciencell cultured on LSEC medium. 
Commercially-sourced liver sinusoidal endothelial cell from Medicyte cultured on their proprietary medium, HLSEC SC (LM): Commercially-sourced liver sinusoidal 
endothelial cell from Medicyte cultured on HLSEC medium
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Figure 3.16: Expression of lymphatic markers on commercial HLSEC 
Relative expression of coagulation VEGFR-3, LYVE-1, PROX-1 and podoplanin in in-house isolated and 
commercial HLSEC. Cells were cultured for 48 h or until 90% confluent. After removal of culture 
medium, cells were washed with ice-cold PBS twice and mRNA was extracted, cDNA synthesised and 
analysed for the expression of the respective genes by qPCR as described. Freshly isolated PHH was 
spun down at 80 g and lysed with buffer RLT to extract mRNA and processed as above.  Results are 
expressed as mean ± SD (n=3, three independent experiments). HLSEC D141: in-house isolated 
human liver sinusoidal endothelial cell, LSEC SC (PM): Commercially-sourced liver sinusoidal 
endothelial cell from Sciencell cultured on their proprietary medium, HLSEC SC (LM): Commercially-
sourced liver sinusoidal endothelial cells from Sciencell cultured on LSEC medium. Commercially-
sourced liver sinusoidal endothelial cell from Medicyte cultured on their proprietary medium, HLSEC 
SC (LM): Commercially-sourced liver sinusoidal endothelial cell from Medicyte cultured on HLSEC 
medium.  
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3.2.3.3 Commercial HLSEC express fibroblast and pericyte  
markers   
 
Since the commercially-sourced cells did not have reliable levels of expression of 
markers of vascular or lymphatic endothelium, they were further probed for the 
expression of markers of some other hepatic components namely, collagen -1 
(marker of fibroblasts) and PDGFR (marker of pericytes). Figure 3.18 below shows 
that the commercial HLSEC had a significantly higher expression of collagen-1 when 
compared with HLSEC D141. It is noteworthy that while there was an almost 2000 
fold expression in PDGFR in HLSEC SC, the level of expression differed in the 
different medium conditions of the HLSEC MED groups. The HLSEC MED cultured in 
their proprietary medium had a 500 fold expression of PDGFR relative to HLSEC 
D141, while those cultured in the in-house HLSEC medium had only about 2-fold 
higher level of PDGR.  
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Figure 3.17: Expression of LSEC specific markers 
Relative expression of coagulation factor VIII, stabilins-1 and -2 and L-SIGN in in-house isolated and 
commercial HLSEC. Cells were cultured for 48 h or until 90% confluent. After removal of culture 
medium, cells were washed with ice-cold PBS twice and mRNA was extracted, cDNA synthesised and 
analysed for the expression of the respective genes by qPCR as described. Results are expressed as 
mean ± SD, (n=3, three independent experiments). HLSEC D141: in-house isolated human liver 
sinusoidal endothelial cell, LSEC SC (PM): Commercially-sourced liver sinusoidal endothelial cell from 
Sciencell cultured on their proprietary medium, HLSEC SC (LM): Commercially-sourced liver 
sinusoidal endothelial cells from Sciencell cultured on LSEC medium. Commercially-sourced liver 
sinusoidal endothelial cell from Medicyte cultured on their proprietary medium, HLSEC SC (LM): 
Commercially-sourced liver sinusoidal endothelial cell from Medicyte cultured on HLSEC medium. 
HHF: human hepatic fibroblast.  
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Figure 3.18: Commercial HLSEC express fibroblast markers 
Relative expression of collagen-1 and PDGFR in in-house isolated and commercial HLSEC. Cells were 
cultured for 48 h or until 90% confluent. After removal of culture medium, cells were washed with 
ice-cold PBS twice and mRNA was extracted, cDNA synthesised and analysed for the expression of 
collagen or PDGFR by qPCR as described. Freshly isolated PHH was spun down at 80 g and lysed with 
buffer RLT to extract mRNA and processed as above.  Results are expressed as mean ± SD, (n=3, 
three independent experiments). HLSEC D141: in-house isolated human liver sinusoidal endothelial 
cell, LSEC SC (PM): Commercially-sourced liver sinusoidal endothelial cell from Sciencell cultured on 
their proprietary medium, HLSEC SC (LM): Commercially-sourced liver sinusoidal endothelial cells 
from Sciencell cultured on LSEC medium. Commercially-sourced liver sinusoidal endothelial cell from 
Medicyte cultured on their proprietary medium, HLSEC SC (LM): Commercially-sourced liver 
sinusoidal endothelial cell from Medicyte cultured on HLSEC medium. HHF: human hepatic 
fibroblast. PDGFR: platelet-derived growth factor receptor.  
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3.3 DISCUSSION 
 
There are a number of methods for the isolation of liver sinusoidal endothelial cells. 
These include immunomagnetic separation (Lalor et al., 2002) and density-gradient 
centrifugation (Braet et al., 1994, Stolz, 2011a). There have been conflicting ideas as 
to the usefulness of immunomagnetic separation using CD-31 conjugated magnetic 
beads. Studies have shown that since CD-31 is upregulated in capillarised LSEC, the 
use of CD-31 in their isolation would result in a population enriched in capillarised 
LSEC (DeLeve et al., 2004, DeLeve et al., 2006). These studies have suggested that 
HLSEC thus isolated would lack the hallmark of HLSEC—fenestrations. While this 
might be valid in preparations involving murine livers, the data obtained in this 
study shows that human HLSEC isolated using CD-31 immuno-sorting are 
fenestrated (figure 3.2). Further, the porosity of these fenestrations were improved 
in the presence of VEGF-A (figure 3.10). This is in agreement with reports showing 
similar effects (Xie et al., 2012). The regulation of fenestral porosity and diameter 
has been reviewed in Chapter 1 of this thesis.             
 
3.3.1 Validation of liver sinusoidal endothelial cells 
isolated from human liver 
 
The definitive identification of liver sinusoidal cells is the presence of fenestrations 
which have been shown by electron microscopy. Aside structural features, it is 
important to show the expression of genes and proteins that are crucial to 
endothelial cell physiology. Consequently, as seen in figure 3.3, HLSEC that were 
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isolated expressed VEGFR-1, VEGFR-2 and CD-31. The level of expression is 
comparable with that in HDMEC and HDLEC. As shown in Chapter One, VEGFR-1 
and VEGFR-2 are important for the physiology of endothelial cells (Zhuang & 
Ferrara, 2015). The expression of these, especially VEGFR-2 both at the mRNA and 
protein levels shows that the cells isolated were valid endothelial cells. In addition 
to these, the expression of VEGFR-3 in HLSEC, which is known as a marker of the 
lymphatic endothelium has been previously reported (Lalor et al., 2006, Ding et al., 
2010a, Sorensen et al., 2015). This is further confirmed by the expression of the 
lymphatic marker, lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1).  
LYVE1 is involved in the endocytosis of hyaluronan in the course of its metabolism 
(Jackson, 2003). While LYVE-1 is expressed in lymphatic endothelial cells, its mere 
presence on an endothelial cell has been shown not to be a definitive marker of the 
lymphatic endothelium as other markers are required (Gordon et al., 2008). 
Accordingly, PROX-1 and podoplanin, which are definitive lymphatic marker have 
been demonstrated (Salven et al., 2003). Figure 3.4 also shows that HLSEC does not 
express podoplanin and expresses only a very low level of PROX-1 compared to 
HDLEC. PROX-1 is a transcription factor involved in the embryonic formation of 
lymphatic endothelium and in the specification of the fate of the lymphatic 
endothelial cell (Wigle et al., 2002, Hong et al., 2002). Another lymphatic marker, 
VEGFR-3, was expressed in HLSEC as earlier reported (Ding et al., 2010a). VEGFR-3 is 
required for lymphangiogenesis (Zhang et al., 2010). This shows the uniqueness of 
LSEC as a ‘hybrid’ endothelial cell population – a vascular endothelial cells with 
features of lymphatic endothelial cells. It would be informative to understand the 
physiologic basis for this. Perhaps the most convincing indication of the identity of 
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the isolated cells as liver sinusoidal endothelial cells is the expression of coagulation 
factor VIII, stabilin-1 and L-SIGN (figure 3.6). Coagulation factor VIII 
(antihaemophilic factor) has been shown to be synthesised in the murine LSEC (Do 
et al., 1999) and an engraftment of human LSEC into murine model of haemophilia 
restored expression of factor VIII (Fomin et al., 2013). L-SIGN is a transmembrane 
receptor involved in cell adhesion and in pathogen recognition  (Khoo et al., 2008). 
It is involved in capturing HIV-1, hepatitis C and Ebola viruses (Pohlmann et al., 
2001, Alvarez et al., 2002, Cormier et al., 2004). All three – coagulation factor VIII, 
stabilin-1 and L-SIGN – have been used as LSEC markers (Lalor et al., 2006, Nonaka 
et al., 2007).   
 
3.3.2 Human liver sinusoidal endothelial cells respond 
to growth factors which modulate endothelial 
cell physiology  
 
In addition to expressing specific endothelial cell markers, it is important for 
endothelial cells to respond to growth factors involved in their physiology. As 
earlier reviewed in Chapter One of this thesis, endothelial cells respond to their 
requisite growth factors to effect their main functions – cell proliferation, 
migration, survival and permeability—in order to maintain the vascular structure or 
to produce new vessels when needed (Koch & Claesson-Welsh, 2012). Accordingly, 
when the isolated HLSEC were stimulated with a range of growth factors, they 
responded with a phosphorylation of the VEGFR-2 which is upstream of the 
pathway (s) involved in the physiology of endothelial cells (figure 3.11). Activation 
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of the VEGFR-2 results in the phosphorylation of extracellular signal-regulated 
protein kinases 1 and 2 (ERK 1/2) and AKT which are involved in cell survival, 
proliferation and migration (Mebratu & Tesfaigzi, 2009).  As shown in figure 3.11 
ERK 1/2 and AKT were phosphorylated by growth factors which induced the 
phosphorylation of VEGFR-2, further confirming phosphorylation of AKT and ERK 
1/2 are downstream of VEGFR-2 (Holmes et al., 2007). Interestingly, other growth 
factors – EGF, FGF and HGF—also induced a phosphorylation of ERK 1/2 and AKT. 
Correspondingly, there was a significant increase in proliferation in cells incubated 
with VEGF-A, VEGF-E, VEGF-C, EGF, FGF and HGF (figure 3.12). This is indicative of 
the involvement of these growth factors in the proliferation of endothelial cells. 
Since VEGFR-2 and VEGFR-3 are intimately involved in angiogenesis, their ligands, 
VEGF-A and VEGF-C were used to study cell migration as shown in figure 3.13. After 
stimulating endothelial cells with VEGF-A or VEGF-C, there was a significant closure 
of the wound created 16 h beforehand.  As earlier described in Chapter One, 
endothelial cells migrate in response to injury to the vascular endothelium and 
during angiogenesis (Michaelis, 2014a). Closely linked to endothelial cell migration 
is their ability to self-organise in the presence of extra cellular matrix (ECM)-
secreting fibroblasts to form a tubular network. This was recapitulated in an in vitro 
angiogenesis assay earlier described (Hetheridge et al., 2011, Richards & Mellor, 
2016). The assay comprises a co-culture of normal human dermal fibroblasts 
(NHDF) grown to confluence with endothelial cells. The fibroblast secrete growth 
factors and ECM components including collagen I and fibronectin (Sorrell et al., 
2007).  This enables the endothelial cells to proliferate and self-organise in 
response to exogenously-supplemented VEGF-A or those secreted by the 
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fibroblasts. The pattern of endothelial cell could be in the form of a cluster, or 
sprouts along the cords of the fibroblasts resulting in elongations, thickening and 
formation of anastomosing structures (Hetheridge et al., 2011, Mavria et al., 2006). 
To induce further branching, endothelial cells might secrete ECM-degrading 
enzymes (particularly matrix metalloproteinases; MMP-2 or MMP-9) which enable 
them to invade the ECM (Taraboletti et al., 2002). The tubular structures formed by 
endothelial cells can then be detected by the use of endothelial-specific markers 
such as CD-31 used in this study, where significant induction of tube formation has 
been demonstrated.     
 
3.3.3 Transcriptomic analysis shows a distinctive 
difference between HLSEC and other 
endothelial cell populations 
 
The data from the transcriptomic analysis of the three endothelial cell types 
showed distinction between liver sinusoidal endothelial cells and dermal vascular 
and lymphatic endothelial cell population studied. As already reported in 
literature and reviewed in the introductory chapter of this thesis, LSEC possess 
scavenger functions, mediated by a range of scavenger and endocytic receptors. 
Prominent among these are the mannose receptor C1 and the C-lectin domain 
receptor 1B. In addition, some other genes earlier reported to be highly expressed 
in LSEC include the coagulation factor VIII which has been shown to be 
synthesised primarily in the LSEC (Everett et al., 2014, Shahani et al., 2014).This 
harmonises with real-time PCR data (figure 3.6). Further, the lymphatic marker 
LYVE-1 was upregulated in HLSEC in comparison with HDMEC and even HDLEC 
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which is a dedicated lymphatic endothelial cell population. However, genes that 
were downregulated in the HLSEC in comparison with HDLEC included PROX-1 and 
podoplanin which are key lymphatic markers. There were also genes directly 
linked with LSEC physiology, further distinguishing them as a unique population. 
One of these is the gene coding for plasmalemma vesicle associated protein 
(PLVAP). PLVAP is an endothelial-cell specific protein that forms part of the 
fenestral diaphragm, stomatal diaphragms of caveolae and diaphragms of 
transendothelial channels (Herrnberger et al., 2012). This integral membrane 
glycoprotein is required for the formation of LSEC fenestrae as indicated in a 
study by Herrnberger et al. (2014) where Plvap -/- mice had a significantly low 
number of fenestrations. Further, their data correlated this low level of LSEC 
fenestration with hyperlipoproteinaemia accompanied by lipid and chylomicron 
deposition in renal and hepatic capillaries, as well as ‘cloudy’ plasma. Other 
important genes upregulated in the HLSEC samples and which are linked to the 
regulation of fenestration are nitric oxide synthase trafficking (NOSTRIN) and 
serotonin (5-hydroxytryptamine [5-HT]) receptor 2B. The link between 5-HT and 
regulation of fenestral diameter has been reviewed in chapter 1 of this thesis.  
Among the differentially upregulated genes in the HLSEC samples are 
ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), tissue factor 
pathway inhibitor 2 (TFPI2), placenta specific 8 (PLAC8), protocadherin 17 (PCH17) 
which are either tumour suppressor genes or oncogenes (Hu et al., 2013, 
Mourtada-Maarabouni et al., 2013, Zhu et al., 2013).  This might be connected to 
the origin of the liver from which the HLSEC were isolated. The HLSEC were 
generally isolated from resections from liver of patients who have had some form 
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of hepatocellular carcinomas. Although the samples used for isolation were those 
without tumours, the fact that tumour-associated genes were detected in the 
HLSEC might be a reflection of the overall tissue they were isolated from. Of the 
downregulated genes in the HLSEC groups, claudin 1 is distinct. Claudin 1 belongs 
to a family of tight junctional proteins involved in the regulation of permeability 
of epithelial cells to ions and other small molecules. They are particularly 
important for the barrier function of the skin (Kirschner et al., 2013). This is an 
important distinguishing factor between the structure of the hepatic sinusoidal 
endothelium and the dermal microvascular endothelium. While a tight junction is 
required for a normal skin endothelium, in order to create access for blood-borne 
drugs, lipids and other substances to the hepatocytes, the liver sinusoid is 
relatively ‘porous’, partly by the presence of fenestrations on their membranes, 
and low expression of tight junction proteins.      
 
3.3.4 Commercially-sourced HLSEC need validation 
before use in experiments 
 
Results from this chapter also indicate that a thorough validation process is 
required whenever cells are procured from external sources. This was 
demonstrated by the comparison performed between HLSEC isolated in-house 
and those obtained from commercial sources. In order to remove any 
confounding effect of culture media, both commercial HSLEC samples were 
cultured in their proprietary media or in the medium generally used for culturing 
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HLSEC in-house. The fact that one of the commercial HLSEC did not express any of 
the vascular or lymphatic endothelial cell markers, but rather markers of 
fibroblasts and pericytes shows that they might have contained a high level of 
contaminants. This observation may betray an inadequate quality control process.  
A major limitation of this analysis is the fact that the liver from which HLSEC was 
isolated was from cancer patients. The experiments would have been more robust 
if liver samples from patient with no underlying liver pathology had been used. 
This could be sourced from implant rejection. 
In conclusion, liver sinusoidal endothelial cells are a population of endothelial 
cells with features of lymphatic and vascular endothelia. They also have unique 
features that distinguish them from other endothelial cell populations. They can 
respond to a variety of growth factors to elicit endothelial-cell specific functions 
which promote formation of vasculature. A comparative study of in-house 
isolated HLSEC with commercially-sourced ones shows the need to adequately 
validate cells that are externally-sourced before use in any experiments. Although 
commercial HLSEC could save time and effort invested into isolating the cells, the 
data from this chapter showed in-house isolated HLSEC using CD-31-based 
immunomagnetic separation to be better suited for subsequent studies in this 
thesis. Hence, the next chapter will examine the response of human liver 
sinusoidal endothelial cells to a range of hepatotoxic drugs. 
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4.1 INTRODUCTION 
 
Results from the previous chapter showed the phenotypic and functional validation 
of HLSEC isolated from donor human liver. It was shown that VEGF-A plays a very 
important role in the physiology of HLSEC, in agreement with literature, as is true 
for endothelial cells from other vascular beds (Holmes et al., 2007, Guangqi et al., 
2012). This includes its ability to form tubular networks reminiscent of in vivo 
vasculature (Zeng et al., 2015), cell proliferation in response to growth factors, 
activation of intracellular signalling that ultimately initiates cell survival and 
proliferation and cell migration. Activation of VEGFR-2 on HLSEC is also an 
important aspect of liver regeneration following partial hepatectomy and/ or 
exposure to hepatotoxic drugs (Ding et al., 2010a, Ding et al., 2014).  
For this chapter, it was hypothesised that known small-molecule receptor tyrosine 
kinase inhibitors (TKIs) that cause liver damage can adversely affect the physiology 
of HLSEC. With focus on regorafenib, a TKI which has been extensively reported to 
cause liver injury in the clinic (Sacré et al., 2016, Takahashi et al., 2016b, Iacovelli et 
al., 2014), it was proposed that TKIs could inhibit the activation of the VEGFR-2 
receptor on the HLSEC thereby blocking the pathways that lead to cell survival and 
proliferation, and ultimately angiogenesis. Building on the fact that regorafenib 
could adversely affect the physiology of the HLSEC, it was proposed that this could 
also lead to toxicity to the HLSEC by causing cell death by apoptosis, abrogation of 
the cytoskeletal structure of the HLSEC and inhibition of the signalling pathway that 
promotes liver regeneration. In addition to TKIs, a comparative toxicity analysis was 
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performed to determine the sensitivity of HLSEC (vis-à-vis other hepatic and non-
liver-derived endothelial cells) to a wide range of known liver toxins. 
Therefore the overall aim of data described in this chapter was to show the effect 
of known hepatotoxins on HLSEC and how this possibly links with the known anti-
angiogenic effect of small-molecule TKIs.    
 
4.2 RESULTS 
 
4.2.1 Comparative toxicity of liver toxins on HLSEC as 
against other hepatic cells and non-hepatic 
endothelial cells 
 
Since HLSEC, which is a hepatic cell population, has been shown to possess features 
of lymphatic and vascular endothelial cells, it has become necessary to analyse its 
sensitivity to a broad range of hepatotoxic drugs in comparison with other vascular 
endothelial and lymphatic cell populations. Also, it would also be informative to 
compare the sensitivity of HLSEC to these drugs and in other hepatic cells.  
 
4.2.1.1 HLSEC is preferentially more sensitive to a series of 
hepatotoxic tyrosine kinase inhibitors 
 
In order to compare the sensitivities of HLSEC with other hepatic and endothelial 
cells to a range of small molecule TKI, primary human hepatocytes (PHH), human 
hepatic fibroblasts (HHF), human liver sinusoidal endothelial cells (HLSEC), human 
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dermal microvascular endothelial cells (HDMEC) and human dermal lymphatic 
endothelial cells (HDLEC) were incubated with regorafenib, pazopanib, axinitib and 
sunitinib for 72 h.  Figure 4.1 shows the dose-response plot of regorafenib, 
pazopanib, axinitib and sunitinib on primary human hepatocyte (PHH), human 
hepatic fibroblasts (HHF), liver sinusoidal endothelial cells (HLSEC), human dermal 
microvascular endothelial cells (HDMEC) and human dermal lymphatic endothelial 
cells (HDLEC).  An overall trend observed is that the IC50 of HLSEC is lowest for all 
TKIs in comparison with the other cells, except for sunitinib where HHF had the 
lowest IC50 value.  
 
Figure 4.1: HLSEC is preferentially more sensitive to a series of tyrosine kinase inhibitors: 
Dose-response curve showing effect of tyrosine-kinase inhibitors on hepatic cells and endothelial 
cells from different vascular beds. Cells were plated at 15.6 X 103 cells/ cm2 (3.13 X 155 for PHH) in a 
collagen-coated 96-well plate for 48 h after which they were dosed with graded concentrations of 
tyrosine-kinase inhibitors originally constituted in DMSO. Final dosing concentrations or blank DMSO 
was made in medium to a uniform concentration of 0.1 % DMSO. Cells were dosed for 72 h after 
which they were washed with ice-cold PBS twice and lysed with Cell Titer Glo reagent and assayed 
for ATP content as described in the method section. IC50 values were determined and dose-response 
curve generated using GraphPad Prism 5. PHH; primary human hepatocytes, HHF: human hepatic 
fibroblasts, HLSEC: liver sinusoidal endothelial cells, HDMEC: human dermal microvascular 
endothelial cells, HDLEC: human dermal lymphatic endothelial cells.  
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The median inhibitory concentration (IC50) of HLSEC was lowest for pazopanib. On 
the other hand, HDLEC was least sensitive to this range of TKIs; it has the highest 
IC50 values. With the exception of regorafenib and pazopanib, of the liver-derived 
cells PHH was most resistant to the toxic effect of the TKIs. 
 
 
4.2.1.2 Effect of hepatotoxic drugs on hepatic and 
endothelial cells 
 
Aside drugs that are known to directly affect the physiology of endothelial cells, 
other drugs that cause liver toxicity by other known mechanisms might also be toxic 
to HLSEC. Figure 4.2 shows the relative sensitivity of PHH, HHF, HLSEC, HDMEC and 
HDLEC to paracetamol, aflatoxin, benzbromarone, perhexiline and desipramine. All 
cells tested were sensitive to paracetamol at the same level, with an IC50 of ≈ 3 mM, 
which suggests that paracetamol toxicity might be non-metabolism related. Median 
inhibitory concentration of aflatoxin was similar for all endothelial cells, at ≈ 10 μM, 
while PHH and HHF had a similar IC50 at ≈ 2 μM. A similar trend can be observed for 
benzbromarone, whereby IC50 of the endothelial cells was about 5-fold of those in 
PHH and HHF.  The only recognisable pattern that can be observed for perhexiline 
was in HDMEC and HDLEC where there was a similar IC50 of ≈ 30 μM, but HLSEC was 
most sensitive to  (IC50: 3.4 μM). Finally, HLSEC and PHH were equally sensitive to 
desipramine (IC50: ≈ 6 μM) whereas HHF, HDMEC and HDLEC were some 5-fold less 
sensitive to the toxic effect of this liver toxin. Therefore this observation implies 
that there is a likelihood that the toxicities of these drugs are due to different 
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factors ranging from direct cell lysis as might be the case for paracetamol, to 
metabolic bioactivation or detoxification. 
 
Figure 4.2: Effect of hepatotoxic drugs on hepatic and endothelial cells. 
 Dose-response curve showing effect of hepatotoxic drugs on hepatic cells and endothelial cells from different 
vascular beds. Cells were plated at 15.6 X 103 cells/ cm2 (3.13 X 155 for PHH) in a collagen-coated 96-well plate 
for 48 h after which they were dosed with graded concentrations of tyrosine-kinase inhibitors originally 
constituted in DMSO. Final dosing concentrations or blank DMSO was made in medium to a uniform 
concentration of 0.1 % DMSO. Cells were dosed for 72 h after which they were washed with ice-cold PBS twice 
and lysed with Cell Titer Glo reagent and assayed for ATP content as described in the method section. IC50 
values were determined and dose-response curve generated using GraphPad Prism 5. PHH; primary human 
hepatocyte, HHF: human hepatic fibroblasts, HLSEC: liver sinusoidal endothelial cells, HDMEC: human dermal 
microvascular endothelial cells, HDLEC: human dermal lymphatic endothelial cells. 
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4.2.2 Effect of small-molecule tyrosine kinase 
inhibitors on HLSEC physiology 
 
4.2.2.1 Determination of the median inhibitory 
concentration (IC50) of tyrosine kinase inhibitors 
 
A dose-response curve was extracted from figure 4.1 above in order to determine 
the working concentration of the TKIs to be used in the subsequent series of 
experiments involving HLSEC. Figure 4.3 shows regorafenib to cause a 50% cell 
death at a dose of 2.9 µM while pazopanib, axitinib and sunitinib seem to be more 
potent at 0.2, 0.3 and 0.7 µM respectively.   
 
 
Figure 4.3: Effect of Selected small molecule tyrosine kinase inhibitors on viability of HLSEC 
Dose-response curve showing effect of tyrosine-kinase inhibitors on HLSEC. Cells were plated at 15.6 
X 103 cells/ cm2 in a collagen-coated 96-well plate for 48 h after which they were dosed with graded 
concentrations of tyrosine-kinase inhibitors originally constituted in DMSO. Final dosing 
concentrations or blank DMSO was made in HLSEC medium to a uniform concentration of 0.1 % 
DMSO. Cells were dosed for 72 h after which they were washed with ice-cold PBS twice and lysed 
with Cell Titer Glo reagent and assayed for ATP content as described in methods. IC50 values were 
estimated and dose-response curve generated using GraphPad Prism 5. 
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4.2.2.2 A range of selected TKIs inhibits the activation of 
VEGFR-2 on the HLSEC  
 
In order to validate the ability of the selected TKIs to block the activation of VEGFR-
2 and to determine the minimum concentration to use in subsequent experiments, 
HLSECs were dosed with drugs at a concentration of 0.01, 0.1, 1 and 10 µM for 30 
min before being stimulated with VEGF-A for 10 min. Figure 4.4 shows the effect of 
regorafenib, pazopanib, axitinib and sunitinib on the activation of VEGFR-2 on 
HLSEC. While regorafenib completely inhibited the activation of VEGFR-2 at 1 µM, 
pazopanib did not seem to completely block this effect even at the highest 
concentration of 10 µM. Sunitinib completely blocked this effect at 10 µM, while 
axitinib was most potent—inhibiting the activation of VEGFR-2 at 10 nM.  A similar 
trend can be seen for activation of the downstream proteins AKT and ERK 1/2, 
especially in regorafenib axitinib and sunitinib where there was a concentration-
dependent inhibition.  
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Figure 4.4: A range of selected tyrosine kinase inhibitors inhibits the activation of VEGFR-2 on the 
HLSEC 
HLSEC were cultured until 90% confluent, kept on medium containing 1% FBS for 16 hours and then 
pre-treated with 0.01, 0.1, 1, 10 µM of TKI or medium containing 1 % FBS for 30 minutes. Then, cells 
were washed and stimulated with 50 ng/ml of VEGF-A for 10 min. Cells were lysed for total protein 
contents using modified RIPA buffer, solubilised in LDS sample buffer, denatured at 90 ⁰C. Protein 
was separated using SDS PAGE for 45 min., transferred unto nitrocellulose membrane for 2 h. and 
blocked with 5% BSA. Membranes were then probed with respective antibodies for phosphorylated 
VEGFR-2, total VEGFR-2, phosphorylated AKT, phosphorylated ERK 1/2 and GAPDH.   
 
 
4.2.2.3 Effect of regorafenib on VEGF-A and VEGF-C-    
mediated cell migration in HLSEC 
 
Once it was established that 1 µM concentration of regorafenib was sufficient to 
cause an inhibition of the intracellular signalling in the HLSEC, experiments were set 
up to test this dose on cell migration. Figure 4.5 shows the effect of regorafenib on 
cell migration in HLSEC. VEGF-A and VEGF-C induced a highly significant (p < 0.01) 
increase in cell migration compared with basal control. This trend was reversed by 
another highly significant (p < 0.01) reduction in cell migration in the presence of 1 
µM regorafenib. 
SUNITINIB 
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Figure 4.5: Effect of regorafenib on VEGF-A and VEGF-C- mediated cell migration in HLSEC 
HLSEC were plated on a collagen-coated 12-well tissue culture plate at 2.63 X 104 cells/cm2 until fully 
confluent. Cell culture medium was removed; cells washed twice with PBS and then place on 
medium containing 1% FBS for 16 hours after which straight-line scratches were introduced with a 
sterile 200 µl pipette tip. Cells were washed with PBS after removal of culture medium to remove 
floating cells and were pre-treated with regorafenib (1 µM) or 1 % FBS for 30 minutes. Cells were 
washed with PBS twice at room temperature. Then 50 ng/ml of VEGF-A, VEGF-C or basal medium 
was added unto the cells. Pictures of the scratch-wounds were taken (mag X4) using an inverted 
light microscope. Cells were incubated at 37° C for 16 h after which there washed twice with PBS at 
room temperature, and fixed with 2% PFA for 15 minutes, washed twice again with PBS twice and 
further processed as earlier described. Images of scratch wounds were taken (t=16 h) and compared 
with those taken at an earlier time point (t= 0 h). Cell migration was calculated as percentage wound 
closure (area covered by growth factor stimulated compared with unstimulated at t= 0 h). Wound 
areas were measured using the scratch wound plugin of the Image-J software. Data are represented 
as mean ± SD (n=3, three independent experiments). They were compared analysed using one way 
analysis of variance ANOVA followed by Dunnett’s multiple comparison test. Values are significant at 
**p<0.01, ***p<0.001, ****p<0.0001. VEGF-A: Vascular endothelial growth factor A, VEGF-C: 
Vascular endothelial growth factor C, REG: regorafenib.     
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4.2.2.4 Regorafenib inhibits in vitro angiogenesis in HLSEC 
 
Angiogenesis consists of the proliferation and coordinated migration of endothelial 
cells to form lumen-containing vessels. An in vitro angiogenesis assay was 
performed according to the method earlier described by Hetheridge et al. (2011), 
and Richards and Mellor (2016). In order to see the effect of regorafenib on the 
ability of HLSEC to form vascular network upon stimulation with VEGF-A and VEGF-
C, HLSEC stimulated with VEGF-A or VEGF-C were treated with 1 µM of regorafenib.  
Figure 4.6 shows the effect of 1 µM regorafenib on the ability of HLSEC to form 
vascular network in an in vitro angiogenesis assay.  
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Figure 4.6: Regorafenib inhibits in-vitro angiogenesis in HLSEC 
Juvenile NHDF were cultured at 7.9 X 10 cells/ cm2  for 3 days in a collagen coated glass coverslips in 
24-well plates after which HLSEC were plated on top at a density of 21 X 103 cells/ cm2 for 24 h. Then 
cells were treated with growth medium containing 1% FBS and/ or 50 ng/ml of VEGF-A and VEGF-C 
for 72 h and then re-exposed to same for another 48 h. Cells were then washed in PBS at room 
temperature and fixed with 2% PFA for 15 min., washed twice with PBS and then stained for CD-31 
following the colorimetric immunocytochemical methods already described in the result section. 
Angiogenesis was quantified using Angioquant. Bars represent mean ± SD (n=3, three independent 
experiments). Basal state compared with growth-factor stimulated state and  analysed using one 
way analysis of variance ANOVA followed by Dunnett’s multiple comparison test. Data are significant 
at * p < 0.05, ** p < 0.01, ***p < 0.001 
 
While VEGF-A stimulation resulted in a highly significant (p < 0.001) increase in tube 
length when compared to basal control, VEGF-C exerted a lower level of significant 
(p < 0.01) increase in tube length. On the other hand, regorafenib caused a highly 
significant (p < 0.001) reduction in VEGF-A-induced tube formation and a significant 
(p < 0.01) reduction in VEGF-C-induced tube formation. 
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4.2.2.5 Regorafenib inhibits upregulation of angiocrine 
factors involved in liver regeneration 
 
A physiological response to liver injury is liver repair and regeneration. Since 
activation of VEGFR-2 on HLSEC has been shown to be involved in this process, the 
effect of regorafenib on the upregulation of the angiocrine factors involved was 
investigated by quantitative real-time polymerase chain reaction (qRT-PCR). Figure 
4.7 shows the effect of regorafenib on the upregulation of Id1, Wnt-2 and HGF 
following VEGF-A, VEGF-c or SDF-1 stimulation. VEGF-A, VEGF-C, and SDF-1 
significantly upregulated Id1 only after 1 h of stimulation. In the presence of 1 µM 
regorafenib, the level of Id1 mRNA was significantly (p < 0.01) reduced in VEGF-A 
and VEGF-C- stimulated HLSEC whereas, regorafenib had no significant effect on the 
level of Id1.   There were significant increases in levels of Wnt2 after 1h and 6 h of 
VEGF-A, VEGF-C and SDF-1 stimulation. However, this was significantly reduced in 
the presence of regorafenib, except for SDF-1 where levels remained unchanged. A 
similar trend can be observed for HGF whereby VEGF-A and VEGF-C significantly 
upregulated the expression of HGF after 1 h and 6 h of stimulation, but SDF-1 only 
effected a significant (p < 0.05) upregulation in HGF after 6 h of HLSEC stimulation. 
As was seen in Wnt2, regorafenib significantly reversed the upregulation of the 
level of HGF at 1h and 6 h post VEGF-A and VEGF-C stimulation; but no significant 
effect was seen for regorafenib in SDF-1-stimulated cells.  
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Figure 4.7: Regorafenib inhibits upregulation of angiocrine factors involved in liver regeneration 
Relative expression of factors involved in liver regeneration. HLSEC were cultured until 90% confluent, kept on 1% FBS for 16 hours and then pre-treated with 1 µM 
regorafenib or 1 % FBS for 30 min. Then, cells were washed and stimulated with 50 ng/ml of VEGF-A, or VEGF-C or 10 ng/ml of SDF-1α for 1 or 6 h. mRNA was extracted, 
cDNA synthesised and analysed for the expression of ID1, HGF and Wnt2 by qPCR. Results are expressed as mean ± SD, (n=3, three independent experiments) and analysed 
using one way analysis of variance ANOVA followed by Dunnett’s multiple comparison test. VEGF-A: vascular endothelial growth factor A, VEGF-C: vascular endothelial 
growth factor C, SDF-1: stromal cell-derived factor 1, REG: regorafenib (1 µM), Id1:  inhibitor of DNA binding 1, wnt2: Wingless-type MMTV integration site family, member 
2, HGF: hepatocyte growth factor.
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4.2.3 Toxicity of regorafenib on HLSEC 
 
As shown above, regorafenib inhibits the physiological functions of HLSEC; this is a 
potential for toxicity. Since an activation of the VEGFR-2 activates the pathways 
that lead to cell proliferation, migration and survival, inhibition of which prevents 
the ability of HLSEC to self-repair following injuries. Therefore, this section focuses 
on the ability of regorafenib to cause induction of apoptosis in HLSEC as well as the 
structural effect it has on the cytoskeleton of HLSEC.   
4.2.3.1 Regorafenib but not paracetamol induces apoptosis 
in HLSEC by activation of caspase 3 
 
Figure 4.8 compares the ability of regorafenib and paracetamol to induce apoptosis 
in HLSEC in a time- and dose-dependent fashion. Regorafenib did not induce the 
activation of caspase 3 at lower concentrations of 0.3 and 3 μM; it did this at a 
higher concentration of 30 μM and at 6 and 24 h time points. However, APAP did 
not induce apoptosis in HLSEC even at the highest dose of 30 mM and maximum 
time point where there was complete cell death and with no expression of actin.    
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Figure 4.8: Regorafenib induces apoptosis in HLSEC 
HLSEC were cultured until 90% confluent, kept on medium containing 1% FBS for 16 hours and then 
treated with 0.3, 3 or 30 µM regorafenib or 0.3, 3, or 30 mM APAP or 1 μM staurosporine or medium 
containing 1% FBS for 1, 6 or 24 h. Cells were lysed for total protein contents using modified RIPA 
buffer, solubilised in LDS sample buffer, denatured at 90 ⁰C. Protein was separated using SDS PAGE 
for 45 min., transferred unto a nitrocellulose membrane for 2 h. and blocked with 5% BSA. 
Membranes were then probed with antibodies for caspase 3 and actin.  
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4.2.3.2 Regorafenib and paracetamol both induce 
apoptosis in primary human hepatocytes 
 
Since Regorafenib induced apoptosis in HLSEC, it was important to investigate 
whether the same could be observed in freshly-isolated primary human 
hepatocytes. Figure 4.9 shows the effect of regorafenib and APAP on primary 
human hepatocytes. There is a hint of induction of cleavage of caspase 3 following 
every dose of regorafenib. Also, paracetamol induced caspase 3 cleavage at 24 h 
time point for 0.3 and 3mM dose levels, and because there was complete cell death 
at 30 mM, protein level in lysate was at an undetectable level.    
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Figure 4.9: Regorafenib and paracetamol both induce apoptosis in primary human hepatocytes 
Freshly-isolated primary human hepatocytes were treated with 0.3, 3 or 30 µM regorafenib or 0.3, 3, 
or 30 mM APAP or 1 μM staurosporine complete primary human hepatocyte medium for 1, 6 or 24 
h. Cells were lysed for total protein contents using modified RIPA buffer, solubilised in LDS sample 
buffer, denatured at 90 ⁰C. Protein was separated using SDS PAGE for 45 min., transferred unto a 
nitrocellulose membrane for 2 h. and blocked with 5% BSA. Membranes were then probed with 
antibodies for caspase 3, and actin. APAP: paracetamol, STAUR: 1 μM Staurosporine. CL casp 3, 
cleaved caspase 3.  
 
 
4.2.3.3 Regorafenib causes a disruption in tight junction 
and cytoskeleton in a time-dependent manner 
 
Following reports that regorafenib induced an effect similar to sinusoidal 
obstruction syndrome (reviewed in chapter 1) in the clinic (Takahashi et al., 2016a), 
the effect of regorafenib on the cytoskeleton and tight junction of HLSEC was 
investigated. Fully confluent HLSEC were treated with regorafenib at similar 
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concentration range and time points as above. Figure 4.10 and figure 4.11 show the 
effect of regorafenib on the tight junctional (ZO-1) and the cytoskeletal (actin) cell 
components. Figure 4.10 reveals that regorafenib adversely affects the cytoskeleton 
and the tight junction of HLSEC in a time- and concentration-dependent manner, 
the highest reduction being observed at the highest concentration of 30 μM.  
Further, figure 4.11 shows that regorafenib induced a significant (p < 0.05) 
reduction in the mRNA level of ZO-1 after 6 and 24 h of treatment with 0.3 and 3 
μM concentrations. At a concentration of 30 μM, regorafenib caused a highly 
significant (p < 0.01) reduction in the expression of ZO-1. As for the cytoskeletal 
cellular component, actin, regorafenib only induced a significant (p < 0.05) 
reduction at 24 h for 0.3 μM and 6 h for 3 μM, and a highly significant (p < 0.01) 
reduction at 24 h for 3 μM. Whereas a much more highly significant (p < 0.001) 
reduction in actin was observed after 24 h in 30-μM-regorafenib-treated cells.   
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Figure 4.10: Regorafenib causes a reduction in tight junction and cytoskeleton in a time-dependent 
manner 
Immunofluorescent micrographs showing expression of tight junctional (ZO-1) and cytoskeletal 
cellular structures in HLSEC. HLSEC were cultured to full confluency over 7 days after which they 
were treated with (A) basal medium, 1 µM cytochalasin D (Cyt D), 0.3 regorafenib, (B) 3 µM 
regorafenib or (C) 30 µM regorafenib for 1, 6 and 24 h. Then, cells were washed in PBS at room 
temperature, fixed with 2% PFA for 15 min and washed twice with PBS. Then cells were stained for 
ZO-1 and phalloidin following the methods earlier described for immunofluorescent staining. ZO-1, 
zonas occludens. Scale bars: 10 µM 
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Figure 4.11: Regorafenib causes a reduction in tight junction and cytoskeleton in a time-dependent 
manner 
Relative expression of tight junctional and cytoskeletal genes in HLSEC. HLSEC were cultured to full 
confluency over 7 days after which they were treated with 0.3, 3 and 30 µM regorafenib or 1 μM 
cytochalasin D or medium for 1, 6 and 24 h. Then, cells were washed and mRNA extracted using RLT 
buffer. cDNA was synthesised and analysed for the expression of ZO-1 and actin by qPCR. Results are 
expressed as mean ± SD, (n=3 of 3 independent experiments) and analysed using one way analysis of 
variance ANOVA followed by Dunnett’s multiple comparison test. Data are significant at *p<0.05, 
**p<0.01, ***p<0.001. REG: regorafenib 
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4.3   DISCUSSION 
 
4.3.1 Effect of tyrosine kinase inhibitors on HLSEC 
physiology 
  
The aim of this chapter was to examine the effect of hepatotoxic drugs on HLSEC 
and to investigate the link between the ability of TKIs to inhibit endothelial cell 
physiology of HLSEC and their toxicity. This is to link with the overall aim of this 
project to explore the involvement of HLSEC in drug-induced liver injury. It is 
established that some small-molecule receptor tyrosine kinase inhibitors used in 
cancer chemotherapy are primarily anti-angiogenic drugs which block the 
formation of new blood vessels from pre-existing ones by inhibiting the activation 
of the receptors tyrosine kinase on endothelial cells (Folkman, 2007, Gotink & 
Verheul, 2010b, Kerbel, 2008).  Principal among these is the VEGFR family, with 
VEGFR-2 and VEGFR-3 expressed mainly on vascular and lymphatic endothelial cells 
respectively. Blocking the activation of these receptors leads to an inhibition of the 
cellular processes that are hallmarks of endothelial cells and ultimately cancer 
progression; as VEGFR-3 is also expressed in tumour cells (Su et al., 2007).  
The results from the initial part of this chapter show the ability of four TKIs to 
inhibit the activation of VEGFR-2, a crucial angiogenesis mediator (Fig. 4.4).  All the 
TKIs tested induced a dose-dependent inhibition of VEGFR-2 phosphorylation as 
well as downstream pathways involving ERK 1/2 and AKT. AKT and ERK 1/2 are 
involved in cell survival and cell proliferation upon activation in response to a wide 
rage of chemical biological stimuli (Lu & Xu, 2006, Liao & Hung, 2010). Axitinib was 
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most potent in its inhibition of the phosphorylation of VEGFR-2. Axitinib has 
previously been reported to be more a selective and more potent TKI against 
VEGFR-1, VEGFR-2 and VEGFR-3 than sunitinib and sorafenib in in vitro studies (van 
Geel et al., 2012, Rini et al., 2011). This specificity might be related to its relative 
toxicity to HLSEC compared to other TKIs tested (fig. 4.1).  
The selection of regorafenib as the drug to carry forward in the remaining studies 
was due to its clinical use and reported toxicity profile (Krishnamoorthy et al., 2015, 
Sacré et al., 2016). Regorafenib inhibited cell migration and in vitro tube formation 
at a sub-toxic concentration (figs. 4.5 and 4.6). These are two interrelated processes 
as endothelial cells migrate in the course of vasculogenesis and angiogenesis 
(Michaelis, 2014b, Lamalice et al., 2007). Results described above (fig 4.5 and fig 
4.6) are similar to published data by Schmieder et al. (2014a) where regorafenib 
was reported to inhibit the intracellular signalling and cell migration in VEGF-C and 
VEGF-A stimulated lymphatic endothelial cells. Also, since regorafenib is known to 
be a potent inhibitor of VEGFR-3, inhibition of VEGF-C-induced vascular network 
formation shown in figure 4.6 confirms earlier reports that blocking VEGFR-3 is an 
important anti-angiogenic mechanism (Tammela et al., 2008). This is beneficial in 
cancer chemotherapy where regorafenib has been reported to induce anti-
migratory effect and abolishment of VEGF-A secretion and tube formation in a 
breast cancer cell line (Su et al., 2016). However, the fact that a sub-toxic dose 
induced an inhibition of cell migration – which could be a physiologic response to a 
compromise in blood vessel integrity (Michaelis, 2014b) – poses a toxicological 
question. This is aptly illustrated by the ability of regorafenib to inhibit the 
upregulation of the angiocrine factors that play a key role in liver regeneration (fig. 
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4.7). Angiogenesis of the HLSEC has been reportedly involved in liver regeneration 
(Hu et al., 2014). As earlier described in the introduction, this is preceded by 
activation of the VEGFR-2 by its ligand, VEGF-A; this initiates a cascade of events 
which involves the upregulation of the endothelial cell-specific transcription factor 
Id1 which in turn activates Wnt2 and HGF, resulting in hepatocyte proliferation 
(Ding et al., 2010a, Rafii et al., 2016). Although this experiment was done in a single 
culture system, the upregulation of these angiocrine factors were demonstrated in 
the presence of VEGF-A and VEGF-C. Pre-treatment with regorafenib significantly 
inhibited this process at every step involved in liver regeneration along the VEGFR-
2-Id1 signalling pathway. This also hints at a likely involvement of VEGFR-3 in this 
process. As an indication that the significant reduction observed in this experiment 
was VEGF-2 and/ or VEGFR-3-dependent, regorafenib had no significant effect on 
the expression of these genes in the stromal cell-derived factor 1 (SDF-1)-
stimulated cells. SDF-1 is a ligand for CXC chemokine receptor 7 (CXCR7)   which is 
widely expressed in the brain, kidney, heart, haematopoietic cells and the vascular 
endothelial cells (Dai et al., 2011). It has been shown that CXCR7 is involved in cell 
proliferation, adhesion, and activation of cell survival cell signalling molecules ERK 
1/2 and/ or Akt (Burns et al., 2006) and angiogenesis (Dai et al., 2011). It is also pro-
regenerative as previously reported in an in vitro study where SDF-1 stimulation of 
human HLSEC effected an upregulation of Id1 which resulted in the production of 
hepatic-active angiocrine factors Wnt2 and HGF  (Ding et al., 2014). The fact that 
regorafenib did not significantly affect the expression of the any of the angiocrine 
factors involved in liver regeneration  in cells stimulated with SDF-1 suggests that 
regorafenib specifically targets VEGFR-2 and / or VEGFR-3 to effect this.  
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4.3.2 Relative toxicity of hepatotoxic drugs on 
HLSEC and other hepatic and endothelial 
cells  
 
When compared with other hepatic and endothelial cells, HLSEC were generally 
more sensitive to TKIs tested in this study (fig. 4.1). More importantly, while 
compared with other hepatic cell types—primary human hepatocyte and human 
hepatic fibroblast—the relatively higher sensitivity of HLSEC may be another insight 
into the possibility of HLSEC as the primary target of this group of drugs in the liver. 
This might suggest their direct involvement in drug induced liver injury caused by 
this class of drugs (Karczmarek-Borowska & Sałek-Zań, 2015).  
On the other hand, known hepatotoxins belonging to other groups showed a 
different pattern of toxicity to the cell types tested (fig. 4.2). For example, 
paracetamol was equitoxic to all the cell types tested. This is a novel finding 
considering what has been published to date on paracetamol toxicity. Published 
studies have linked paracetamol toxicity mainly to metabolic bioactivation whereby 
its electrophilic metabolite N-acetyl p-benzoquinone imine (NAPQI) causes a 
depletion of glutathione as a result of oxidative stress, resulting in hepatocellular 
necrosis (Hinson et al., 1990, Hinson et al., 2010). However, the uniform IC50 seen in 
metabolically-competent and non-metabolically competent cells suggests that 
another mechanism of toxicity must be predominant in paracetamol toxicity, 
including mitochondrial damage (Jaeschke et al., 2012, McGill et al., 2012).  Indeed, 
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it has been shown that paracetamol targets the HLSEC with a resultant collapse of 
the sinusoidal structure (DeLeve et al., 1997) 
 
4.3.3 Toxic effect of regorafenib on HLSEC 
 
To further show that regorafenib targets the HLSEC in liver toxicity, HLSEC were 
incubated with varying doses of with regorafenib over a 24-hour period. Figure 4.6 
shows that at 30 μM, regorafenib induces the cleavage of caspase 3 after 6 h while 
this was not the case with 30 mM paracetamol. In addition, lower doses of 
regorafenib induced caspase 3 cleavage in primary human hepatocytes (fig. 4.8). 
This is different from reports from a recent study by Weng et al. (2015) where 
regorafenib, at a maximum concentration of 15 μM, did not induce the activation of 
caspase 3 in rat hepatocytes in vitro. This might be due to species difference in drug 
response. For example Lu and Li (2001) reported that the CYP 3A family is induced 
differently in human and rat hepatocytes. Since regorafenib is metabolised by 
CYP3A4 in humans (FDA, 2012), the difference in biotransformation which might 
lead to metabolic bioactivation in a species and detoxification in another might be 
an explanation for this observation.  This requires further investigation.  
Regorafenib caused a significant reduction of cytoskeletal cellular components 
(actin) of HLSEC as seen both at mRNA level and by immunofluorescence in a time- 
and dose-dependent manner (fig 4.10 and fig 4.11).  This might be an indication of 
the structural effect of regorafenib on HLSEC. This is important in view of the fact 
that regorafenib has recently been linked to sinusoidal obstruction syndrome 
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(Takahashi et al., 2016b), which involves the polymerisation of F-actin on the 
cytoskeleton of HLSEC, activation of increased synthesis of matrix 
metalloproteinase-9 (MMP-9) which digests the extracellular matrix components. 
This culminates in a rounding up of the HLSEC, gap formation in the endothelial 
barrier in the hepatic sinusoid, obstruction of the hepatic microcirculation and 
hepatocyte necrosis (DeLeve, 2008b). This has been fully described in chapter 1. 
Also, since, actin fibres are involved in cell migration—a feature of cell repair and 
wound healing—the effect of regorafenib on the cytoskeletal structure must have a 
far-reaching consequence (Lamalice et al., 2007).  
The drawback from this section is the fact that data were derived from in vitro 
experiments. In vivo experiments would be required to ascertain these. Also, the 
experiments on the effects of the TKIs on the physiology of HLSEC were conducted 
only on regorafenib. Given the fact that other TKIs do not have exactly the same 
molecular targets as regorafenib, the response of HLSEC to these might be different 
from what was obtained. Also, the cytotoxicity assays carried out were only ATP-
based, which were a measure of viable cells. Such other measures of toxicity as LDH 
leakage, MTT assay and other would have been more robust, while further creating 
a better picture of mechanism of toxicity of all the drugs tested.  
Taken together, the data from this chapter shows that regorafenib causes a 
disruption in the physiology of human liver sinusoidal endothelial cells which might 
partly explain its toxicity. Also, HLSEC appear to be direct targets of TKIs, 
particularly regorafenib which results in apoptosis, and a potential polymerisation 
of cytoskeletal cellular components—a feature of sinusoidal obstruction syndrome. 
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Finally, the propensity of regorafenib to inhibit the homeostatic process of liver 
regeneration may further exacerbate any direct toxicity that it might have initiated 
both on HLSEC and the parenchymal cells of the liver.   
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CHAPTER FIVE 
 
LIVER SINUSODIAL 
ENDOTHELIAL CELLS IN A CO-
CULTURE LIVER MICROTISSUE 
SYSTEM 
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5.1 INTRODUCTION 
 
Data from the previous chapter demonstrated that human liver sinusoidal 
endothelial cells (HLSEC) are potential targets of hepatotoxic drugs, particularly 
small molecule tyrosine kinase inhibitors that have an established profile of 
inducing liver toxicity in the clinic. 
The focus of this chapter is the use of HLSEC in multicellular liver microtissue. As 
reviewed in the introduction to this thesis, studies have shown that liver 
microtissues, which are a 3D cell aggregation that allows for a more efficient cell-
cell contact and interaction, constitute a better model for investigation liver 
pathophysiology compared to hepatocytes in a monolayer, as they preserve and 
better reconstitute liver functions (Bell et al., 2016). Furthermore, it has been 
shown that inclusion of non-parenchymal cells, such as endothelial cells, have 
proven more physiologically relevant in liver microtissues (Takebe et al., 2013, 
Takebe et al., 2014). Since most of the studies carried out were performed on non-
microvascular and non-hepatic endothelial cells, it would be interesting to 
investigate some of the findings using primary liver sinusoidal endothelial cells. 
Following observation that vascular endothelial growth factor (VEGF-A) was 
secreted from hepatocytes following exposure of rats to hepatotoxic doses of 
paracetamol and that exogenous administration of VEGF-A offered protection 
against paracetamol toxicity (Donahower et al., 2006, Donahower et al., 2010a), it 
was hypothesised that inclusion of VEGF-A or VEGF-C could offer protection to the 
liver microtissues following exposure to hepatotoxic drugs. Finally, since activation 
of VEGFR-2 on HLSEC has been shown to induce liver regeneration in vivo, it was 
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hypothesised that growth factor stimulation of triculture microtissues could 
improve drug-metabolising capability of liver microtissues.      
5.2 RESULTS 
 
5.2.1 Triculture human liver microtissues enables 
recapitulation of the vascularisation of the liver 
sinusoids 
 
Figure 5.1 shows the relative position of different cellular components of the 
human liver microtissues, as well as the differing degrees of details that can be 
revealed by different imaging methods. Figure 5.1 A is an image of liver tissue 
section revealing the vascularisation of the liver sinusoids. Figure 5.1 B which shows 
Haematoxylin and Eosin staining of a triculture liver microtissue only reveals details 
of nucleus and cytoplasm of the constituent cells. Figure 5.1 C shows the actin fibre 
of the fluorescently stained microtissue revealing the actin as a common feature of 
all cellular components. Figure 5.1 D shows the expression of albumin, a hepatocyte 
marker, on a primary human hepatocyte-only microtissue. On the other hand, 
figures 5.1 E & F reveal more structural details as they show the relative position of 
HLSEC in the microtissue environment. Liver sinusoidal endothelial cells self-
organise to form a vascular-like structure reminiscent of the native liver sinusoidal 
environment as seen in figure 5.1 A.  
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Figure 5.1: Structure of triculture human liver microtissues-    
(A) Immunofluorescent image of human liver section (B) Light microscopy of the Haematoxylin and Eosin stained triculture human liver microtissue (C) immunofluorescent 
image of triculture liver microtissue stained for actin fibre, (Phalloidin in red) (D) immunofluorescent image of liver microtissue stained for albumin, in red (E) 
immunofluorescent image of liver microtissue, comprising primary human hepatocyte and liver sinusoidal endothelial cells stained for albumin (in red) and CD-31 (green) 
and nucleus (blue) (F) immunofluorescent image of liver microtissue, comprising primary human hepatocyte, liver sinusoidal endothelial cells and human hepatic 
fibroblasts stained for albumin (in red), CD-31 (green), collagen type 1 (white) and nucleus (blue). A total of 1500 cells were seeded on ultra-low attachment plates, 
centrifuged and incubated at 37°C for 7 d to allow cells to self-aggregate into microtissues as described in the methods section. On day 7, microtissues were harvested, 
medium removed and processed for immunoflourescent staining as previously described in the method section for Immunofluorescent staining for liver microtissues. 
Microtissues were stained for albumin (red), CD-31 (green), and nucleus (blue). Image A was taken using light microscope at a magnification of X100 while images (C-E) 
were taken at a magnification of X10 using an immunofluorescent microscope. (B) microtissues were harvested and processed  histologically using as described in the 
methods section for haematoxylin and Eosin staining (C) PHH: microtissues comprising 1500 freshly-isolated primary human hepatocytes (D) PHH + HLSEC: microtissues 
comprising freshly isolated primary human hepatocytes and liver sinusoidal endothelial cells at a ratio of 2:1 to a total of 1500 cells, (B, E) PHH + HLSEC+ HHF: Microtissues 
comprising primary human hepatocytes, liver sinusoidal endothelial cells and human hepatic fibroblasts in a ratio of 8:2:2 to a total of 1500 cells. As for the human liver 
tissue sections, sections were prepared as described in material and methods and immunofluorescently stained for albumin (hepatocyte marker in green) and CD-31 
(endothelial cell marker in red) as described in methods section. 
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5.2.2 Effect of growth factor stimulation on 
vascularisation pattern of human liver micro-
tissues 
 
Since LSEC have been shown to self-organise into vascular-like structure in the 
micro-tissue environment, triculture liver micro-tissues were stimulated with VEGF-
A and VEGF-C to see the effect of these growth factors on the formation pf these 
vascular structures. The fact that these receptors are neither expressed in primary 
human hepatocytes nor human hepatic fibroblast makes HLSEC a specific of these 
growth factors. Figure 5.2 shows the effect of growth factor stimulation on the 
vascular structure of HLSEC in the triculture liver microtissue. CD-31 (green stain) is 
was used to reveal vascular structures. In the presence of VEGF-A, the vasculature 
formed resembled sprouting angiogenesis. On the other hand, VEGF-C induced 
formation of vascular structures round the hepatocytes in a manner similar to the 
liver sinusoids. This observation might suggest that VEGF-A and VEGF-C play 
different roles during organogenesis.   
 
5.2.3 Expression of drug-metabolising enzymes in 
liver microtissues  
 
In order to functionally validate the liver microtissues, they were assayed for the 
expression of oxidative (phase I) and conjugative (phase II) drug-metabolising 
enzymes. Figure 5.3 shows the expression of CYP 3A4, CYP 2D6, CYP 2E1 (phase I) 
and UGT 1A1 (phase II) in liver microtissues in comparison with cells grown in 
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monolayer. Protein expression had been corrected for in the quantification to 
accurately reflect the difference in expression profile between monoculture and 
multiculture systems. After 7 days in culture, the cells in monolayer lost their 
expression of CYPs 3A4 and 2E1 while the level of CYP 2D6 and UGT 1A1 were 
highly reduced in comparison with that in freshly-isolated hepatocytes. As  
regards the liver microtissues, the triculture system had a lower expression of CYPs 
3A4, 2D6 and UGT 1A1 in comparison with the hepatocyte-only microtissues.
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Figure 5.2: Effect of growth factor stimulation on vascularisation pattern of human liver microtissues 
A total of 1500 cells were seeded on ultra-low attachment plates, centrifuged and incubated at 37°C for 7 d to allow cells to self-aggregate into microtissues as described in 
the Method section. On day 7, microtissues were harvested, medium removed and processed for immunofluorescent staining as previously described in the method 
section for Immunofluorescent staining for liver microtissues. Microtissues were stained for albumin (red), CD-31 (green), and nucleus (blue). Images were taken at a 
magnification of X100 using an immunofluorescent microscope. Microtissues comprised primary human hepatocytes, liver sinusoidal endothelial cells and human hepatic 
fibroblasts in a ratio of 8:2:2 to a total of 1500 cells. BASAL, VEGF-A, and VEGF-C: microtissue incubated with culture medium, culture medium supplemented with 50 ng/ml 
VEGF-A, culture medium supplemented with 50 ng/ml VEGF-C respectively.   
 195 
 
Also, the level of expression of these enzymes was the same in the triculture 
microtissues system regardless of whether the constituent HLSEC were stimulated 
with vascular endothelial growth factors or not.  
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Figure 5.3: Expression of drug-metabolising enzymes in the liver microtissues- 
A total of 1500 cells were seeded on ultra-low attachment plates, centrifuged and incubated at 37°C for 7 d to allow cells to self-aggregate into microtissues as described in 
the Method section. On day 7, microtissues were harvested, sonicated, centrifuged and quantified for total protein as previously described in methods section. Total 
protein from liver tissues, freshly isolated human hepatocytes and cells cultured in monolayer were prepared as earlier described in the methods section. Protein lysates 
were solubilised in LDS sample buffer, denatured at 90 ⁰C. Protein was separated using SDS PAGE for 45 min., transferred unto nitrocellulose membrane for 2 h. and 
blocked with 10 % milk. Membranes were then probed with respective antibodies CYP 3A4, CYP 2D6, CYP 2E1, UGT 1A1 and GAPDH.  Band intensity was quantified using 
Image J version 1.48v. Data is representative of three independent experiments. Differences in hepatocyte number between the monoculture and triculture systems were 
corrected for by multiplying the band intensities of UGT protein in the triculture system by a factor of 1.5.PHH; primary human hepatocyte, HHF: human hepatic fibroblasts, 
HLSEC: liver sinusoidal endothelial cells. 
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5.2.4 Drug metabolism in tri-culture liver 
microtissues.  
 
In order to determine whether the microtissues analysed for the expression of 
drug-metabolising enzymes were metabolically competent, a drug-metabolism 
study was conducted. This follows the observation that the tri-culture microtissues 
showed a lower expression of certain drug-metabolising enzymes. The metabolism 
of drugs known to be oxidatively metabolised by CYPs 2D6 and 2E1 and conjugated 
by UGT 1A1 was investigated.     
5.2.4.1 Paracetamol metabolism is reduced in triculture 
liver microtissues 
 
Paracetamol is principally metabolised by CYP 2E1 and CYP 3A4 to form N-acetyl p-
benzoquinone imine (NAPQI) which is unstable, highly reactive and not readily 
detectable experimentally (Trettin et al., 2014). NAPQI readily reacts with 
glutathione, which after a series of steps form cysteine and mercapturic acid 
conjugates, which are detectable using mass spectrometry. In addition, 
paracetamol is glucuronidated and sulphated to form glucuronide and sulphate 
conjugates respectively. Liver microtissues in monoculture or triculture were 
incubated with 1 mM of paracetamol for 24 h after which culture medium 
(containing parental drug and metabolites) were analysed for the presence of 
oxidative and conjugative metabolites. Figure 5.5 is a chromatogram showing the 
levels of metabolites of paracetamol in mono-culture and triculture liver 
microtissues after analysis by mass spectrometry. Retention time (on x-axis) 
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identified the peaks obtained to be metabolites of paracetamol. While the 
intensities of the peaks showed amount of the metabolite of interest. The 
intensities of the peaks on the chromatograms show that the levels of the 
metabolites formed in the triculture microtissues were lower than in their 
monoculture counterparts. This is further confirmed in figure 5.4 which shows the 
amount of metabolites of paracetamol produced per hepatocyte in the mono-
cellular and tri-culture liver microtissues. There were significantly (p < 0.001) lower 
levels of the cysteine and glucuronide conjugates of paracetamol in the tri-culture 
microtissue system in comparison to the PHH-only microtissues. A similar trend was 
also seen for the sulphated paracetamol metabolite whereby there was a highly 
significant (p < 0.01) lower level of the sulphate metabolite in the tri-culture 
microtissue than in the mono-culture system.   
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Figure 5.4: Paracetamol metabolism in liver microtissues 
A total of 1500 cells were seeded on an ultra-low attachment plate, centrifuged and incubated at 37°C 
for 7 d to allow cells to self-aggregate into microtissues as described in the Method section. On day 7, 
microtissues were incubated with 1 mM of paracetamol for 24 h after which samples were snap frozen 
and stored at -20C before analysis. Samples were analysed for LC/MS/MS for identification of 
metabolites of paracetamol as described in the method section. Amount of metabolites produced in the 
samples were corrected for the number of hepatocytes in liver microtissues. Concentration of 
metabolites were compared using Student t-test. Values are significant at **p < 0.01, ***p < 0.001. 
(n=3, from three different donors). PHH only: Microtissues containing a total of 1500 freshly-isolated 
primary human hepatocytes, TCC: triculture microtissues comprising primary human hepatocytes, liver 
sinusoidal endothelial cells and human hepatic fibroblasts in a ratio of 8:2:2 to a total of 1500 cells.  
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Figure 5.5: Chromatogram of paracetamol metabolism- 
A total of 1500 cells were seeded on an ultra-low attachment plate, centrifuged and incubated at 37°C for 7 d to allow cells to self-aggregate into microtissues as described in the Method 
section. On day 7, microtissues were incubated with 1 mM of paracetamol for 24 h after which samples were snap frozen and stored at -20C before analysis. Samples were analysed for 
LC/MS/MS for identification of metabolites of paracetamol as described in the method section. Amount of metabolites produced in the samples were corrected for the number of 
hepatocytes in liver microtissues. CYS, Cysteine conjugate of paracetamol.    
0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6
Time, min
1.0e4
2.0e4
3.0e4
4.0e4
In
te
n
sity, cp
s
X 10
CYS
SULPHATE
TRICULTURE MICRO-TISSUE
GLUCURONIDE
0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6
Time, min
0.0
1.0e4
2.0e4
3.0e4In
te
n
sity, cp
s
X 5
CYS
MONOCULTURE MICRO-TISSUE GLUCURONIDE
SULPHATE
 201 
 
5.2.4.2 Paracetamol metabolism at varying cell ratios in 
human liver microtissues  
 
To further determine the effect of cell number and age on the metabolism of 
paracetamol, liver microtissues were prepared with PHH, HLSEC and HHF at 
different ratios of 2:1:1, 4:1:1, 8:1:1 and 10:7:2. Microtissues were incubated with 1 
mM paracetamol for 24 h on days 7, 14 and 28 after they were formed. As shown in 
figure 5.6, there was significant reduction in the amount of phase I and phase II 
metabolites across the different cell ratios of triculture microtissues when 
compared with the PHH-only liver microtissues. In the liver microtissues formed at 
a ratio of 2:1:1, there were significant reductions in the levels of all metabolites in 
14- and 28-day old microtissues when compared with their 7-day old counterparts. 
However, the levels of the cysteine conjugate of paracetamol in microtissues 
formed at ratios of 4:1:1, 8:1:1 and 10:7:2 remained stable over the course of 21 
days. Also the levels of the glucuronide of paracetamol remained unchanged in the 
liver microtissues of the 8:1:1 configuration over the course of 21 days, while there 
was a significant (p < 0.05) reduction in the level of this metabolite in the 28-day, 
4:1:1 and 10:7:2 microtissues. The amount of sulphated paracetamol produced was 
significantly (p < 0.05) reduced in the 14- and 28-day old microtissues produced at 
the ratio of 10:7:2 when compared with their 7-day old counterparts.  While there 
was no significant difference in the level of paracetamol sulphate in the 14-day old 
microtissues made at the ratios of 4:1:1 and 8:1:1 as against the 7-day old 
microtissues, their levels significantly declined after 28 days.    
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Figure 5.6: Paracetamol metabolism at varying cell ratios in liver microtissues- 
A total of 1500 cells were seeded on an ultra-low attachment plate, centrifuged and incubated at 
37°C for 7 d to allow cells to self-aggregate into microtissues as described in the Method section. On 
days 7, 14 or 28, microtissues were incubated with 1 mM of paracetamol for 24 h after which 
samples were snap frozen and stored at -20C before analysis. Samples were analysed for LC/MS/MS 
for identification of metabolites of paracetamol as described in the method section. Amount of 
metabolites produced in the samples were corrected for the number of hepatocytes in liver 
microtissues. Concentration of metabolites were compared using one way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparison. Values are significant at **p < 0.01, ***p < 
0.001 and ****p<0.0001 (vs corresponding cell ratio at 7 days); #p < 0.05, ##p<0.01, and ###p < 0.001 
(7-day old microtissues in PHH vs triculture groups). (n=8, from eight different microtissues). PHH 
only: Microtissues containing a total of 1500 freshly-isolated primary human hepatocytes, triculture 
microtissues comprise primary human hepatocytes (PHH), human liver sinusoidal endothelial cells 
(HLSEC) and human hepatic fibroblasts (HHF) at ratios of 2:1:1, 4:1:1, 8:1:1 and 10:7:2 to a total of 
1500 cells.  
 
 
5.2.4.3 Metabolism of Perhexiline 
 
Perhexiline is primarily metabolised by CYP 2D6 to form a mixture of trans- and cis-
hydroxylated metabolites (Davies et al., 2007). Figure 5.8 is a chromatogram 
showing the oxidative metabolites of perhexiline formed after incubation with 5 
μM of the parent compound.  Perhexiline was metabolised to form two trans- and 
two cis- hydroxyl perhexiline metabolites. After correction for cell number in the 
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liver microtissues, there was significantly (p < 0.05) low level of cis-hydroxy 
perhexiline 1 formed in the unstimulated liver microtissues compared to the PHH-
only group (Fig. 5.7). There was also a significantly (p < 0.01) low level of cis-
hydroxy perhexiline 1 in the VEGF-A and VEGF-C-stimulated microtissues in 
comparison with the PHH-only microtissues. The same trend is also true for the 
formation of cis-hydroxy perhexiline 2 in the tri-culture microtissues. Similarly, the 
triculture microtissues formed significantly (p < 0.01) lower levels of trans-hydroxy 
perhexiline 1 and 2. This might suggest that the presence of HLSEC and HHF in a 
liver microtissue does not improve metabolic competence.  
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Figure 5.7: Inclusion of non-parenchymal cells inhibits the metabolism of perhexiline in human 
liver microtissues- 
A total of 1500 cells were seeded on an ultra-low attachment plate, centrifuged and incubated at 
37°C for 7 d to allow cells to self-aggregate into microtissues as described in the Method section. On 
day 7, microtissues were incubated with 5 µM of perhexiline for 24 h after which samples were snap 
frozen and stored at -20C before analysis. Samples were analysed for LC/MS/MS for identification of 
metabolites of perhexiline as described in the method section. Amount of metabolites produced in 
the samples were corrected for the number of hepatocytes in liver microtissues. Concentration of 
metabolites analysed and compared using one way analysis of variance ANOVA followed by 
Dunnett’s multiple comparison test. Values are significant at *p < 0.05, **p < 0.01. (n=6).  PHH only: 
Microtissues containing a total of 1500 freshly-isolated primary human hepatocytes, TCC: triculture 
microtissues comprising primary human hepatocytes, liver sinusoidal endothelial cells and human 
hepatic fibroblasts in a ratio of 8:2:2 to a total of 1500 cells. BASAL, VEGF-A, and VEGF-C: microtissue 
incubated with culture medium, culture medium supplemented with 50 ng/ml VEGF-A, culture 
medium supplemented with 50 ng/ml VEGF-C respectively.  PHX-OH: hydroxy perhexiline.  
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Figure 5.8: Chromatogram of perhexiline metabolism- 
A total of 1500 cells were seeded on a ultra-low attachment plate, centrifuged and incubated at 37°C for 7 d to allow cells to self-aggregate into microtissues as described in the Method 
section. On day 7, microtissues were incubated with 5 µM of perhexiline for 24 h after which samples were snap frozen and stored at -20C before analysis. Samples were analysed for 
LC/MS/MS for identification of metabolites of perhexiline as described in the method section. Amount of metabolites produced in the samples were corrected for the number of hepatocytes 
in liver microtissues. PHH only: Microtissues containing a total of 1500 freshly-isolated primary human hepatocytes, TCC: triculture microtissues comprising primary human hepatocytes, liver 
sinusoidal endothelial cells and human hepatic fibroblasts in a ratio of 8:2:2 to a total of 1500 cells. BASAL, VEGF-A, and VEGF-C: microtissues incubated with culture medium, culture medium 
supplemented with 50 ng/ml VEGF-A, culture medium supplemented with 50 ng/ml VEGF-C respectively.   
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
Time (min.)
0.0
1000.0
2000.0
3000.0
4000.0
5000.0
6000.0
7000.0
8000.0
9000.0
1.0e4
1.1e4
1.2e4
1.3e4
1.4e4
1.5e4
1.6e4
1.7e4
1.8e4
In
te
n
si
ty
(c
p
s)
3.07
3.46
3.21
3.78
3.40
4.17
3.66 4.10
TRANS-OH ISOMERS
CIS-OH ISOMERS
HYDROXY-PERHEXILINE
 207 
 
5.2.5 Sensitivity of liver microtissues to hepatotoxic 
drugs  
 
Having observed a significant difference in the expression and activity of drug 
metabolising enzymes in mono-culture and tri-culture liver microtissues, their 
relative sensitivity to a range of hepatotoxic drugs was investigated. This was done 
in order to explore the possibility of a correlation between the metabolism and 
toxicity. Also, since VEGF-A and VEGF-C were shown in chapter 4 above to induce 
the factors responsible for liver regeneration, and that exogenous administration of 
VEGF-A significantly reduced paracetamol-induced liver toxicity in rats (Donahower 
et al., 2010a), it was hypothesised that VEGF-A and VEGF-C might confer a 
protective effect on the liver microtissues.  
 
5.2.5.1 Paracetamol toxicity 
  
The sensitivity of primary human hepatocyte in monolayer was compared to that in 
a microtissue configuration.  Figure 5.9 shows that paracetamol is more toxic to 
PHH in monolayer than in the microtissue configuration. While the IC50 value for 
paracetamol in the monolayer was 3.3 mM, it was approximately 10 mM in 
microtissues. This represents a 3-fold difference in sensitivity. The presence of 
other cell types in the microtissues did not make any difference in this respect. 
Figure 5.10 shows a different trend in the presence of growth factors. Neither 
VEGF-A nor VEGF-C protected the liver microtissues against paracetamol toxicity as 
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the IC50 was constant in all the systems. This shows that growth factors do not 
confer any protection to liver microtissues.       
   
 
 
Figure 5.9: Primary human hepatocytes in monolayer are more sensitive than liver microtissues to 
paracetamol toxicity- 
Dose-response curve comparing toxicity of paracetamol on liver microtissues with primary human 
hepatocytes in monolayer. For liver microtissues, a total of 1500 cells were seeded on ultra-low 
attachment plates, centrifuged and incubated at 37°C for 7 d to allow cells to self-aggregate into 
microtissues as described in the Method section. On day 7, serial doses of paracetamol were 
prepared in culture medium. Microtissues were dosed for 72 h with 100 µl of drugs or medium, after 
which an equal volume of 3D Cell Titer Glo® reagent was added and assayed for ATP content as 
described in methods. Primary human hepatocytes in monolayers were plated, incubated, treated 
and assayed for ATP as previously described. IC50 values were estimated and dose-response curve 
generated using GraphPad Prism 5. (n=3, three independent experiments). PHH monolayer: Primary 
human hepatocytes seeded out in a monolayer configuration, PHH microtissue: microtissue 
containing primary human hepatocytes only. Triculture microtissue: microtissue comprising primary 
human hepatocytes, liver sinusoidal endothelial cells and human hepatic fibroblasts in a ratio of 
8:2:2 to a total of 1500 cells. 
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Figure 5.10: Growth factor supplementation does not impact on the toxicity of paracetamol on 
liver microtissues- 
Dose-response curve showing effect of paracetamol on liver microtissues. A total of 1500 cells were 
seeded on ultra-low attachment plates, centrifuged and incubated at 37°C for 7 d to allow cells to 
self-aggregate into microtissues as described in the Method section. On day 7, serial doses of 
paracetamol were prepared in culture medium. Microtissues were dosed for 72 h with 100 µl of 
drugs or medium, after which an equal volume of 3D Cell Titer Glo® reagent was added and assayed 
for ATP content as described in methods. IC50 values were estimated and dose-response curve 
generated using GraphPad Prism 5. (n=3, three independent experiments). VEGF-A: triculture 
microtissues comprising primary human hepatocytes, liver sinusoidal endothelial cells and human 
hepatic fibroblasts in a ratio of 8:2:2 to a total of 1500 cells and supplemented with 50 ng/ml of 
VEGF-A, VEGF-C: triculture microtissues comprising primary human hepatocytes, liver sinusoidal 
endothelial cells and human hepatic fibroblasts in a ratio of 8:2:2 to a total of 1500 cells and 
supplemented with 50 ng/ml of VEGF-C. 
 
5.2.5.2 Regorafenib toxicity 
 
To test whether the effect seen above was specific to paracetamol, and to 
investigate if growth factor administration could protect against TKI-induced 
toxicity, the experiments were repeated using regorafenib. Figure 5.11 shows a 
different trend. It reveals that in addition to growth factor stimulation not 
influencing the IC50 of regorafenib, the toxicity of regorafenib was the same in 
 
PARACETAMOL
Log [Dose] (mM)
Pe
rc
en
ta
ge
 v
ia
bi
lit
y
0.01 0.1 1 10 100
0
50
100
150
 BASAL VEGF-A VEGF-C 
IC50 (mM) 9.9 9.8 9.7 
 
 210 
 
monolayer (monoculture and triculture) and well as in microtissues (monoculture, 
tri-culture, agonist stimulated or basal).   
 
Figure 5.11: Regorafenib is equitoxic to hepatic cells in monolayer and in microtissue 
configuration- 
Dose-response curve showing effect of regorafenib on liver monoculture and triculture liver 
microtissue and in monolayer system. A total of 1500 cells were seeded on an ultra-low attachment 
plate, centrifuged and incubated at 37°C for 7 d to allow cells to self-aggregate into microtissues as 
described in the Method section. On day 7, serial doses of the regorafenib originally constituted in 
DMSO were prepared. Final dosing concentrations or blank DMSO was made in HLSEC medium to a 
uniform concentration of 0.1 % DMSO. Microtissues were dosed for 72 h with 100 µl of drugs or 
medium containing 0.1 % DMSO, after which an equal volume of 3D Cell Titer Glo® reagent was 
added and assayed for ATP content as described in methods. Primary human hepatocytes in 
monolayers (monoculture and triculture) were plated, incubated, treated and assayed for ATP as 
previously described. IC50 values were estimated and dose-response curve generated using 
GraphPad Prism 5. (n=3). PHH; microtissues containing a total of 1500 freshly-isolated primary 
human hepatocytes, TCC: triculture microtissues comprising primary human hepatocytes, liver 
sinusoidal endothelial cells and human hepatic fibroblasts in a ratio of 8:2:2 to a total of 1500 cells. 
BASAL, VEGF-A, and VEGF-C: microtissue incubated with culture medium, culture medium 
supplemented with 50 ng/ml VEGF-A, culture medium supplemented with 50 ng/ml VEGF-C 
respectively.   
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5.2.5.3 Toxicities of other liver toxins 
 
In order to extend the observations made with paracetamol and regorafenib, liver 
microtissues were dosed with aflatoxin, benzbromarone, desipramine and 
perhexiline. These drugs have been reported to induce liver injury via different 
mechanisms, including generation of reactive metabolites, mitotoxicity and 
induction of apoptosis. Figure 5.12 shows the toxicities of benzbromarone, 
desipramine and perhexiline in monoculture liver microtissues relative to 
microtissues with or without growth factor supplementation. The IC50 of aflatoxin 
was less than 1 μM in all systems whereas benzbromarone had similar IC50 in the 
range of 95-108 μM in all the conditions. A different trend was seen for 
desipramine and perhexiline. As for desipramine, the monoculture and 
unstimulated triculture microtissues had a similar IC50 at approximately 18 μM. On 
the other hand, the VEGF-A and VEGF-C- stimulated microtissues were less 
sensitive, with 50 % cell death at 31 and 32.6 μM respectively. Primary human 
hepatocyte-only microtissues were more than 5-fold less sensitive to perhexiline 
compared to triculture microtissues. This observation suggests that the presence of 
non-parenchymal cell makes liver microtissues more sensitive to perhexiline toxicity 
irrespective of growth factor stimulation.  
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Figure 5.12: Effect of hepatotoxic drugs on liver microtissues- 
Dose-response curve showing effect of hepatotoxic drugs on liver monoculture and triculture liver microtissue. A total of 1500 cells were seeded on an ultra-low 
attachment plate, centrifuged and incubated at 37°C for 7 d to allow cells to self-aggregate into microtissues as described in the Method section. On day 7, serial doses of 
the drugs originally constituted in DMSO were prepared. Final dosing concentrations or blank DMSO was made in HLSEC medium to a uniform concentration of 0.1 % 
DMSO. Microtissues were dosed for 72 h with 100 µl of drugs or medium containing 0.1 % DMSO, after which an equal volume of 3D Cell Titer Glo® reagent was added and 
assayed for ATP content as described in methods. IC50 values were estimated and dose-response curve generated using GraphPad Prism 5. (n=3). PHH; microtissues 
containing a total of 1500 freshly-isolated primary human hepatocytes, TCC: triculture microtissues comprising primary human hepatocytes, liver sinusoidal endothelial 
cells and human hepatic fibroblasts in a ratio of 8:2:2 to a total of 1500 cells. BASAL, VEGF-A, and VEGF-C: microtissues incubated with culture medium, culture medium 
supplemented with 50 ng/ml VEGF-A, culture medium supplemented with 50 ng/ml VEGF-C respectively.   
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5.3 DISCUSSION  
 
Liver sinusoidal endothelial cells self-organise in liver microtissues to form a 
network that can take different appearances depending on the predominant 
growth factor environment. This can be very important while studying the cell-
specific toxic effect of drugs in a multicellular liver microtissue system. As reviewed 
in the introductory section, the VEGF-A/ VEGFR-2 signalling pathway plays a key 
role in organogenesis whereby the nascent HLSEC create a pattern for the 
formation of lobular organisation of the liver by directing the liver into cords 
(Matsumoto et al., 2001, McLin & Yazigi, 2011). The observation made in figure 5.2 
whereby VEGF-A and VEGF-C formed different patterns of HLSEC growth within the 
liver microtissue might suggest different roles of these angiogenic factors. It stands 
to reason that during hepatogenesis, VEGF-A may be responsible for proliferation of 
the primordial HLSEC while VEGF-C helps direct the pattern of growth to form the 
sinusoid. This might involve the VEGF-C/VEGFR-3 axis as VEGFR-3 is essential during 
embryonic angiogenesis (Paavonen et al., 2000), and a knockout of the VEGFR-3 has 
been shown to be embryonically lethal (Dumont et al., 1998). It would be 
informative to investigate the role of VEGF-C/VEGFR-3 in hepatogenesis. 
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5.3.1 Expression and activity of drug-metabolising 
enzymes in liver microtissues 
 
There was a dramatically low level of drug-metabolising enzymes in the cells 
cultured as monolayers over a period of 7 d (Fig. 5.3). This is in agreement with 
previously published data that showed that hepatocytes de-differentiate in culture 
(Heslop et al., 2016).  This shows that presence of other non-parenchymal cells 
does not improve the expression of these enzymes. On the other hand PHH-only 
microtissues maintained a level of CYPs 3A4 and 2D6 as well as UGT 1A1 
comparable to what was observed in freshly-isolated PHH and whole liver tissue. 
Takahashi et al. (2015) and Gaskell et al. (2016) have reported an improved hepatic 
phenotype in 3D liver spheroids compared with cells cultured as a monolayer. 
While these were performed on HepaRG and HepG2 cells, Bell et al. (2016) have 
shown that PHH microtissues exhibit a remarkably improved maintenance of 
hepatocyte-specific functions including drug metabolism. However, none of these 
studies have included primary HLSEC and/ or HHF.   The finding that inclusion of 
non-parenchymal cells (HLSEC and HHF) reduced the protein expression of these 
enzymes in tri-culture microtissues (figs. 5.3, 5.4, 5.6 and 5.7) is indicative of the 
possibility of an enzyme inhibitory activity in the presence of these cells. This 
‘inhibitory’ effect was also seen in the drug metabolism studies wherein the 
triculture microtissues effected a significant reduction in the metabolites – 
oxidative and conjugative— formed in paracetamol and perhexiline (figs. 5.4, 5.6 
and 5.7). This shows that presence of non-parenchymal cells (HLSEC and HHF) not 
only affected the protein expression of these enzymes, it also affected their 
catalytic activities.     
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5.3.2 Sensitivities of liver microtissues to 
hepatotoxic drugs 
 
As shown in the previous chapter, paracetamol was equitoxic to all the monolayer-
grown cells tested in the comparative toxicological analysis. However, microtissues 
were 3-fold less sensitive to this toxic effect regardless of presence of non-
parenchymal cells or growth factor supplementation. Previous studies have shown 
that paracetamol causes LDH leakage—an indication of loss of plasma membrane 
integrity in hepatocytes (Bajt et al., 2004). This observation may be indicative of the 
possibility that the microtissues provide a protective layer against this effect as 
constituent cells in microtissues are held together by adhesion molecules and the 
formation of extracellular matrix (Lin et al., 2006). The inability of growth factor 
supplementation to confer protection on the triculture liver microtissue may 
suggest that the effect reported by Donahower et al. (2010a), that administration of 
recombinant VEGF-A protected against a mouse model of paracetamol toxicity, 
cannot yet be replicated in vitro using this model of human liver microtissues. This 
might also be suggestive of species difference in sensitivity to hepatotoxic drugs. A 
more relevant direct comparison would probably require an experiment with liver 
microtissues using hepatic cells derived from mice. On the other hand, regorafenib 
was toxic to liver microtissues at the same concentration as hepatocytes in 
monolayer. The fact that regorafenib targets both hepatocytes and HLSEC as shown 
in the previous chapter might explain the result obtained with the liver microtissue, 
in which the presence or absence of HLSEC did not offer any protection. This was 
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different in the case of perhexiline where the presence of non-parenchymal cells 
resulted in liver microtissues being 5-fold more sensitive to perhexiline.  Perhexiline 
is metabolised by CYP 2D6 (Davies et al., 2007) which is polymorphic in expression 
wherein about 5-10% of Caucasians are poor metabolisers with two non-functional 
allelic variants of the CYP 2D6 gene (Zhou, 2009).   An early study associated 
perhexiline-induced liver injury with impaired debrisoquine metabolism (Morgan et 
al., 1984); and debrisoquine is a probe drug for CYP 2D6 activity. Since the 
elimination of perhexiline is dependent on its oxidative metabolism to its hydroxy 
derivatives which make it more hydrophilic and so more excretable, a deficiency in 
this would increase the plasma half-life of the parental compound up to 30 days 
compared to 3-12 days in normal metabolisers (Wright et al., 1973, Ashrafian et al., 
2007). This increases the time of exposure to perhexiline which increases the 
likelihood of its toxicity among the poor metabolisers. As reviewed in Chapter 1 of 
this thesis, the amphiphilic nature of the perhexiline molecule predisposes it to be 
rapidly accumulated in the mitochondrion at high concentrations where it 
uncouples mitochondrial oxidative phosphorylation by inhibiting complexes I and II, 
resulting in decreased ATP formation (Deschamps et al., 1994, Fromenty & 
Pessayre, 1995). Although it was not a case of genetic polymorphism, a direct link 
can be established between the CYP expression data (fig. 5.3), the metabolism data 
(figure 5.7) and the toxicity data (fig. 5.12) wherein the low expression of CYP 2D6 
in the triculture liver microtissue led to a significantly low metabolism in 
comparison with the PHH-only microtissues. The relatively poor metabolism of 
perhexiline in the triculture microtissues explains the low IC50 seen as a high level of 
the parental would have accumulated in the cells, leading to increased toxicity.   
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A major limitation of the experimental setup in this chapter was the inability to 
utilise cells from same donor for the triculture microtissues. This emanated from 
the fact that primary human hepatocytes needed to be used freshly after isolation 
while HLSEC and HHF used required time to expand before being ready for 
experiments. If the primary human hepatocytes had been cryopreservable, then it 
would have been possible to donor-match all the cells in every triculture liver 
microtissue experiments. This would have possibly improved the expression of 
hepatocyte specific markers.   
In conclusion, the data in this chapter has shown that HLSEC have the propensity to 
form a vascular-like network in a triculture liver microtissue environment which 
opens up the possibility to study the effect of growth factor stimulation on these. 
This could be further developed to enable the evaluation of cell-specific effects of 
xenobiotics in a multicellular system. While the microtissues had a higher 
expression of key metabolic enzymes compared to cells in monolayer configuration, 
the triculture liver microtissue system seems to inhibit this. Metabolism studies also 
support this as CYP 2D6 and CYP 2E1-dependent metabolisms were significantly 
lower in the triculture liver microtissues. Finally, the low metabolic competence of 
the tri-culture liver microtissue may explain the high toxicity of perhexiline in 
triculture liver microtissue as hydroxylation is an important detoxification and 
elimination pathway for perhexiline.  
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OVERALL DISCUSSION 
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6.1 INTRODUCTION 
 
Drug-induced liver injury (DILI) remains a leading cause of drug withdrawal and 
attrition at different stages of development (Laverty et al., 2011, Haque et al., 
2016), resulting in loss of time and other resources invested into drug development, 
hence a loss of potentially efficacious therapeutic agents. Reasons for withdrawal 
range from mild elevation of liver transaminases to chronic liver failure 
(Akingbasote et al., 2016). As a result of these, there remains the need for an in 
vitro model system that can detect hepatotoxicity earlier on during pre-clinical 
development. To date, most preclinical studies have primarily employed the use of 
hepatocytes aimed at understanding and preventing DILI due to their overall 
abundance within the hepatic lobule as they make up over 60% of hepatic cell 
population (Rogers & Dintzis, 2012). Nevertheless, other resident cell types of the 
liver can and do play a role in DILI. This was the aim of this thesis—specifically to 
investigate the role of liver sinusoidal endothelial cells (LSEC) in DILI. The data 
shown and discussed in the previous chapters have highlighted the uniqueness of 
LSEC especially in comparison with endothelial cells from other vascular beds. It 
shows the response of HLSEC to hepatotoxic drugs of different classes, with 
emphasis on small-molecule receptor tyrosine kinase inhibitors. The result chapters 
also addressed the inclusion of HLSEC in a multicellular liver microtissue system. 
This final chapter is a summary of the findings from this study— new findings, 
potentials and future directions.   
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6.1.1 Liver sinusoidal endothelial cells are a unique 
endothelial cell population and differ from 
other endothelial cell populations  
 
Results obtained from this thesis further confirms liver sinusoidal endothelial cells 
as a unique endothelial cell population. In addition to the expression of markers – 
CD-31, VEGFR-1, and VEGFR-2 which indicates their identity as endothelial cells 
(Zhuang & Ferrara, 2015), they also responded to a range of relevant growth factors 
that mediate their physiologic functions of proliferation, migration and tubular 
morphogenesis (Holmes et al., 2007, Koch & Claesson-Welsh, 2012). Data in 
Chapter 3 shows that HLSEC have a higher expression of VEGFR-2 relative to 
HDMEC and HDLEC. Being a liver-resident cell population and the first point of 
contact with xenobiotics and other pathogenic substances, LSEC might have been 
well adapted to this environment by the expression of this cell-survival mediating 
receptor, since VEGFR-2 is key to the activation of the intracellular signalling 
pathways that mediate endothelial cell survival, proliferation, and migration 
culminating in angiogenesis. Another important scenario that makes the high 
expression of VEGFR-2 on LSEC very important to liver physiology is in liver 
regeneration. In a ground-breaking research by Ding and co-workers, it was 
demonstrated that during liver injury or partial hepatectomy in mice, hepatocytes 
released VEGF-A (Ding et al., 2010a, Ding et al., 2014). LSEC respond to this via a 
cascade of events that results in the release of hepatocyte growth factor (HGF) 
which then stimulate hepatocyte proliferation and consequent liver regeneration. 
During this process, there is also a high rate of LSEC proliferation which help create 
the vasculature that guide the arrangement of the hepatocytes into cords and in 
 221 
 
the perfusion of the regenerated liver.  It is therefore conceivable that a high 
expression of VEGFR-2 on LSEC would be key to this process. VEGFR-3 is expressed 
on HLSEC as shown in Chapter 3. Whilst the experiments carried out focussed 
primarily on the activation of VEGFR-2 on HLSEC upon exposure to VEGF-A and 
VEGF-C, the importance of the formation of VEGFR-2/VEGFR-3 heterodimer might 
need investigating. By employing in situ proximity ligation assay (PLA), Nilsson et al. 
(2010) have demonstrated that VEGF-C or VEGF-A could form VEGFR-2/VEGFR-3 
heterodimers in primary human saphenous endothelial cells. They further showed 
that neutralising VEGFR-3 and preventing the formation of VEGFR-2/ VEGFR-3 
heterodimers in an embryoid body model of angiogenesis prevented angiogenic 
sprouting. Since HLSEC express VEGFR-3, the formation of such heterodimers is 
likely; that might provide new insight into the regulation of the sinusoidal 
vasculature. Other important aspects of the uniqueness of the LSEC is the 
expression of L-SIGN, stabilin-1, stabilin-2, mannose receptor C1, which play key 
roles in scavenging and endocytosis of foreign substances (Politz et al., 2002, 
Gardner et al., 2003, Cormier et al., 2004, Malovic et al., 2007).  
As shown in chapter 3, the presence of fenestration on the surface of LSEC by 
scanning electron microscopy and the high expression of plasmalemma vesicle 
associated protein (PLVAP) and serotonin (5-hydroxytryptamine [5-HT]) receptor 
2B detected by whole transcriptome analysis is another indication of the 
uniqueness of LSEC as an endothelial cell population. As already reviewed in 
chapter 1 and discussed in chapter 3, liver sinusoidal endothelial cells are the only 
endothelial cell population that are fenestrated and they lack an organised 
basement membrane; glomerular endothelial cells are also fenestrated, but they 
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do have an organised basement membrane (DeLeve, 2007). A basement 
membrane is a thin layer of fibrous tissue or extracellular matrix material that 
separates the endothelium from the underlying tissue (Kierszenbaum & Tres, 
2015). In the kidney,  glomerular basement membrane (Miner, 2012) is an 
important component of the glomerular filtration system, which separates the 
glomerular vasculature from the urinary space. It is important to note that the 
fenestrations on the glomerular endothelial cells are ‘plugged’ by a glycocalyx-like 
material which further imparts a barrier function to the endothelium (Haraldsson 
& Jeansson, 2009). On the contrary, LSEC lack a basement membrane, but an 
interstitial space referred to as space of Disse (SD) is present between the 
endothelial compartment and the underlying hepatocytes. As reviewed in Chapter 
1, the fenestration on LSEC permits the movement of xenobiotics and 
chylomicrons of diameters less than those of the fenestrations to gain access to 
hepatocyte in order to effect their metabolism (Wisse et al., 1996). Any process 
that causes the reduction of these ‘transcellular windows’ is termed 
capillarisation or pseudocapillarisation and is deleterious to both LSEC function 
and obviously liver physiology (DeLeve et al., 2004), resulting in hyperlipidaemia 
and atherosclerosis (Stolz, 2011a). An important finding in this study was the high 
expression of the plasmalemma vesicle associated protein (PLVAP) on HLSEC 
which has been shown to be important in the regulation of fenestrations. As 
discussed in chapter 3, a knock out of PLVAP results in hyperlipoproteinaemia 
(Herrnberger et al., 2012). A study identified PLVAP as a molecular target in 
hepatocellular carcinoma due to the high expression of PLVAP in this cancer type 
(Wang et al., 2014), without regard for its role in LSEC physiology. A monoclonal 
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antibody directed against PLVAP was shown to reduce tumour size in a mouse 
model of hepatocellular carcinoma. The problem with this strategy is the fact that 
this target is present on normal cells and are needed for their physiology. In fact, 
it is possible that the high expression of PLVAP in hepatocellular carcinoma was 
due to angiogenesis-derived LSEC which evidently would also express this gene. 
Therefore, should this anti-PLVAP monoclonal antibody be carried forward into 
development, there is all likelihood of patients being later diagnosed with 
hyperlipidaemia. Another important aspect relating to the uniqueness of LSEC and 
their possession of fenestration is the result obtained in Chapter 3 which shows a 
significant increase in fenestration in VEGF-A stimulated cells in comparison with 
unstimulated control. A link can be established here with PLVAP expression on the 
LSEC. Strickland et al. (2005) demonstrated that VEGF-A, in a time dependent 
manner, produced an increase in the expression of PLVAP via VEGFR-2-AKT 
signalling pathway. Hence, the findings that PLVAP was highly expressed on HLSEC 
and that VEGF-A induced a significant increase in HLSEC fenestration may be 
related.   
As reviewed in chapter 1, fenestration on LSEC is regulated via serotonin receptor 
2 (5-HT2) activation (Gatmaitan et al., 1996). Some antidepressant drugs are 
known to induce liver injury among which is desipramine which acts by inhibiting 
the uptake of serotonin in the post synaptic cleft (Peppin & Raffa, 2015). It has 
been shown that desipramine treatment induced a downregulation of the 5-HT2 
receptor in the brains of rodents (Yatham et al., 1999). There is a high possibility 
of desipramine inducing this effect on the liver sinusoidal endothelial cells, being 
the first group of cells to come in contact with the drug as it enters into the liver 
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via hepatic portal vein. That being the case, a downregulation of the 5-HT2 
receptor would indeed impact on the regulation of the fenestration on the LSEC, 
thereby reducing its contractile ability and enabling the entry of larger substances 
into the SD and the hepatocyte. The relative sensitivity of HLSEC to desipramine in 
an in vitro cell viability assay as shown in Chapter 4 might be an indication of this 
possibility. Further, transcriptomic analysis has shown the expression of other 
genes like nitric oxide synthase trafficking (NOSTRIN) which is involved in the 
regulation of the synthesis of NO by lowering the activity of eNOS (Xu et al., 2013).  
Since LSEC is a major site of NO production (Perri & Shah, 2005b), the relatively high 
expression of NOSTRIN might be required to control the amount of NO produced so 
as to regulate local vascular dilation in the liver sinusoid.  
 
6.1.2 Liver sinusoidal endothelial cells are direct 
targets of hepatotoxic drugs 
 
Data from Chapter 4 of this thesis shows the relative sensitivity of HLSEC to a range 
of hepatotoxic drugs in comparison with dermal vascular and lymphatic endothelial 
cells, human hepatic fibroblasts and primary human hepatocytes. HLSEC was 
relatively more sensitive to the small molecule receptor tyrosine kinase inhibitors 
(TKIs) screened. These TKIs inhibited the activation of VEGFR-2 with the subsequent 
inhibition of the downstream signalling pathways. The different TKIs inhibited the 
VEGFR-2 activation to different extents and at different concentrations. 
Regorafenib was chosen as the representative TKI due to its well-reported liver 
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toxicity in the clinic (Grothey et al., 2013, Demetri et al., 2013). Regorafenib 
induced an inhibition of VEGFR-2 mediated cell migration, tubular morphogenesis 
and upregulation of angiocrine factors involved in liver regeneration following 
stimulation with VEGF-A or VEGF-C. It also induced apoptosis by activation of 
caspase 3 in HLSEC as well as in hepatocytes. It caused a disruption of the actin 
cytoskeleton in HLSEC. Put together, this set of data shows that the HLSEC is a 
direct target in TKI toxicity. Effects of regorafenib on HLSEC could be summed up 
into functional and structural toxicity. The fact that anti-angiogenic drugs mainly 
target the mechanisms involved in the formation and maintenance of vasculature 
increases the chances of vascular toxicity; the same molecular targets are also 
required for normal endothelial cell physiology (Widakowich et al., 2007, Gotink & 
Verheul, 2010a). This shows the need to discover more tumour-vasculature-specific 
molecular targets to address this problem. One way this can be done is to isolate 
the endothelial cells from tumours and profile their gene expression pattern with 
that of normal vasculature from the same organ. This should make it possible to 
avoid these on-target toxic effects. Secondly, the finding that HLSEC are selectively 
more sensitive to hepatotoxic drugs than primary human hepatocytes or human 
hepatic fibroblasts, as shown in this study, is an indication of their potential as early 
targets of DILI compounds as confirmed in previous studies (McCuskey et al., 2001, 
McCuskey et al., 2005, McCuskey, 2006).  Ito et al. (2003) demonstrated that injury 
to LSEC occurred before hepatocytes during paracetamol toxicity. This is not 
surprising as any substances entering the liver would first interact with LSEC before 
gaining access to the hepatocyte either for metabolic bioactivation or 
detoxification. From this perspective, it seems urgent to discover an LSEC specific 
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liver biomarker of DILI. This may not be far-fetched as is evidenced in the discovery 
of MiR-122 as a liver- and hepatocyte-specific biomarker of drug-induced liver 
injury (Wang et al., 2009, Antoine et al., 2013). A paracetamol model of liver injury 
might also be explored as a pilot study in this regard. Briefly, LSEC from normal 
control and paracetamol-treated mouse livers could be isolated and profiled for 
miRNA.  
Another indication of LSEC being a direct target of hepatotoxic drugs is the 
structural effect seen with regorafenib as shown in Chapter 4. Regorafenib induced 
a time- and dose-dependent disruption in the cytoskeletal structure of HLSEC. This 
is in agreement with recent data by Wilkinson et al. (2016) who showed that the 
cardiotoxic anticancer drug, doxorubicin, does cause a disruption in the 
endothelium by interfering with the cytoskeletal structure of the human cardiac 
microvascular endothelial cells. Recent data shows that targeting the 
microvasculature with VEGF-B can protect against doxorubicin-induced 
cardiovascular injury (Räsänen et al., 2016). A similar strategy could be adopted to 
protect against DILI.  
Perhaps the novel finding in this aspect of the study is the data showing the 
inhibitory effect of regorafenib on one of the pathways required for liver 
regeneration. A physiologic response to liver injury is the activation of VEGFR-2 on 
LSEC by VEGF-A secreted by hepatocytes thereby starting a cascade that result in 
secretion of HGF which informs hepatocyte proliferation (Discussed in details in 
Chapter 1). The fact that regorafenib blocked this process is an indication of 
another likely mechanism of its mode of contribution to DILI. This is because if after 
exposure to hepatotoxic drugs, the homeostatic response of liver repair and 
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regeneration is disrupted, the initial insult would be exacerbated resulting in more 
severe damage to the liver. In the future, it would be informative to test this in an 
in vivo model.   
 
6.1.3 Human liver sinusoidal endothelial cells in a 
triculture microtissue system 
  
Chapter 5 showed the inclusion of HLSEC in a 3-cell liver microtissue system. This is 
perhaps the first time triculture liver microtissue has been generated using freshly-
isolated primary human hepatocytes, primary human liver sinusoidal endothelial 
cells and primary human hepatic fibroblasts. Previous studies have relied upon  
immortalised cells as the source of one or all of the constituent cells (Gaskell et al., 
2016). Some studies have also used non-liver derived endothelial cells including 
HUVEC (Takebe et al., 2013, Nelson et al., 2015). While the studies claimed 
improvement in liver function in comparison with hepatocytes or hepatocyte-like 
cells in monolayer, the results could not be directly related to what would have 
been obtained if primary liver cells were used. This was the case as reported by 
Ravenscroft et al. (2016) who demonstrated that contractile function of the cardiac 
microtissue depended on a triculture system comprising stem cell derived 
cardiomyocytes, cardiac microvascular endothelial cells and cardiac fibroblasts. 
They further showed that inclusion of non-cardiac fibroblast or non-cardiac 
endothelial cells did not impart functionality on the microtissues generated. This 
supports the strategy employed in the development of the liver microtissues 
presented in this thesis. Data in the initial part of Chapter 5 shows the ability of 
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HLSEC to vascularise the liver microtissues as demonstrated by 
immunofluorescence microscopy. This could be developed to create a novel model 
for the study of liver-specific angiogenesis. Also, as seen in chapter 4, HLSEC are 
selectively more sensitive to a range of hepatotoxic drugs especially small molecule 
tyrosine kinase inhibitors. This could be further explored in a multicellular 
microtissue system such that, with the use of imaging techniques that enable the 
visualisation of different constituent cell types, structural effect of drugs in these 
could be explored.  
Chapter 5 also highlighted the advantage of 3D liver microtissue over hepatocytes 
in monolayer. Results confirmed previous findings that the 3D system better 
reconstitutes the in vivo environment wherein constituent cells are able to interact 
and communicate, thus enabling improved viability and functionality (Achilli et al., 
2012, Takebe et al., 2013). In order to further this result, HLSEC, and human hepatic 
fibroblasts were included in the liver microtissues to recreate a more in vivo-
relevant environment. Structurally, LSECs form the conduit that convey oxygen and 
nutrient into the liver while fibroblasts secrete extracellular matrix materials like 
collagen thereby enabling the organ to maintain its structure. In the experiments 
performed, it took hepatocyte-only microtissues almost twice the time it took 
triculture liver organoid to mature (data not shown). It was easier to handle 
triculture liver microtissues than their monoculture counterparts during the 
rigorous process of histological processing, as the inclusion of these other cell types 
conferred structure to the microtissues. This structural stability was expected to be 
translated into functionality. Surprisingly, the expression of drug-metabolising 
enzymes –CYP2D6, CYP3A4 and UGT1A1—was lower in the triculture liver 
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microtissues. These effects were further observed in drug metabolism studies using 
paracetamol (a CYP 2E1 and UGT 1A1 substrate) and perhexiline (a CYP 2D6 and 
UGT 1A1 substrate). After correcting for the cell number (for hepatocytes) in the 
liver microtissues, drug metabolism was significantly lower in the triculture 
microtissues than in their monoculture equivalent. Following this, the triculture 
liver microtissues were supplemented with VEGF-A and VEGF-C to stimulate the 
HLSEC to investigate if they (HLSEC) could produce factors that might ultimately 
improve function in hepatocytes. This was attempted since activation of VEGFR-2 
on LSEC was an important first step in liver regeneration (Ding et al., 2010a, Ding et 
al., 2014). However, growth factor supplementation did not induce any 
improvement in expression and activities of these oxidative and conjugative 
enzymes. This raises questions as to why an opposite effect of hypothesised 
outcome was produced. This might have been a direct result of the isolation 
process that involved the use of collagenase which might have contributed to the 
rapid de-differentiation process of the hepatocytes in vitro (Bell et al., 2016, Heslop 
et al., 2016). Another highly likely explanation for this observation was the 
possibility of HLSEC and HHF producing cytokines with inhibitory effect on the 
expression of these liver enzymes. This line of argument may be worth examining as 
Abdel-Razzak et al. (1993) and Muntane-Relat et al. (1995) have demonstrated that 
such pro-inflammatory cytokines as interleukin-6 (Il-6), interleukin-1 alpha (Il-1 
alpha), interferon gamma (IF-γ) and tumour necrosis factor-alpha (TNF-alpha) 
induced a suppression of CYP1A2, CYP2C, CYP2E1 and CYP3A mRNA and proteins in 
primary human hepatocyte culture. In studies carried out by Pascussi et al. (2000), 
and Ding and Staudinger (2005), it was suggested that these inflammatory 
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mediators, especially Il-6, repressed the phosphorylation of pregnane-X receptor 
(PXR) via the protein kinase C pathway which occurs in inflammation. PXR is the 
nuclear receptor involved in the transcription of the CYP3A family of genes 
(Bertilsson et al., 1998). The fact that endothelial cells and fibroblast have been 
shown to produce Il-6 might partly explain the significant reduction in expression 
and activity of some of these drug-metabolising enzymes (Shalaby et al., 1989, 
Tiggelman et al., 1995). The regulation of CYP activity by inflammation mediators 
and by protein-protein interactions has been reviewed by Morgan (2001) and 
Oladimeji et al. (2016). Further work is required to establish this link in the 
triculture liver microtissue model. Another likely explanation for the observed 
reduction in the expression of these drug-metabolising enzymes is the ‘zonation 
effect’. It is known that the expression and activity of drug-metabolising enzymes 
vary along the gradient of the zones of the liver as shown in Chapter 1; metabolism 
increases from periportal to centrilobular regions of the liver (Lindros, 1997) such 
that centrilobular hepatocytes are more metabolically competent. It has been 
shown that expressions of CYP 2E1 and CYP 3A4 are highest at the centrilobular 
zone of the liver (LeCluyse et al., 2012a). Whether the inclusion of HLSEC and HHF 
induced a zonation effect on the liver microtissues is a question that requires 
answering. It is worth noting, however, that liver zonation has been suggested to be 
regulated by cytokines (Gebhardt & Matz-Soja, 2014). As the metabolic gradient 
increases, the oxygen tension decreases along the periportal to centrilobular 
gradient (Colnot & Perret, 2011), implying that oxygen tension may have a direct 
bearing on the metabolic capabilities of hepatocytes. Traditionally, and as in this 
study, cell culture was carried out at the atmospheric oxygen tension of 20 % while 
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oxygen level in the centrilobular zone of the liver is usually at around 6.7% 
(Martinez et al., 2008). Consequently, a future experiment would ideally perform all 
procedures at the physiologically-relevant oxygen tension of 5-6.7 % as this might 
make a difference in metabolic competence of the hepatocytes in the microtissues. 
Further, liver microtissues in this study were prepared with only HLSEC and HHF in 
addition to PHH. Stellate cells and Kupffer cells might be included in a ‘complete’ 
liver microtissue.          
6.2 CONCLUSION AND FUTURE DIRECTION 
 
The data from this thesis shows that human liver sinusoidal endothelial cells 
constitute a unique population that makes them well-suited to their vascular bed 
and a potential source of a liver specific marker of early–onset vascular toxicity. 
Its unique expression of lymphatic endothelial cell markers – VEGFR-3 and LYVE-
1—also need to be further explored in order to uncover a unique role of LSEC in 
liver physiology which is as at yet not fully understood (Tanaka & Iwakiri, 2016).  
As transcriptomic data has shown, the high expression of oncogenes and tumour 
suppressor genes in HLSEC which might be a reflection of the tissue environment 
where the cells where isolated, it would be ideal to isolate HLSEC from liver of 
non-cancer patients (possibly from rejected liver transplants).   
Human liver sinusoidal endothelial cells are a direct target of hepatotoxic drugs, 
especially small molecule receptor tyrosine kinase inhibitors as these inhibit 
endothelial cell physiology. In addition to inhibiting angiogenic mechanisms, 
regorafenib induced apoptosis in HLSEC via caspase 3 activation, caused a 
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disruption of cytoskeletal structure and blocked one of the important pathways 
required for liver regeneration via inhibition of VEGFR-2 activation. These in vitro 
outcomes – disruption of cytoskeletal structure of the HLSEC and inhibition of the 
VEGF-A/ VEGFR-2-mediated liver regeneration – need to be tested in vivo. While 
the exact molecular mechanism of the disruption of the cytoskeletal structure 
need to be elucidated, it would be imperative to employ the murine 
monocrotaline model of sinusoidal obstruction syndrome (SOS) to better 
understand this in vivo (DeLeve et al., 2003, Wang et al., 2005).           
Finally, while liver microtissues are an improvement over hepatocytes cultured in 
monolayer in terms of expression of drug-metabolising enzymes, triculture liver 
microtissues had no advantage over their monocellular counterparts. Future work 
would need to address the hypothesis involving the release of proinflammatory 
cytokines which inhibit the activation of the nuclear receptors responsible for 
transcription of the genes coding for the cytochromes P450 proteins. In addition, 
an ideal multicellular microtissue should include other hepatic cells comprising 
primary human hepatocytes and additional non-parenchymal cells like stellate 
and Kupffer cells. 
This study has demonstrated the uniqueness of liver sinusoidal endothelial cells and 
serves as a confirmation that any biological, pharmacological or toxicological 
research intended to study liver sinusoidal endothelial cells must indeed utilise liver 
sinusoidal endothelial cells. This has become clear as shown in this study because 
several published articles that purported to investigate LSEC utilised endothelial 
cells from other vascular beds. Only when LSEC is used can any study carried out 
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reflect LSEC-specific effect. Also, this study has shown that while LSEC is a direct 
target of hepatotoxic drugs and exhibit relatively higher sensitivity to hepatotoxic 
drugs, there is need to further develop experimental models that can specifically 
and directly elucidate the contribution of LSEC to DILI especially in a multicellular 
system. By means of this study, the potential role of liver sinusoidal endothelial 
cells in drug induced liver injury (by tyrosine kinase inhibitors) has been elucidated 
to be by blockage of the physiology of LSEC, structural damage by cytoskeletal 
disruption, and cell death by apoptosis via activation of caspase 3.   
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Figure 6.1: Summary figure of the role of liver sinusoidal endothelial cells in regorafenib-mediated drug-induced liver injury. 
Regorafenib induces an inhibition of the activation of the VEGFR-2 receptor which normally initiates a series of cellular event including cell proliferation, 
migration and tubular morphogenesis. All these process were blocked in the presence of regorafenib. It causes a disruption of cytoskeletal structure of 
the LSEC. Regorafenib further blocks the process of liver regeneration and rather initiates apoptosis both on hepatocytes and the LSEC. 
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